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Zusammenfassung 
 
Konventionelle Therapien, wie die operative Entfernung von Tumoren oder 
chemotherapeutische Ansätze, sind zwar bei der Beseitigung von soliden 
Tumoren besonders effizient, scheitern jedoch häufig daran, streuende 
Tumorzellen zu beseitigen ("Minimal Residual Disease"). Meist sind es aber 
genau diese Zellen, die Metastasen oder auch Rezidive verursachen. Sowohl die 
systemische Verteilung als auch die Langlebigkeit dieser Zellen in den für das 
Immunsystem schwer zugänglichen Nischen stellen die Krebstherapie vor eine 
besondere Herausforderung. Aus diesem Grunde ist die Kombination aus 
konventioneller Therapie und einer zusätzlichen Aktivierung des Immunsystems 
ein viel versprechender Ansatz in der Krebstherapie, um Tumorzellen mit 
metastasierendem Potenzial zu eliminieren.  
Vor allem bei Patienten mit akuter myeloischer Leukämie (AML) bedeuten 
diese im Körper verbleibenden Tumorzellen eine lebensbedrohliche Gefahr, die 
nicht selten (70 % der Patienten) mit Rezidiven einhergeht. Deshalb sind gerade 
für die Bekämpfung von Leukämien weiterreichende Therapieformen von 
besonderer Bedeutung. In meiner Arbeit habe ich mich vor allem auf zwei 
Formen der Immmuntherapie konzentriert. Zum einem, auf die Verwendung von 
Dendritischen Zellen (DC) als therapeutisches Vakzin, zum anderen auf den 
adoptiven Transfer von T-Zell-Rezeptor (TCR)-transgenen Lymphozyten.  
Eine Möglichkeit, das Immunsystem zu aktivieren, besteht in der Anwendung 
von ex vivo generierten DC, welche ein ausgezeichnetes immunstimulatorisches 
Potenzial besitzen. Für eine Anti-Tumor-Immunantwort sollten die DC sowohl 
IFN-γ-produzierende CD4+-T-Zellen (Th1) wie auch zytotoxische T-Zellen (CTL) 
und natürliche Killer-Zellen (NK) induzieren können. Innerhalb dieser 
Doktorarbeit war es möglich, über einen Zeitraum von drei Tagen (3d), DC mit 
einem aktivierenden Phänotyp zu generieren. Hierfür wurden synthetische Toll-
like-Rezeptor-3-,-7/8-Agonisten verwendet, welche eine Virus-abhängige 
Aktivierung nachahmen. Die auf diese Weise generierten DC waren in der Lage, 
hohe Mengen an bioaktivem IL-12 freizusetzen, und in der Folge, wirkungsvoll 
Effektorzellen zu aktivieren. Verglichen mit 7d-DC, die derzeit in klinischen 
Studien verwendet werden, konnte für die hier generierten 3d-DC eine 
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verbesserte Fähigkeit zur Aktivierung des angeborenen (NK Zellen) als auch des 
adaptiven Immunsystems (T-Zellen) nachgewiesen werden.  Darüber hinaus 
wurde ein humanisiertes Mausmodell etabliert, welches die In-Vitro-Ergebnisse 
auch in vivo bestätigte. Hierfür wurden NOD/scid/IL2Rgnull-Mäuse mit humanen 
peripheren mononukleären Zellen rekonstituiert und mit reifen DC immunisiert. 
Im Einklang mit den in-vitro-Ergebnissen ergaben auch die in-vivo-
Untersuchungen, dass die kürzer kultivierten, TLR-aktivierten DC in der Lage 
waren, eine potente anti-Tumor-Immunantwort zu induzieren. 
Der adoptive T-Zelltransfer mit Hilfe von TCR-modifizierten Lymphozyten, 
stellt eine elegante und relativ leicht umzusetzende Möglichkeit für die 
Übertragung einer anti-Tumorantwort auf den Patienten dar. Bei diesem Ansatz 
werden zuvor isolierte TCR-Sequenzen, und somit auch deren Antigen-
Spezifität, auf Lymphozyten des Patienten übertragen. Ein entscheidender 
Schritt hierbei ist die Isolierung von T-Zellen, die einen TCR mit hoher Affinität für 
Tumor-assoziierte Selbst-Antigene besitzen. Vor allem nicht im Thymus negativ 
selektionierte Lymphozyten besitzen TCR mit hoher Affinität für das jeweilige 
Antigen. Aus diesem Grund wurde ein fremdes MHC Molekül in Kombination mit 
Epitopen von Tumor-assoziierten Antigenen für die Induktion hochaffiner T-
Zellen verwendet. In dieser Arbeit konnten T-Zellen mit hochaffinen TCR für die 
Tumor-Antigene Tyrosinase, Survivin und HMMR (hyaluronan-mediated motility 
receptor) gewonnen werden. TCR, die spezifisch für die beiden AML-assoziierten 
Antigene HMMR und Survivin sind, wurden isoliert und in Empfänger-
Lymphozyten transferiert. Bei der Verwendung von Survivin-spezifischen TCR 
konnte ein "Brudermord" der eingesetzten Lymphozyten festgestellt werden. Eine 
Beobachtung, welche die Anwendung von Survivin-spezifischen TCR für den 
TCR-Gen-Transfer erheblich einschränkt. Weitere Analysen ergaben, dass diese 
Erkennung auf eine erhöhte Survivin-Expression in aktivierten Lymphozyten 
zurückzuführen war.  
Im Gegensatz zu Survivin-spezifischen TCR zeigten Lymphozyten, welche mit 
HMMR-spezifischen TCR transduziert wurden, eine spezifische In-Vitro-
Reaktiviät gegen AML-Zellen. Neben der Funktionalität in vitro ist das In-Vivo-
Verhalten der TCR-modifizierten Lymphozyten für das therapeutische Ergebnis 
von entscheidender Bedeutung. Um dies zu analysieren, wurde ein Mausmodel 
etabliert, in welchem sowohl solide als auch leukämische humane Tumorzellen in 
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NOD/scid/IL2Rgnull Mäusen verwendet wurden. Ein signifikanter Rückgang der 
Tumorlast konnte nach einem Transfer von Lymphozyten, welche zuvor mit 
einem HMMR-spezifischen TCR modifiziert worden waren, beobachtet werden. 
Der Rückgang des Tumorwachstums konnte noch verstärkt werden, wenn die 
Empfänger-Lymphozyten einen Zytokin-induzierten Gedächtnis-Phänotyp 
aufwiesen. Im Einklang mit den In-Vitro-Analysen stellte sich heraus, dass ein Il-
15-induzierter (Effektor-Gedächtnis) T-Zell-Subtyp das größte Anti-Tumor-
Potenzial besaß.  
Zusammenfassend konnte in dieser Arbeit gezeigt werden, dass sowohl die 
DC-basierte Vakzinierung, als auch der Transfer von spezifisch TCR-Gen-
modifizierten Lymphozyten einen starken In-Vivo-Anti-Tumoreffekt zeigen und 
folglich vielversprechende Methoden für die Krebstherapie darstellen.  
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Summary 
 
Conventional cancer therapies like surgery, radiation and chemotherapy help to 
eliminate primary tumor masses but often fail to eradicate disseminated tumor 
cells. However, it is such residual tumor cells that frequently underlie metastasis 
and relapse. Major obstacles for targeting such cells are wide spread 
dissemination and long-term persistence in niches that are difficult to reach. For 
example, many patients with acute myeloid leukemia (AML) show persistence of 
leukemia after chemotherapy – so-called minimal residual disease (MRD) – 
which confers a life-threatening risk for relapse in over 70% of patients. Arming 
the immune system to attack residual tumor cells has high therapeutic potential 
since immune cells can patrol the body to find and destroy residual tumor cells. 
Therapeutic approaches using the immune system - so-called immunotherapies - 
can take several forms. My project concentrated on preclinical studies of two 
strategies: 1) use of dendritic cells (DC) for therapeutic vaccination and 2) 
adoptive T cell therapy with lymphocytes expressing transgenic T cell receptors 
(TCR) specific for tumor-associated antigens (TAA).   
In therapeutic vaccination a highly potent vaccine is needed to induce a valid 
immune response in patients with cancer. Effective antitumor immunity requires 
mobilization of IFN-γ-producing CD4+ T cells (Th1 cells) and lymphocytes with 
cytotoxic function, including cytotoxic T lymphocytes (CTL) and natural killer (NK) 
cells. In my studies, high potency vaccines were developed using mature DC 
generated in 3 days (3d-mDC) that were stimulated with synthetic Toll-like 
receptor TLR3 and/or TLR7/8 agonists. This TLR stimulation mimics DC 
interaction with viruses and causes mDC to secrete the bioactive form of IL-12, 
supporting induction of effector cells. Characterization in vitro showed that TLR-
activated 3d-mDC were superior to conventional 7d-mDC in capacity to induce 
Th1 cells as well as CTL. A humanized mouse model was established to verify 
these observations in vivo. NOD/scid IL2Rgnull mice, lacking murine T, B and NK 
cells, were reconstituted with human peripheral mononuclear cells and 
vaccinated with 3d-mDC, stimulated or not with TLR agonists, and conventional 
7d-mDC. Induction of CTL was quantified ex vivo using splenocyte populations 
containing human lymphocytes. The in vivo results were concordant with in vitro 
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observations, demonstrating the superior capacity of 3d-mDC that were 
stimulated with TLR agonists to induce CTL.  
Adoptive T cell therapy using TCR-modified lymphocytes represents a second 
powerful way to provide patients with specific antitumor immunity. Here 
previously isolated TCR gene sequences are introduced into activated patient-
derived lymphocytes, assigning them new antigen specificities. First, T cells must 
be isolated with TAA specificities that express high-affinity TCR which effectively 
recognize tumor cells. It was contended that T cell stimulation using peptide-
epitopes from TAA presented on foreign MHC would allow isolation of high-
affinity TCR, since these T cells had not yet undergone negative selection in the 
thymus. This contention was proved in individual experiments, as described in 
this thesis, for the antigens tyrosinase, survivin and HMMR (hyaluronan-
mediated motility receptor). Since survivin and HMMR are broadly expressed in 
AML, TCR specific for these TAA were isolated and subsequently transferred into 
recipient lymphocytes. Expression of survivin-specific TCR resulted in MHC-
restricted death of transduced lymphocytes due to their elevated survivin 
expression after activation. This precludes use of survivin-specific TCR for 
therapy of AML.  
In contrast, transfer of an HMMR-specific TCR yielded effector lymphocytes 
that effectively killed AML cells in vitro. The behavior in vivo of TCR transduced 
lymphocytes is crucial for therapeutic outcome. To explore this capacity a 
xenograft mouse model was established using solid and disseminated human 
tumor cells injected into NOD/scid IL2Rgnull mice. Adoptive transfer of 
lymphocytes expressing an HMMR-specific TCR into tumor-bearing mice 
resulted in significant retardation of tumor outgrowth. Adoptive transfer of 
memory-like lymphocytes with higher proliferative potential and prolonged in vivo 
survival may also affect tumor growth. Analyses in vivo and in vitro showed that 
IL-15-induced effector memory T cells conferred the most potent antitumor 
immunity.  
In summary, this work provides evidence for potent in vivo antitumor effects by 
either using DC-based vaccines or adoptive transfer of TCR transduced 
lymphocytes, opening application of both strategies for immunotherapy of cancer. 
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1 Introduction 
1.1 The human immune system 
1.1.1 Hematopoiesis and function  
The human immune system is the most dynamic and flexible organ of the human 
body. Hematopoetic stem cells (HSC) give rise to all immune cells, display a 
well-characterized compartment of tissue specific stem cells and descendants of 
HSC maintain the steady state levels of cells within the peripheral blood 
(Carpenter et al. 2010). The self-renewal function of the immune system has 
been under investigation since Till and McCulloch showed that bone marrow 
cells give rise to spleen colonies in the 1960s (Till et al. 1961). Within the last 
decade, the hierarchical scheme of hematopoiesis was a matter of controversial 
debate, due to reports of leakage of cells within the conventional lineage-
branches (Bell et al. 2008; Graf 2008; Wada et al. 2008). Exemplary reports 
show that lymphoid progenitors (e.g. pro-B-cells) lose the possibility to give rise 
to mature myeloid cells (Rolink et al. 1999; Adolfsson et al. 2005; Balciunaite et 
al. 2005). Nevertheless, conceptional tree models display the origin of all crucial 
subsets of the immune system by relying on the lymphoid-myeloid dichotomy 
model. The basis of all models is the decreasing self-renewal function of long 
term-HSC (LT-HSC), developing into short-term HSC (ST-HSC) and multi-potent 
progenitors (MPP) during the process of differentiation. The MPP still have the 
potential to evolve into all kinds of immune cell progenitors but have lost self-
renewal potential. During further differentiation to common lymphoid progenitors 
(CLP) or common myeloid progenitors (CMP) this poly-potent differentiation 
capability decreases (Rosenbauer et al. 2007; Ceredig et al. 2009). CMP are 
determined to give rise only to myeloid cell types (megacaryocytes, erythrocytes, 
granulocytes, monocytes), while CLP evolve to lymphoid cell-types (natural killer 
(NK) cells, T lymphocytes (T cells), B lymphocytes (B cells)).  
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The leukocytes (or white blood cells) compose the immune system, which can 
be subdivided into the innate and adaptive immune components. Cellular 
constituents of the innate system are myeloid-derived neutrophils, eosinophils, 
basophils, mast cells and monocytes as well as the lymphoid-derived NK cells. A 
common feature of “innate” cell types is their fast response to foreign particles or 
danger signals, without antigen-specific stimulation. In contrast, the adaptive 
immune system consists only of lymphoid-derived cells (T and B lymphocytes) 
and activation requires recognition of antigens via specific receptors (T cell 
receptor, TCR and B cell receptor, BCR) that are unique for each single 
lymphocyte. The BCR recognizes antigens directly via a membrane bound BCR 
or the soluble variant of the BCR, known as antibody. In contrast, TCR-mediated 
recognition is restricted to processed peptide sequences presented on special 
peptide-presenting molecules, named major-histocompartibility complexes 
(MHC), or human leukocyte antigen (HLA) in humans. Furthermore, for full 
Fig. 1: Model of hematopoiesis 
Lineage-based tree-scheme of hematopoiesis. The myeloid and lymphoid branches separate 
at the stage of multi-potent progenitors. The common lymphoid or myeloid progenitors only 
give rise to lymphoid or myeloid cells, respectively.  
HSC (hematopoetic stem cell), MPP (multi-potent progenitor), CLP (common lymphoid 
progenitor), CMP (common myeloid progenitor), GMP (granulocyte/monocyte progenitor), 
MEP (megakaryocyt/erythrocyte progenitor) modified from (Raffegerst 2009).  
Introduction 
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activation lymphocytes need costimulatory signals provided by the innate 
immune system. Potent activators of T cells are professional antigen-presenting 
cells (APC), primarily mature dendritic cells (mDC). These APC are able to ingest 
and process antigens and present peptide sequences to T cells on MHC-
molecules. This mechanism of authorization, presenting a foreign peptide by a 
self-molecule, is necessary, since uncontrolled lymphocyte reactions can lead to 
severe damage of the body. Another control mechanism to eliminate auto-
reactive T lymphocytes is founded in the thymic-selection process and described 
below. After thymic selection, the naïve T cell repertoire comprises cells that 
specifically recognize peptide-MHC (pMHC) ligands and encompass a potential 
diversity of at least 1015 different TCR (Davis et al. 1988).  
 
1.1.2 Development of T lymphocytes 
T lymphocytes are named after their location of development, the thymus, a 
primary lymphoid organ. Thymocytes evolve from CLP progenitors, which receive 
stimuli from thymic epithelial cells (TEC), initiating the development into 
thymocyte progenitors (Schlenner et al. 2010). Ongoing differentiation into fully 
mature T cells can be further separated into double-negative (DN), expressing no 
co-receptors, and double-positive (DP), expressing both CD4 and CD8 co-
receptors. Those stages combined with a thymic selection process, are leading 
to single positive mature thymocytes (Carpenter et al. 2010; Hernandez et al. 
2010). The stages of gradual differentiation within the DN stage can be further 
subdivided into the DN1 through DN4 stage (Fig. 2) (Godfrey et al. 1993). While 
DN1 cells are still able to give rise to DC, as well as NK cells, the DN2 phase is 
characterized by up-regulation of CD25, determining the T lymphocyte lineage. 
Cell survival of DN1 and DN2 is mediated by the Notch1 transcription factor, 
which is crucial for T cell development (Chi et al. 2009; Radtke et al. 2010). 
During the DN2 phase the rearrangement of TCR-β chain gene segments is 
initiated by fusion of D- and J-gene segments, followed by the V-segment joining 
within stage DN3 (Krangel 2009). These recombination-activating-gene (Rag) 
mediated rearrangements include additions and deletions of nucleotides within 
three “complementarity determining regions” (CDR) of the TCR β-chain resulting 
in an individual recognition pattern for each TCR chain.  
Introduction 
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To prove the functionality of each β-TCR chain, β-selection occurs during DN4 
stage of differentiation. Oligomerization of the β-chain with a pre-α-chain and 
CD3 induces a positive survival signal, initiation of the α-gene-segment 
rearrangement (V-J-recombination) and allelic exclusion of the non-rearranged β-
chain gene. After passing the DN stages, T cell progenitors express an α- and β-
chain comprising newly displayed TCR in combination with CD4 and CD8, 
characterizing the DP stage. DP thymocytes undergo a developmental process 
inducing central tolerance encompassing three stages (Starr et al. 2003): 
I. Positive selection: 
Comprises a process in which TCR binding to pMHC ligands is verified. T 
cells with non-binding TCR do not receive a positive survival signal and 
die within the next three to four days.  
II. Negative selection: 
This process reflects the core function of central tolerance, eliminating all 
T cells recognizing MHC ligands loaded with self-peptides by a 
Fig. 2: Scheme of thymocyte development  
Shows schematically the differentiation progress in the thymus starting with HCS through DN4 
stage. Stem cell factor (SCF) and Interleukin-7 (IL-7) are shown as soluble factors maintaining 
the early survival. Steps of TCR rearrangements as well as TCR expression are also depicted. 
Cell surface markers to discriminate the different stages are listed below. (modified from 
(Hernandez 2010).  
Introduction 
___________________________________________________________________ 
14 
programmed cell-death mechanism (von Boehmer et al. 2010). The TEC 
present these self-pMHC ligands on their surface, which are than 
screened by developing lymphocytes. The expression of tissue-specific 
proteins by TEC is mediated by the transcription factor AIRE (autoimmune 
regulator) (Mathis et al. 2009). 
III. Acquisition of functional competence: 
The functional differentiation takes place in accordance with attainment of 
CD4 or CD8 co-receptor expression. The characteristics and gene 
expression profiles of helper T cells (Th) and cytotoxic T lymphocytes 
(CTL) are linked with the expression of the particular co-receptor (Corbella 
et al. 1994; Matechak et al. 1996). Lineage-decision is based on the TCR 
recognizing either MHC class I for CD8 or MHC class II for CD4 and is 
realized by gradual down-regulation of CD4 or CD8, in combination with 
ongoing MHC:TCR interactions (Brugnera et al. 2000; Germain 2002). 
The terminal maturation of thymocytes depends on the transcription factor Klf2 
(Kruppel-like factor 2), inducing L-selectin and sphingosine-1-phosphate-receptor 
expression, allowing the migration into the blood stream. These naïve T 
lymphocytes are positive for the transcription factor Fox01 (Forkhead box protein 
01), which mediates homeostasis and survival in the periphery, until they receive 
an antigen dependent stimulation (Fabre et al. 2008; Kerdiles et al. 2009; 
Ouyang et al. 2009). 
  
1.1.3 T lymphocyte-mediated immunity  
Naïve T cells migrate via the blood stream to secondary lymphoid organs, e.g. 
lymph nodes or red pulp of the spleen, screening APC in the T cell area for the 
specific recognition of antigen. Professional APC, e.g. DC, have the ability to 
present endogenous and exogenous antigen on MHC class I and II molecules 
activating CD8+ or CD4+ T cells, respectively. Induction of effector T cells 
requires three signals delivered by the DC: (I) Interaction of pMHC ligands with 
TCR, (II) co-stimulatory molecules of the B7-familiy fostering the activation via 
CD28 or inhibition via CTLA-4 (cytotoxic T lymphocyte antigen-4) and PD-1 
(programmed-death-1) of the T cell and (III) cytokines, secreted by the APC, 
orchestrating the immune response (Valitutti et al. 1995; Viola et al. 1999; 
Schuler et al. 2003). Only fully mature DC can deliver these signals in an 
Introduction 
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adequate fashion, while insufficient stimulation leads to T cell anergy. Over 
stimulation results in programmed cell death, known as “activation induced cell 
death” (AICD) (Marrack et al. 2000). Following specific antigen-recognition, a 
differentiation and proliferation process is initiated generating an oligoclonal 
effector T cell population. Among the CD4 cells, subtypes like Th1, Th2 or Th17 
cells are induced with respect to the cytokine-milieu present during their priming 
process, conducting immune responses into distinct directions (Zheng et al. 
1997; Szabo et al. 2000; Ivanov et al. 2006). After clearance of antigen, a 
“contraction” phase proceeds, leading to a reduction of the antigen-specific T cell 
population leaving several long-lived cells behind. These residual T cells are 
described as memory T cells, which are well specified for CD8+ T cells, while the 
heterogenic phenotype of CD4+ memory T cells are less well characterized. For 
the development of memory T cells two theories are currently under 
consideration: direct determination during the priming process or evolvement 
from the pool of effector T cells (Gerlach et al. 2011). There is consensus that the 
transit of T cells into the memory compartment depends on the antigen dose of 
stimulation but the required signal strength is controversially discussed (Ahmed 
et al. 1996; Lanzavecchia et al. 2000; Lanzavecchia et al. 2002). Memory cells 
are characterized by long-term persistence without antigen stimulation and can 
be subdivided into central (TCM) and effector memory cells (TEM) (Sallusto et al. 
1999). Whether these memory subsets are distinct or if central memory cells give 
rise to disposing effector memory cells is still not completely understood 
(Lanzavecchia et al. 2002). Both memory subsets are maintained by interleukin-7 
(IL-7) and IL-15, providing a lifelong immediate protection following a repeated 
encounter to the same antigen (Ahmed et al. 1996; Becker et al. 2002; Goldrath 
et al. 2002; Kieper et al. 2002) 
 
1.2 Acute myeloid leukemia - tumorigenesis of the immune system  
Leukemia is a cancer of blood or bone marrow cells and is clinically detectable 
by increased white blood cell counts. It was first characterized by the German 
physician Rudolph Virchow in 1845 (“leukos” – white; “haimia” – blood). 
Leukemia can be subdivided according to disease progression into acute or 
chronic subtypes, while the chronic variants result in a final acute state. The 
acute variants are characterized by rapid increase of immature (mostly bone-
Introduction 
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marrow-derived) cells while a slower progression of more differentiated cell types 
characterizes chronic variants. Additionally, leukemic diseases are further divided 
by their lineage origin into lymphoid and myeloid types.  
AML is distinguished by the clonal outgrowth of immature progenitor cells 
(blasts) and clinically characterized by the morphological stage of differentiation 
in which the transforming event took place (French-American-British system 
(FAB)). Furthermore, cytogenetic, molecular and immunophenotyping techniques 
are applied to further discriminate the stage of differentiation, recently specified 
by the WHO (World Health Organization) classification (Swerdlow et al. 2008). In 
2010, the Leukemia and Lymphoma Society reported on a total of 43,050 newly 
diagnosed leukemic diseases in the USA (ALL 5,330; CLL 14,990; AML 12,330; 
CML 4,870). With respect to survival rates reported within the same time frame, 
AML displays the most life-threatening form of leukemia here shown as percent 
survival: ALL 66.4%; CLL 79.7%; AML 24.2%; CML 54.6% (www.lls.org). 
Leukemia ranges among the 10 most life-threatening cancer diseases, related to 
the death rates of other cancer types (Fig. 3, status 2007, United States). These 
statistical data are in consistence with observations in Germany.  
 
 
 
 
Standard therapy, applying chemotherapy (cytarabine, anthracycline) alone or 
in combination with bone marrow transplantation, results in 65-80% complete 
Fig. 3: Death per 100.000 U.S. citizens caused by cancer  
Death rates per 100.000, age-adjusted, U.S. citizens, listing the 10 most life threatening 
cancer types. Statistical data of the last published evaluation in 2007. Leukemia on 
position 7 causing 7 deaths within 100.000 people. (http://apps.nccd.cdc.gov).  
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remission of AML, but only in 30% of the patients, does therapy result in a long-
term disease-free survival without relapse (Greiner et al. 2004).   
AML is characterized by often-occurring abnormal karyotypes (45%) and 
about 15% of AML show at least 3 genetic alterations (Poppe et al. 2004). These 
chromosomal translocations, deletions, insertions or duplications generally lead 
to activation of “oncogenes” or inhibition of “tumor-suppression genes”, 
respectively. Affected genes mainly contribute to proliferation, cell survival and 
hematopoetic differentiation. A common theory for leukemogenesis is a two-hit 
model, in which the first mutation affects genes of proliferation and survival (e.g. 
KIT, FLT3, NRAS/KRAS), while the second mutation occurs at a later stage and 
influences the differentiation process (e.g. CEBPA, NPM1) (Kelly et al. 2002). 
Expression levels of proteins favoring survival and proliferation of AML cells are 
mostly aberrantly upregulated and required for ongoing tumor survival. 
Therefore, these proteins, including survivin and hyaluronan-mediated motility 
receptor (HMMR/Rhamm), display potential targets for immune-mediated 
therapeutic approaches (Greiner et al. 2008; Jiang et al. 2010). 
 
1.3 Cancer immunosurveillance and immunoediting 
As early as 1909, Paul Ehrlich claimed: “Ich bin überzeugt, dass abberrierende 
Keime bei dem kolossal komplizierten Verlauf der fötalen und post-fötalen 
Entwickung außerordentlich häufig vorkommen, dass sie aber glücklicherweise 
bei der überwiegenden Mehrzahl der Menschen vollkommen latent bleiben, dank 
der Schutzvorrichtungen des Organismus. Würden diese nicht bestehen, so 
könnte man vermuten, dass das Karzinom in einer gradezu ungeheuerlichen 
Frequenz auftreten würde.” (by P. Ehrlich (Ehrlich 1909)). Thus, he postulated 
that the immune system protects the organism from its own abnormal cells. 
Referring to this theory Thomas and Burnet described independently the theory 
on cancer immunosurveillance (Burnet 1964). Immunosurveillance describes the 
recognition and elimination of abnormal cells by the organisms’ own immune 
system (Dunn et al. 2002; Dunn et al. 2004a). There are several studies using 
immuno-incompetent mouse models proving this theory, as well as clinical data 
demonstrating this effect in humans (Dunn et al. 2004a). Direct impact on tumor 
cells by components of the immune system leads to drastic changes within the 
tumor mass. This process is described as “immunoediting”. In general, this phase 
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describes the protective mechanism by which the tumor is eliminated. However, 
this goes along with selection of tumor escape variants. Dunn and colleagues 
split the process of immunoediting into three major phases: (I) elimination, (II) 
equilibrium and (III) escape (Dunn et al. 2004b).   
(I) Elimination: 
This comprises the immune response directed against the cancer and 
can be further subdivided into four phases. During the first phase, the 
innate immune system recognizes rapid tumor growth accompanied by 
tissue damage. Inflammatory danger signals lead to recruitment of NK 
cells as well as DC. Within the second phase high amounts of secreted 
interferon-γ (IFN-γ) result in tumor damage, causing activation of DC to 
ingest tumor fragments and migrate to draining lymph nodes. During 
the third phase, tumor damage and inhibition of vascularization, 
mediated by the innate immune system, proceeds. Meanwhile, tumor-
specific DC recruit and activate CD4+ (Th1) and CD8+ T lymphocytes, 
specific for TAA. Phase four describes the infiltration of those activated 
T cells into the tumor, leading to complete tumor cell elimination.   
(II) Equilibrium: 
During this phase the tumor stops growing and moves towards a long 
period of dormancy. This is accomplished by the immune system 
decreasing the cancer’s capability to further grow. It eliminates some 
tumor cells but not enough to eradicate the tumor completely. This 
ongoing immune response is likely to cause escape variants of tumor 
cells, resulting in resistance to elimination.  
(III) Escape: 
This comprises a reinitiated uncontrolled tumor growth of 
immunologically “silent” escape variants. Cancer cells, which have 
escaped from the immune response, give rise to growing malignant 
tumors together with tumor cell spread.  
With respect to AML, evidence for immunosurveillance mechanisms can be 
detected in patients, although it is not resolved if those mechanisms are of 
primary origin or induced by therapeutic approaches (Barrett et al. 2010). 
Nevertheless, increased lymphocyte counts are related to decreased and 
retarded relapse rates (Bruserud et al. 1998; Behl et al. 2006; Barrett et al. 
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2009). In addition to these clinical observations, several immunoescape 
mechanisms are described, indicating a process of immunoediting. Evidence for 
suppression of NK cell-mediated immunity include elevated expression levels of 
killer-inhibitory-receptors (KIR) on tumor cells as well as secretion of soluble 
suppressing factors (Panoskaltsis et al. 2003; Verheyden et al. 2004). In 
concordance to NK cell suppression, T cell immunity can be affected by many 
tumor escape mechanisms, e.g. aberrant peptide presentation or down-
regulation of MHC molecules (Vago et al. 2009; van Luijn et al. 2010). Moreover, 
numerous observations have demonstrated that changed expression profiles of 
costimulatory molecules have a profound impact on T cell responses and down-
regulation of B7.1 and B7.2 results in worse prognosis (Whiteway et al. 2003). 
There is a correlation of a particular CTLA-4 genotype with a higher frequency of 
disease (Perez-Garcia et al. 2009). In addition, most AML patients exhibit an 
immunosuppressive microenvironment, while the bone marrow comprises an 
ideal environment for the maintenance of leukemic stem cells (Lapidot et al. 
2007; Zhi-Gang et al. 2008). 
 
 
 
A unique feature of AML to suppress the immune system is based on the 
origin of tumor cells. These myeloid-derived tumor cells mostly share the ability 
Fig. 4: Interactions of the immune system and AML cells  
Escape mechanisms of AML tumor cells to conquer the immune system as well as 
suppressive mechanisms on T cells by tumor-derived DC (Barrett et al. 2010). 
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to become tolerogenic APC, comprising the dangerous potential to induce 
antigen-specific anergy in tumor-reactive T cells or even induce regulatory T cells 
(Mohty et al. 2001; Narita et al. 2001; Schui et al. 2002; Tong et al. 2008; Ge et 
al. 2009).  
 
1.4 Immunotherapy  
1.4.1 A general survey 
The concept behind immunotherapy is to reinforce the patient’s own immune 
system for recognition of tumor cells and elimination of residual cells after 
primary treatment, including surgery or chemotherapy. Therapeutic approaches 
can be subdivided along two basic principles. The first is based on boosting the 
immune system using classical vaccination strategies all the way through to 
whole cell-vaccines. The second involves transfer of antitumor immunity to the 
patient via the application of tumor-specific antibodies, T cells or transgenically-
engineered lymphocytes.  
With respect to AML, already the standard clinically applied bone marrow 
transplantation utilizes an approach arming components of the immune system. 
While transplantation of solid organs primarily uses HLA-matched donor-recipient 
pairs, mismatches in major histocompatibility complexes can be even beneficial 
for the therapy of leukemia. It has been reported that allogeneic primed 
lymphocytes can efficiently limit tumor outgrowth in mouse models (Bonnet et al. 
1999; Distler et al. 2008). In concordance to these results, Barrett reported on an 
elevated Graft-versus-Leukemia (GvL) effect in patients treated with allogeneic 
transplants (Barrett 2008). A successful therapeutic approach of allogeneic stem 
cell therapy was introduced by Kolb et al. and is described as “haplo-identical” 
bone marrow transplantation (Kolb 2008). This therapeutic approach uses donor-
recipient pairs, which differ in one HLA-haplotype (e.g. partial-mismatched 
siblings or parent-child combinations). After acceptance of the stem cell graft by 
the recipient (induced chimerism), donor lymphocytes are transferred to induce 
an allogeneic mediated GvL-response.  
A more broadly used immunotherapeutic approach is the administration of 
cytokines to boost the immune system. In particular, high-dose or low-dose IL-2 
was proven to prolong the survival of cancer patients by inducing antitumor 
immune responses (Antony et al. 2010). The usage of IL-2 therapy for AML is 
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discussed controversially due to some reports, which demonstrate beneficial 
effects as well as reports which show IL-2-induced relapse (Macdonald et al. 
1991; Meloni et al. 1994; Stone et al. 2008).  
Application of antibodies comprises another promising approach, which is 
already successfully used to treat cancer diseases. Interestingly, the treatment of 
Her2-positive breast cancer patients with Herceptin, an anti-Her2 antibody, is 
able to prolong significantly the disease-free survival (in mean 33 weeks) 
(Mannocci et al. 2010). Possible AML-associated targets for antibody-therapy are 
CD123, CD47, CD64 and CD33. Especially, Gemtuzumab, targeting CD33, in 
combination with other therapeutic strategies, showed promising clinical data 
(Estey et al. 2002; Amadori et al. 2005; Larson et al. 2005). Besides antibodies, 
that target TAA, blocking-antibodies are potent tools to boost or redirect immune 
responses (Callahan et al. 2010). For instance, Ipilimumab, an anti-CTLA-4 
blocking-antibody, silencing an inhibitory costimulatory receptor on T cells and 
thereby enhancing immune responses against tumor cells showed first benefits 
in patients with metastatic melanoma (Hodi et al. 2010).  
In addition to the previously described therapies, peptide vaccines in 
combination with strong adjuvants, such as Toll-like-receptor (TLR) agonists, like 
poly(I:C) or lipopolysaccarides (LPS), have been proven to be effective for the 
induction of potent Th1/CD8 antitumor responses. Promising antigens to target 
AML have been reviewed by Greiner and colleagues and include Wilms-Tumor-1 
(WT-1), proteinase-3  (PR-3) and HMMR (Schmitt et al. 2006; Schmitt et al. 
2009). Several studies demonstrated increased T cell responses combined with 
prolonged survival (Saliba et al. 2007; Rezvani et al. 2009; Greiner et al. 2010). 
Beyond the above described modulations of the immune system, 
administration of whole cells, including DC and T cells, can confer antitumor 
immunity to patients, and will be described below. 
 
1.4.2 Dendritic cell-based vaccination 
Deduced from classical vaccination against foreign pathogens, two basic 
observations were made that (I) DC play a central role in inducing immune 
responses and (II) adjuvants used for vaccination are potent DC activators 
(Palucka et al. 2010). The main goal of establishing DC-based vaccines for 
cancer treatment is to prime and redirect the immune system, resulting in 
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reinforced recognition and elimination of tumor cells. The immune response that 
is needed for an effective antitumor effect can be compared to leprosy, where the 
indolent variant is characterized by a Th1 response, whereas the lepramatous 
form is characterized by a mostly lethal Th2 response. Therefore, the potent 
induction of a CD4+ Th1-response goes along with activation of cytotoxic CD8+ T 
cells and hence is of outstanding importance and essential for the development 
of antitumor vaccines (Janssen et al. 2003). Th1 responses or cellular immunity 
in general, typically are directed against intracellular pathogens, like M. 
tuberculosis, and are characterized by secretion of IFN-γ. In contrast, Th2 
responses combat extracellular pathogens via secretion of IL-4 and IL-13 
resulting in humoral immunity (Mosmann et al. 1986). DC deliver three “activator-
signals” that conduct the induced immune response: signal 1 - pMHC ligands for 
the presentation of antigens to T lymphocytes; signal 2 - costimulatory 
molecules; and signal 3 - secretion of Th1 polarizing cytokines. For instance, 
defined members of the IL-12 family influence the type of Th response, with IL-
12p70 being a potent activator of Th1 responses (Macatonia et al. 1995). 
Costimulatory signals are mostly dependent on B7-family members binding to 
CD28 and thereby deliver positive signals to T cells during the priming process, 
whereas their binding to CTLA-4 inhibits immune responses (Krummel et al. 
1995). Depending on the signal strength and duration leading to maturation, 
expression profiles of these costimulatory molecules can be very diverse on 
mDC (Chen 2004; Greenwald et al. 2005).  
In parallel, mDC possess an enhanced ability to interact with T cells, while 
immature DC (iDC) have the unique capacity to ingest antigens (Lanzavecchia et 
al. 2001). In addition, iDC contain an excellent machinery to process and present 
peptides on MHC molecules, but lack activating signals. The expression of high 
levels of costimulatory molecules as well as MHC molecules distinguishes fully 
mDC from iDC. Thus, it is not surprising that several clinical studies using iDC for 
antitumor vaccination failed, due to their tolerogenic phenotype (Schuler et al. 
2003; Steinman et al. 2003). Therefore, much effort is undertaken to reveal 
potent adjuvants, such as microbial-derived components, to optimally induce DC 
maturation (Reis e Sousa 2006). Receptors that recognize such pathogen-
derived structures can be sub-grouped into C-type lectins, TLR, NOD-like 
receptors and RIG-I-like receptors (Manicassamy et al. 2010; Takeuchi et al. 
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2010). In particular, TLR are known to represent potent stimulators of DC 
maturation. TLR downstream signaling results in activation of NFkB (nuclear 
factor kappa-light-chain-enhancer of activated B cells) and other 
immunomodulatory genes. Thereby, a modulation of the secreted cytokines as 
well as expression of costimulatory molecules is initiated (Gautier et al. 2005; 
Napolitani et al. 2005).  
In contrast to conventional vaccination, where a vaccine is given preventively, 
antitumor vaccination is mostly applied therapeutically, with the intention to 
eliminate residual tumor cells. In addition, potential target antigens for 
vaccination are limited to overexpressed self-antigens or to antigens with rare 
gene mutations. Compared to over-expressed antigens, mutated epitopes 
provide the advantage that responses can be generated from a non-selected 
TCR repertoire, whereas T cells recognizing self-antigens will have undergone 
negative selection for high aviditiy T cells in the thymus (Parmiani et al. 2007; 
Appay et al. 2008). Furthermore, overcoming the tumor microenvironment that 
simultaneously limits potent immune responses, is one of the biggest hurdles for 
DC-based vaccine usage. The tolerogenic milieu in the tumor microenvironment 
is determined mainly by regulatory T cells as well as tolerogenic subtypes of DC, 
often described as myeloid-derived suppressor cells (MDSC) (Gabrilovich et al. 
2009). These factors counteract a potent induction of antitumor immunity. 
Therefore, a better understanding of DC biology, resulting in robust mDC that 
can induce potent antitumor immunity is under intensive investigation (Steinman 
et al. 2007; Melief 2008). 
With respect to AML, several attempts were made to generate DC loaded with 
tumor lysates or RNA-encoding TAA (Roddie et al. 2006; Lei et al. 2009; Smith et 
al. 2009; Van Driessche et al. 2009). So far, these attempts resulted induced 
antitumor responses in vitro, while the clinical benefits were poor.   
 
1.4.3 Adoptive T cell transfer 
Shortly after the discovery of the cellular immune response, Alexander and 
colleagues cured mice with murine sarcomas using syngeneic lymphocytes of 
previously immunized mice (Alexander et al. 1964). Fefer and colleagues 
reported on the beneficial usage of chemotherapy in combination with 
lymphocyte transfer into mouse models (Fefer 1969). Later on, Eberlein 
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described an improved effect of lymphocytes that were cultured ex vivo with IL-2, 
resulting in the cure of disseminated murine tumors (Eberlein et al. 1982). 
Likewise, Rosenberg reported on IL-2-mediated reactivation of tumor-infiltrating 
lymphocytes (TIL) before adoptive transfer (Rosenberg et al. 1986). All of these 
mouse models paved the way towards the usage of T lymphocytes as 
therapeutic agents to treat cancer. However, when compared to antibody 
therapy, adoptive T cell therapy still lags behind in development although several 
clinical applications have been very successful. In general, adoptive T cell 
therapy can be subdivided into the usage of primary T cells or genetically-
modified lymphocytes.  
Primary T cells can be of various origins and comprise patient-derived TIL, ex 
vivo primed T cell bulk cultures of autologous or allogeneic origin or even single 
cell-derived T cell clones. Therapeutic approaches using those T cell types were 
shown to be highly efficient in treating post-transplant lymphoproliferating 
disorders (PTLD), induced by Epstein-Barr virus (EBV) infections (Heslop et al. 
2010). Furthermore, TIL isolated from melanoma patients, transferred into 
lympho-depleted patients, were demonstrated to have impressive clinical benefit 
(Dudley et al. 2002). Primary isolated lymphocytes are associated with high costs 
and laborious individual preparation procedures and a non-predictable efficacy.  
Therefore, genetically-engineered lymphocytes provide a promising tool for 
adoptive cell therapy. Modifications mainly concentrate on the introduction of 
TCR, specific for certain TAA. In addition, provision of costimulatory molecules, 
beneficial cytokines or survival factors is also feasable. Several studies on 
isolation and transfer of high-affinity TCR into recipient lymphocytes were 
published and are still a subject of intense research (Cole et al. 1995; Morgan et 
al. 2003; Hughes et al. 2005; Zhao et al. 2005). Initial clinical studies, focusing 
mainly on advanced melanoma, have proven efficacy of TCR-modified 
lymphocytes, but also showed severe side effects due to on-target toxicity 
directed against normal tissues expressing the same self-proteins as the targeted 
tumor cell (Johnson et al. 2009). The clinical results of those studies suggest the 
combination of several different TCR to avoid selection of escape variants. 
Furthermore, to avoid cross-reactivity due to pairing of endogenous and 
transgenic TCR, modifications of the TCR genes are considered (Cohen et al. 
2006; Sommermeyer et al. 2010). Such modifications concentrate mainly on the 
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replacement of specific amino acids or exchange of the constant regions by the 
murine counterparts (“murinization”) to foster pairing of the introduced TCR 
chains and to avoid mispairing with the endogenous chains.  
An additional subject of intense research focuses on the recipient lymphocytes 
that are used for TCR transfer. Conflicting statements have been made regarding 
the T cell phenotypes that yield convincing results in vivo with respect to naïve, 
effector as well as central memory phenotypes (Berger et al. 2008; Hinrichs et al. 
2009a; Heslop et al. 2010). Considerations to apply long-term persistent anti-viral 
memory cells or gamma-delta T cells are ongoing (van der Veken et al. 2009). 
Studies provide evidence that the phenotype of the recipient lymphocytes 
determines whether the TCR-transgenic lymphocyte will become anergic or 
serve as potent effector cells, thereby this topic is of outstanding interest (Dossett 
et al. 2009). In addition, since the function and importance of 
immunosuppression to eliminate regulatory T cells was demonstrated, pre-
conditioning of therapeutic recipients is also a subject of intense research 
(Antony et al. 2005).  
The main use of targeting mainly over-expressed self-antigens is a major 
pitfall of adoptive T cell transfer. For application of primary, patient-derived T 
cells, this fact limits mainly the avidity of T cells that are used for adoptive 
transfer. In contrast, transgenic TCR used for modification of lymphocytes can be 
of high affinity if they are obtained via allogeneic in vitro priming approaches or 
following genetic modifications (Morris et al. 2006; Kuball et al. 2007). 
Nevertheless, use of high-affinity TCR directed against self-antigens carries the 
risk of autoimmune reactions that affect antigen-expressing organs. It has been 
demonstrated by Overwijk that such autoimmune reactions accompany a potent 
antitumor effect (Overwijk et al. 2003). Therefore, the selection of target antigens 
has to be a carefully considered.  
For the treatment of AML, haploidentical T lymphocyte transfusion into non-
transplanted recipients resulted in positive clinical effects (Colvin et al. 2009). 
Additionally, several reports identifying anti-leukemic T cells in patients that 
would allow the application of autologous TIL were published (Zhong et al. 2008; 
Rezvani et al. 2009). In the meantime, attempts to isolate high-aviditiy TCR 
specific for AML-associated antigens and suitable for lymphocyte modification 
were initiated (Wolfl et al. 2007; Stauss et al. 2008). 
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2 Project Aims 
Immunotherapeutic approaches for treatment of AML using DC-based vaccines or 
adoptive T cell therapy constitute promising therapeutic strategies but both still 
require improvement. Therefore, this thesis project was designed to focus first on 
in vitro optimization to generate such cellular agents with subsequent assessment 
of their efficacy in vivo using mouse models. 
 
2.1 Optimization of ex vivo-generated DC and in vivo evaluation 
Due to the fact that DC are potent activators of the immune system, utilization of 
this cell type for development of an antitumor immune response seems 
reasonable. Nevertheless clinical studies resulted in only poor benefit due to the 
marginal immune responses that were induced in patients. Several studies 
reported on the importance of DC-activation stimuli to induce a potent immune 
stimulatory phenotype in murine DC, particularly through modulation of their 
cytokine production (Reis e Sousa 2006). Therefore, one of the major aims of this 
thesis was to optimize the composition of human DC maturation cocktails by 
including activation signals using Toll-like receptors (TLR), which can modulate 
their capacity to secrete cytokines. This optimization process involved comparison 
of the impact of various maturation cocktails on the functional capacity of DC to 
activate innate and adaptive immune responses. This was assessed using a 
variety of immune monitoring assays including phenotypical analysis of the DC 
themselves as well as the activation status of NK and T cells. Further assays 
concentrated on the potential of those effector cells to recognize and kill tumor 
cells.  
     In addition, the duration of DC generation is an important factor, impacting on 
the viability and function of DC. Therefore, comparison of the most frequently 
used clinical form of mDC generated using a 7-day protocol and a newly 
established 3-day protocol was considered. These DC were compared for their 
potential in antigen-presentation as well as their capacity to induce antigen-
specific immune responses.  
Given that DC-based vaccines are usually injected intradermally or near lymph 
nodes, the capacity to enter secondary lymphoid organs, like lymph nodes, as 
well as their ability to induce potent immune responses in vivo are essential. 
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Therefore, humanized in vivo mouse models are needed to assess the potential 
of ex vivo-generated DC to induce immune responses. Thus, a second major aim 
was to establish a NOD/scid IL2Rgnull (NSG)-based mouse model, reconstituted 
with human PBMC, to allow comparison of different forms of mature DC.   
 
2.2 De novo-induction of AML-specific T lymphocytes and functional analysis 
using xenograft mouse models  
The adoptive transfer of tumor-specific T lymphocytes into patients encompasses 
another promising strategy to overcome insufficient antitumor immunity. Included 
in this approach is the use of patient-derived lymphocytes that express a pre-
selected TCR as a transgenic protein, providing them with a new antigen 
specificity. Here it is essential to isolate high-affinity TCR, specific for broadly 
expressed TAA that are restricted to prevalent HLA alleles. To obtain high-affinity 
TCR a priming approach can be used employing DC of an HLA-A2-negative 
donor that are provided with ivt-RNA encoding a TAA of choice in combination 
with HLA-A2 ivt-RNA, in order to create new allogeneic pMHC ligands at the DC 
surface that can be recognized by T cells. By this means it is possible to activate 
T cells autologous to the DC that express high-affinity TCR since they were not 
negatively selected against allo-pMHC ligands in the thymus. Since HLA-A2 
represents a prevalent allele within the Caucasian population use of this MHC 
was given first preference for development of potential therapeutic TCR. This DC 
priming approach was established using the melanoma associated antigen 
tyrosinase and consequently used to isolate T cells directed against the AML-
associated antigens survivin and HMMR.  
     Stimulation using DC loaded with ivt-RNA encoding the entire antigenic protein 
allows the isolation of T cells directed against all intrinsic immunogenic peptides 
in the TAA that bind to the MHC. However, this priming approach also induces T 
cells that recognize the allogeneic MHC molecules expressing peptides that are 
not derived from the TAA, but from other proteins expressed in the DC. Therefore, 
methods are needed to efficiently distinguish alloreactive versus allo-restricted 
peptide-specific T cells of choice. Often TCR binding of MHC-peptide multimers is 
used to enrich specific T cell populations which are then cloned by limiting dilution 
and further characterized for specificity. Use of MHC-multimers for selection limits 
the enriched T cells to those specific for the single peptide used to construct the 
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MHC-multimer. Therefore, another goal of this thesis was to develop an 
alternative method to isolate primed T cells via the CD137 activation marker that 
is upregulated upon TCR stimulation. Enriched T cells are then cloned and 
characterized for alloreactivity versus allo-restricted peptide-specific specificity to 
find the TCR with the desired specificity.  
     Following these methodical developments, the next focus of this project was to 
generate TCR-modified lymphocytes and to characterize them in vitro for 
phenotype and function as well as to determine if the “new” tumor specificity was 
transferred via the TCR. This characterization relies on application of the same 
immune monitoring methods used for the characterization of effector cells 
induced by DC vaccines. Further investigations addressed the use of various 
cytokines for expansion of the TCR-transgenic recipient lymphocytes. In 
particular, cytokines like IL-15 and IL-7, which are linked to memory-like 
phenotypes, were used to improve their in vitro function.   
A final intention of these studies was to develop a xenograft mouse model to 
characterize the therapeutic impact of TCR-modified lymphocytes on in vivo 
tumor growth. This consisted of establishing xenograft model systems for solid as 
well as disseminated human tumors based on the same immunodeficient NSG 
mice. NSG mice were first injected with tumor cells and then given adoptive T cell 
therapy with TCR-transgenic lymphocytes. To address the impact on solid tumors 
subcutaneous injection of either a human AML cell line (THP-1) or a human 
melanoma cell line (mel624.38) was performed. To assess control of 
disseminated tumors, as leukemia, intravenous injection of luciferase tagged 
THP-1 cells was performed and resulted in a leukemia-like disease. Finally, in 
subsequent adoptive transfer experiments, an HMMR-specific TCR expressed in 
different effector cell phenotypes was used to assess their role in retarding 
outgrowth of both solid or disseminated tumor cells.  
 
 	  	  	   	  	  	  	   	  
Discussion 
___________________________________________________________________ 	  
29 
3 Discussion  
3.1 Dendritic cell-based vaccine  
DC-based vaccines represent potent activators of the immune system and 
thereby exhibit the capacity to induce an antitumor immunity. For this purpose 
DC must carry optimal stimulatory properties comprising high levels of pMHC 
ligands, a positive costimulatory profile and a cytokine-profile conducive for 
antitumor immune responses. In addition, a good migratory capacity and a 
distinctive capacity for antigen-processing contribute to a potent induction of the 
immune system.  
 
3.1.1 Improvement of ex vivo-generated dendritic cells 
One part of this doctoral thesis comprised the optimization of ex vivo generated 
DC, to induce potent antitumor immunity. Although the commonly used DC-
maturation cocktail (hereafter 4C), containing IL-1β, tumor necroses factor-α 
(TNF-α), prostaglandin E2 (PGE2) and IL-6, results in fully mDC, those DC fail to 
induce potent Th1-directed immune responses (Jonuleit et al. 1997). Several 
studies in mice have demonstrated that TLR agonist-induced DC activation 
results in Th1-polarizing DC, and recent reports have described the expression of 
all known TLR on human myeloid-derived DC (Toubi et al. 2004; Napolitani et al. 
2005; Schreibelt et al. 2010). Therefore, multiple studies focusing on the 
activation of human DC via TLR agonists, as well as the resulting biological 
differences, were initiated (Jurk et al. 2002; Mailliard et al. 2004; Banchereau et 
al. 2005; Gautier et al. 2005; Gorden et al. 2005; Philbin et al. 2007; Zobywalski 
et al. 2007). In particular, recently published observations described that DC 
matured in the presence of a synthetic TLR7/8 agonist (R848) showed elevated 
secretion of IL-12(p70), resulting in an enhanced Th1-driven immune response 
(Zobywalski et al. 2007). The basic cocktail combination, comprising IL-1β, TNF-
α, IFN-γ, PGE2 and poly(I:C) - a TLR3 ligand mimicking double-stranded RNA 
(hereafter 5C) was combined with the TLR7/8 agonist R848 (hereafter 5C+R848) 
(Roelofs et al. 2005). 
This work focused on the comparison of R848 and CL075, two quinoline-like 
molecules that interact with TLR7/8 and thereby result in a DC activation signal. 
The impact of different maturation cocktails were assessed using a 3-day-
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generation protocol for DC, which will be discussed below. The different 
maturation cocktails used in this work are summarized in Table 1.  
 
Table 1. Composition of cocktails used for DC maturation 
 
Cocktail  
Inflammatory 
cytokines/interferons 
Other  
additives TLR-ligands 
Used DC 
protocol Published 
      
4C TNF-α, IL-1β, IL-6 PGE2  
7d-DC 
3d-DC 
Jonuleit 1997 
Bürdek 2010 
5C TNF-α, IL-1β, IFN-γ PGE2 poly I:C 3d-DC Spranger 2010 
5C + R848 TNF-α, IL-1β, IFN-γ PGE2 poly I:C, R848 
7d-DC 
3d-DC 
Zobywalski 2005 
Spranger 2010 
  5C + CL075 TNF-α, IL-1β, IFN-γ PGE2 poly I:C, CL075 3d-DC Spranger 2010 
      
Modified from (Spranger et al. 2010). 
 
Initial analyses focused on the maturation status, assessed by typical surface 
markers on differently matured DC. Comparisons were made to cocktail 4C as 
the standard maturation protocol widely used for clinical studies. All compositions 
indicated in Table 1, induced equal expression of the typical DC maturation 
markers CD83, CD86 and HLA-DR. Furthermore, the different maturation stimuli 
did not alter migratory capacity, a very important feature of activated DC to foster 
entry into secondary lymphoid organs (Martin-Fontecha et al. 2009). However, 
DC matured with cocktails containing a TLR7/8 agonist (R848 or CL075) resulted 
in an elevated amount of secreted IL-12(p70), while the amount of secreted IL-10 
was not affected. Cocktail 5C, which contains only poly(I:C) as a TLR3 agonist, 
failed to elevate levels of bioactive IL-12(p70) to a similar extent. The biological 
active variant of IL-12 is a key modulator for the induction of NK cells, as well as 
for Th1-driven T cell responses, while IL-10 is related to Th2-mediated immunity 
(Karimi et al. 2008; Pallandre et al. 2008).  
To confirm this assumption, studies were performed focusing on innate and 
adaptive immunity. First, the impact of differently matured DC on the NK cell-
activation status was assessed. Recent studies have revealed that DC-NK cell 
interactions display a central role in the induction of a potent antitumor immunity 
(Adam et al. 2005). Consistent with the elevated levels of IL-12(p70), DC 
matured with TLR7/8-containing cocktails showed an increased ability to activate 
NK cells, measured via IFN-γ secretion, CD69 expression and specific target cell 
lysis. In contrast, DC matured with cocktails 4C or 5C failed to activate NK cells. 
Second, the ability of mDC to induce CD4+ Th1 cells as well as antigen-specific 
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CD8+ CTL was determined. By implication, TLR7/8-matured DC resulted in an 
elevated percentage of IFN-γ positive T cells, suggesting a Th1-mediated 
immunity (Zhou et al. 2009). Furthermore, only DC matured using TLR7/8 
agonists were able to induce antigen-specific CTL, resulting in specific lysis of 
antigen positive target cells, while 4C and 5C matured DC were not able to 
induce comparable responses.  
Besides the cytokine profile, the composition of positive and negative 
costimulatory molecules, expressed by mDC, is important for T cell activation. 
Observations that TLR7/8-matured DC showed enhanced levels of the positive 
costimulatory molecule B7.1 (CD80) was consistent with an enhanced immune 
response, as discussed previously. Unexpectedly, B7-H1 (CD274), a molecule 
with primarily inhibitory characteristics, also showed slightly elevated expression 
levels when compared to the conventional 4C-matured DC (Keir et al. 2008). 
Several reports claim that the balance between stimulatory and inhibitory signals 
needs to be shifted towards a positive signal to induce potent T cell immunity 
(Pentcheva-Hoang et al. 2007). Therefore, it is very likely that TLR7/8-matured 
DC convey improved costimulation through this profile, compared to 4C-matured 
DC.  
A more dramatic shift of the costimulatory profile could be observed when DC 
generated over different time periods were compared. Standard protocols for 
generation of peripheral blood-derived DC rely on a 7-day generation protocol, 
resulting in fully differentiated mDC (also called 7d-DC). Several studies 
attempted to reduce the generation time for mDC and demonstrated that these 
so-called “fast-DC” were superior in the induction of immune responses when 
compared to the 7d-matured DC (Dauer et al. 2003; Dauer et al. 2005). Minor 
modifications of this “fast-DC” protocol resulted in a 3-day protocol to generate 
so-called “young/3d-DC” ((Frankenberger et al. 2011) and Figure 5).  
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Morphological comparisons of 7d- and 3d-DC revealed that 3d-DC were 
smaller in size, lower in granularity and, by trend, more robust. Analysis of 
surface molecules, marking the stage of maturation, did not result in significant 
differences between both protocols, whereas differences in the expression of the 
costimulatory molecules B7.1 (CD80) and B7-H1 (CD247) were striking. The 
observation that 7d-DC expressed higher levels of B7-H1 compared to B7.1, 
whereas 3d-DC showed higher expression of B7.1 than B7-H1, would suggest an 
enhanced costimulatory profile of 3d-DC. Indeed, functional assays 
demonstrated that 3d-DC generated better antigen-specific immune responses 
compared to 7d-DC. Improved antigen processing and presentation were 
determined as additional features that resulted in the enhanced immune 
response induced by 3d-DC.  
Taken together, TLR7/8-matured 3d-DC showed superior characteristics in the 
induction of innate as well as antigen-specific Th1-mediated T cell responses.  
 
3.1.2 Vaccination of humanized mice using matured dendritic cells 
So far a solid in vivo model system for the comparison of differently matured 
human DC has not been reported. Therefore, a major aspect of this work was to 
establish an in vivo mouse model for validation of ex vivo generated human DC.  
Several humanized mouse models and methods to generate humanized mice 
have been published (Shultz et al. 2007). Most models rely on NOD/scid mouse 
strains, which contain additional mutations in the common-gamma-chain of the 
IL-2 receptor gene. This mutation can either be a truncated mutation in the case 
of so-called NOG mice or a null mutation in NSG mice (Ito et al. 2002; Ishikawa 
Fig. 5: Timeschedule for 
generation of 7d- and 
3d-DC.  
(Spranger, published in 
(Frankenberger et al. 
2011)).  
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et al. 2005). Both strains are characterized by a similar phenotype, lacking T 
cells, B cells and NK cells. Therefore, these mouse strains are optimal hosts for 
xenograft-transplantation. While transplantation models using human cord blood 
stem cells for repopulation result in an extremely low GvHD (graft versus host 
disease), models relying on the transplantation of peripheral blood lymphocytes 
(PBL) show higher rates of meanwhile severe GvHD (Shultz et al. 2007). 
Transplantation of stem cells entails other disadvantages, including a non-
human-based selection process in the thymus, which potentially result in an 
abnormal TCR repertoire. Thus, attempts are made to express human MHC 
molecules as transgenes in mice for a more appropriate selection process 
(Shultz et al. 2010). 
The engraftment of PBL emerged as an adequate system for this study, due to 
the difficulties in obtaining cord blood stem cells in combination with monocytes 
for DC generation from the same healthy donor. In the first experiment, two 
different protocols were compared for the engraftment of human PBL in NSG 
mice. The more “passive” protocol used a lower cell number (1x106) in 
combination with a low irradiation dose of 100 cGy, while the more “aggressive” 
method utilized a 10-fold higher cell dose (10x106). The engraftment process 
lasted for 9 weeks or 4 weeks, respectively, and included two vaccinations with 
ex vivo generated human mDC of an autologous donor. While several mice 
treated with the “passive” 9-week protocol suffered from severe GvHD, all mice 
treated with the “aggressive”, 4-week protocol stayed healthy throughout the 
procedure of vaccination.  
Consequently, the 4-week engraftment protocol was used for DC vaccination 
experiments to compare the in vivo impact of 7d-DC and 3d-DC matured with 4C 
cocktail to that of 3d-DC matured with a TLR7/8 agonist containing cocktail 
(5C+R848). Using an allogeneic model system, re-isolated splenocytes of mice 
vaccinated with 3d-DC resulted in an enhanced killing capacity of positive target 
cells. In addition, vaccination with DC matured using 5C+R848 showed increased 
levels of specific lysis after re-isolation. Those observations could be confirmed 
in an autologous setting using MART-1/Melan-A as a model antigen. Multimer-
staining revealed that only 3d-DC had the capacity to induce detectable immune 
responses. Moreover, re-isolated human T cells of mice, vaccinated with 
5C+R848 matured DC, showed elevated antigen-specific lysis of target cells, 
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when compared to mice immunized with 4C-matured DC. However, not all 
vaccinated mice showed a T cell-mediated immune response and conclusions 
between engraftment efficacy and percentage of CD8+ T cells could not be 
drawn. This effect, observed for individual mice, can be explained by a 
presumably short survival period of DC in combination with a failure of entry into 
the lymph node in time. In clinical vaccination protocols, multiple applications of 
DC near lymph nodes may reduce this risk of failure.  
Nevertheless, this in vivo model system encompasses the key features 
required for an adequate pre-clinical model system to validate and, in particular, 
to compare in vivo effects of differently generated DC-based vaccines. 
 
3.2 Adoptive T cell transfer 
While the application of DC-based vaccines represents an active strategy to 
induce antitumor immunity, the adoptive T cell transfer (ATT) is characterized by 
a passive transfer of antitumor reactive cells. Several studies have shown the 
efficacy of adoptively transferred T cell in mouse models as well as in clinical 
studies (Rosenberg et al. 2008). Compared to other immunotherapeutic 
approaches, ATT still lags in development due to a difficult and laborious 
preparation of the therapeutic agents in large numbers, as well as in availability 
of high-affinity TCR.  
 
3.2.1 In vitro generation of antigen-specific T lymphocytes 
The generation of T cells with high-affinity TCR, specific for TAA is up to now a 
critical bottleneck for the ATT approach using TCR-modified lymphocytes. 
Several studies, using patient-derived T cells or TIL-derived TCR resulted in poor 
clinical benefit, probably due to low-affinity TCR (Johnson et al. 2009). Reports 
have shown that TCR, derived from autologous cells, recognizing TAA derived 
from self antigens, are of low affinity to self-peptide/self-MHC ligands, while 
efficient tumor cell recognition involves high-affinity TCR (de Visser et al. 2001; 
Johnson et al. 2006). Theoretically, the induction of antigen-specific T cells, using 
foreign pMHC ligands, results in T cells with a presumably higher functional 
avidity (Rammensee et al. 1984). Recent studies have shown improved tumor 
recognition by T cells generated using allogeneic priming approaches (Morris et 
al. 2006; Schuster et al. 2007). Due to the excellent priming capacity of DC, 
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discussed above, as well as their capacity to process and present whole 
proteins, we established a semi-allogeneic priming approach, utilizing mDC as 
stimulators (Nair et al. 1999). Application of DC from an HLA-A2 negative donor, 
pulsed with ivt-RNA encoding the antigen of choice as well as HLA-A2, allows 
presentation of self-protein fragments on a foreign MHC molecules. This results 
in antigen-specific T cells carrying TCR with presumably higher functional avidity. 
Table 2 summarizes priming results for the TAA tyrosinase, survivin and HMMR. 
While tyrosinase is a well-described antigen to target melanoma, survivin and 
HMMR are potential targets for the treatment of AML (Ambrosini et al. 1997; 
Rhodes et al. 2004; Schmid et al. 2006; Slingluff et al. 2006; Mita et al. 2008). 
Both AML-associated antigens that are over-expressed in multiple types of 
cancer have been described and consequently several antitumor vaccination 
studies targeting these antigens, have proven their safety (Greiner et al. 2002; 
Altieri 2003; Pisarev et al. 2003; Greiner et al. 2005; Casini et al. 2010). Survivin 
is also ranked in a recently published NIH-list, which proposed suitable antigen 
candidates for adoptive T cell transfer, whereas HMMR was not included 
(Cheever et al. 2009).  
 
Table 2. Composition of priming approaches tyrosinase, survivin and 
HMMR 
   Number of clones with (%)  
 
Antigen 
 
Setting 
Method of        
  sorting 
No 
reactivity 
Allo-
reactivity 
Antigen-
specific 
reactivity Published 
tyrosinase autologous multimer 21 (55) 0 (0) 17 (45) Wilde 2009 
tyrosinase allogeneic multimer 8 (16) 27 (53) 16 (31) Wilde 2009 
survivin autologous multimer 46 (100) 0 (0) 0 (0) Leisegang 2010 
survivin allogeneic multimer 9 (12) 44 (60) 21 (28) Leisegang 2010 
HMMR allogeneic CD137 35 (23) 38 (25) 78 (52) Spranger (manuscript) 
       
   
 
 The approaches for tyrosinase as well as for survivin mainly focused on the 
comparison of autologous and allogeneic priming. Supporting our contention, 
autologous-derived, tyrosinase-specific T cell clones resulted in lower functional 
avidity and poor antitumor recognition compared to allogeneically primed T cell 
clones. In contrast to the priming using tyrosinase, no survivin-specific T cell 
clones were obtained using the autologous priming approach, while the 
allogeneic setting repeatedly resulted in antigen-specific T cell clones with high 
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functional avidities. Possible reasons leading to the failure to isolate autologously 
primed, surivivin-specific T cell clones are discussed below. In addition to the 
increased functional aviditiy, T cells generated following an allogeneic setting 
show a higher proportion of T cell clones with a polyfunctional phenotype 
(unpublished observations from S. Wilde). This polyfunctional phenotype, 
characterized by secretion of multiple cytokines, including IFN-γ, IL-2 and TNF-α, 
is associated with increased recognition of tumor cells and higher functional 
avidity of the attendant TCR.  
While the previously discussed priming approaches for the generation of 
tyrosinase- and survivin-specific T cells used a multimer-dependent step of 
isolation, the activation marker CD137 was utilized to enrich HMMR-specific 
lymphocytes. Several studies have proven the suitability of this CD8+-restricted 
activation marker to eliminate allo-restricted T cells or to enrich antigen-specific T 
cells in an autologous priming (Wehler et al. 2007; Wolfl et al. 2007). This 
approach, theoretically, would allow the isolation of T cells recognizing all 
potential immunogenic epitopes throughout HMMR, while a multimer-dependent 
isolation step would have limited the specificity to a single peptide. Additionally, 
multimer sorting requires the validation of multimers with T cell clones that 
recognize the targeted peptide and are rarely at hand. Comparisons of the 
CD137-mediated enrichment with the multimer-sorted priming approaches 
resulted in a higher percentage (52%) of antigen-specific cells (see Table 2). This 
observation can be explained by the potentially higher number of immunogenic 
epitopes recognized by isolated T cell clones. This assumption is supported by a 
comparable absolute number of isolated, alloreactive T cell clones, indicating 
similar priming efficiency. In addition, analysis of the polyfunctional phenotype of 
HMMR-specific T cell clones revealed similar patterns compared to other priming 
approaches (unpublished observations). However, an evident disadvantage of 
this T cell-enrichment method is the laborious identification of targeted epitopes. 
Several approaches, including ivt-RNA-screening libraries or over-lapping 
peptides, are reasonable methods to identify targeted peptides, but require high 
numbers of T cells for the screening assays. Due to limitations in the expansion 
of primary T cell cultures, TCR-gene transfer into recipient lymphocytes is not 
only conceivable for adoptive transfer but also for further in vitro characterization 
of the obtained TCR.  
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3.2.2 Characteristics of TCR-modified lymphocytes 
Since the expansion of primary T cell clones is limited, TCR gene isolation from T 
cell clones with strong evidence for valid tumor recognition represents an 
approach for further TCR characterization in the absence of sufficient T cell 
clones. Optional TCR transfer methods can be either transient, by electroporation 
of ivt-RNA, or stable using retroviral or lentiviral transduction approaches 
(Morgan et al. 2003; Hughes et al. 2005; Zhao et al. 2005; Morgan et al. 2006; 
Qasim et al. 2007; Zhou et al. 2009; Zhao et al. 2010). Since lentiviral 
transduction does not require proliferation of recipient cells for transgene 
integration, this method would allow transfer of naïve T cells without adverse in 
vitro stimulation (Morgan et al. 2006; Qasim et al. 2007). Nevertheless, 
integration of lentiviral transgenes can be mutagenic (Pauwels et al. 2009). In 
contrast, integration of retroviral transgenes requires potent in vitro stimulation to 
induce proliferation of lymphocytes, but is supposed to be less mutagenic 
(Leisegang et al. 2008). In addition to the TCR transfer method, isolated TCR 
genes can be the subject of several modifications. Improved translation of the 
transgenes can be achieved by codon optimization, introducing changes in the 
nucleodide sequence which result in enhanced translation (Scholten et al. 2006). 
In particular, modifications enhancing the likelihood of pairing of introduced TCR 
chains are under intensive investigation. These modifications are necessary, due 
to potential misspairing of the introduced chains with endogenously expressed 
TCR, which potentially causes severe and unpredictable side effects (van der 
Veken et al. 2009). The exchange of human constant regions by their murine 
counterparts resulted in a dramatic increase of pairing of the introduced TCR α- 
and β-chains (Cohen et al. 2006). While this modification can potentially result in 
a xenoreactive response, point mutations enhancing the chain-specific binding, 
have been described not to be immunogenic in humans (Cohen et al. 2006; 
Sommermeyer et al. 2010). Since aspects of this work comprised proliferation-
mediated modulations of the recipient lymphocyte phenotypes as well as 
adoptive transfer into immuno-suppressed mice, usage of retrovirally-transferred 
TCR genes carrying the murine constant regions was adequate and non-
problematic.  
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At first, the TCR-mediated transfer of tumor specificity was evaluated. All 
analyzed and successfully expressed TCR, specific for tyrosinase, survivin and 
HMMR, showed similar patterns of specific tumor-recognition when compared to 
the original T cell clones. Certainly not all TCR could be expressed on the 
surface of lymphocytes. This could be due to a low likelihood of TCR-chain 
pairing or the introduced TCR may be a “weak” competitor to endogenous TCR 
for expression. In particular, competition between the introduced and the 
endogenous TCR for expression on the cell surface is a main parameter, 
impacting on the expression of the introduced TCR (Heemskerk et al. 2007).  
An unexpected observation was made when survivin-specific TCR were 
introduced into recipient lymphocytes. While introduction of survivin-specific TCR 
into lymphocytes of HLA-A2- donors resulted in viable TCR-positive cells with an 
expected tumor recognition pattern, PBL of an HLA-A2+ donor showed 
dramatically increased numbers of apoptotic cells after TCR introduction. Further 
analyses, using activated and non-activated HLA-A2+ lymphocytes as target 
cells, revealed that PBL were specifically recognized and killed off by 
lymphocytes carrying survivin-specific TCR. While other studies report on suicide 
of T cells with high-affinity TCR, the percentage of dead cells detected in 
survivin-specific tgTCR-HLA-A2+ lymphocyte-populations exceeded the amount 
of TCR-positive cells (Molldrem et al. 2003). This observation indicates a 
fratricide-mediated death of tgTCR-negative lymphocytes. Futhermore, T cell 
clones with a designated non-survivin specificity were targeted by survivin-
specific tgTCR-PBL, suggesting general on-target recognition of lymphocytes. 
Referring back to the above-mentioned observation that no autologously primed, 
survivin-specific T cell clones were obtained, even though multimer sorting 
indicated the existence of such T cells. A reasonable explanation for this 
discrepancy supports the contention that fratricide-mediated death occurred in 
emerging HLA-A2+ T cell clones. Altogether these results preclude the usage of 
survivin-specific TCR for TCR gene transfer. Also the usage of survivin for 
antitumor vaccination seems problematic, due to probable limitations in 
proliferation of high-avidity survivin-specific T cells in the draining lymph nodes.  
Analyses of expression levels of other possible targets for immunotherapeutic 
approaches in non-activated and activated PBL on the basis of mRNA 
(messenger RNA) prevalence were performed. These comparisons revealed that 
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survivin is extreme in “x-fold” increase (non-activated vs. activated PBL) and in 
the amount of mRNA levels in activated PBL. Several studies speculated on 
fratricide-mediated limitations in the expansion of p53- and hTERT- (human 
telomerase reverse transcriptase) specific T cells (Kyburz et al. 1993; Chen et al. 
2007). Analyzing the mRNA levels for these potentially fratricide-inducing 
candidate genes, revealed comparably high expression levels in activated PBL, 
as seen for survivin. These observations could explain why clinical approaches 
for induction of antitumor immunity utilizing these proteins have failed in the past 
(Liu et al. 2007; Theoret et al. 2008). Although the expression level of HMMR in 
activated PBL is comparable to that of survivin, transfer of HMMR-specific TCR 
into HLA-A2+ PBL did not induce fratricide (unpublished observations). Feasible 
reasons could be founded in different protein localization or differences in protein 
degradation. While survivin is an anti-apoptotic protein, located in the cytosol and 
characterized by a fast turnover, HMMR is localized at the inner-surface of the 
cellular membrane. Cellular functions of this protein are still not completely 
resolved, though co-localization with ERK (extracellular signal-regulated kinase) 
as well as a transforming potential in fibroblasts have been observed (Jiang et al. 
2010). Therefore, further analysis of the expression profile on the basis of protein 
localization, protein turnover as well as protein processing and presentation are 
needed, to make a more precise prediction of the suitability of various proteins as 
targets for immunotherapy. Nevertheless, a final proof will only be possible when 
target-specific TCR are available for specific analysis.  
Since TCR150, targeting HMMR, evolved to be a suitable candidate for further 
analysis, expression of TCR150 in varying phenotypes of recipient lymphocytes 
was assessed in in vitro assays. Several studies are focusing on the phenotype 
of recipient cells that is optimal for adoptive T cell transfer (Hinrichs et al. 2009b; 
Klebanoff et al. 2009; Lin et al. 2009; Wang et al. 2011; Yang et al. 2011). While 
some mouse models revealed a Tc17-phenotype as potentially best suited for in 
vivo tumor recognition, consistent with published observations, Tc17-induced 
cells did not lyse tumor cells in vitro (Hinrichs et al. 2009b; Garcia-Hernandez 
Mde et al. 2010). In contrast to other analyzed culture conditions, tumor cell 
stimulation of Tc17 cells resulted in a significantly higher production of IFN-γ and 
TNF-α. Reports focusing on the in vitro characterization of killing capacity and 
cytokine production, comparing naïve T cells to TEM and TCM, proposed that a 
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memory-like T cell phenotype is favorable (Boyman et al. 2009; Lin et al. 2009; 
Neeson et al. 2010). Within the memory-like T cell phenotype, the capacities of 
TEM and TCM to recognize and retard tumor are still discussed controversially 
(Klebanoff et al. 2009; Mitchell et al. 2010; Berger et al. 2011; Wang et al. 2011; 
Yang et al. 2011). While TEM are mainly characterized by a rapid antigen-specific 
reaction in vitro as well as in vivo, TCM are distinguished by a particular long 
survival in vivo. Depending on the method of generation (isolation or induction) 
as well as the applied test system, TEM reveal favorable properties or TCM are 
superior in tumor retardation. The comparison of an IL-7-induced TCM-phenotype 
to an IL-15-mediated TEM phenotype, resulted in a dramatically increased in vitro 
tumor recognition by the TEM phenotype. These results indicate that TCR 
expression in combination with an IL-15-induced TEM phenotype has favorable 
properties for adoptive transfer of genetically-modified lymphocytes, at least in 
this test system.  
 
3.2.3 Adoptive transfer of TCR-modified lymphocytes 
To assess the use of TCR-modified human lymphocytes in an in vivo setting, 
xenograft-tumor transplantation models needed to be established. For this 
purpose, NSG mice were utilized due to their optimal immuno-suppressed status 
to engraft xeno-transplants, as discussed above. Initial adoptive transfer 
experiments targeted a solid tumor of the AML cell line THP-1 (HLA-A2+, 
HMMR+) generated using matrigel, while the final goal of this work was to 
validate HMMR-specific TCR150-modified lymphocytes for their benefit in 
targeting THP-1 as a disseminated tumor.  
 Adoptive transfer of a single dose of TCR150-modified lymphocytes (2x105) 
prepared in the presence of IL-2, resulted in a significantly reduced tumor 
outgrowth, when compared to mock-treated lymphocytes. Consistent with other 
publications, transferred lymphocytes were only detectable in mice for 
approximately three weeks after transfer (Wang et al. 2011). Additional adoptive 
transfer experiments using increased numbers of TCR-positive lymphocytes 
(5x105) did not result in further benefit. Nevertheless, T cell infiltrates were only 
detected in isolated tumors of mice treated with TCR150-transduced 
lymphocytes, while tumors of mice treated with mock-PBL or transduced with an 
irrelevant TCR, did not show such infiltrates. This observation indicated a TCR-
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mediated antigen-specific infiltration, but further investigations are needed to 
resolve the abortive tumor elimination. Multiple molecular mechanisms inducing 
T cell anergy or exhaustion are possible. Those mechanisms could include 
expression of inhibitory molecules (e.g. PD-1), soluble inhibitory factors (e.g. 
IDO) or numerous combinations of other immunosuppressive mechanisms 
(Gajewski et al. 2006). Another obstacle in the treatment of tumor cell lines used 
in this study is their prominent capacity to rapidly grow in mice, compared to 
other xenograft systems or even syngeneic murine tumor models (Klebanoff et 
al. 2005; Distler et al. 2008; Carpenito et al. 2009; Hinrichs et al. 2009b; Wang et 
al. 2011).  
To improve the persistence of transferred lymphocytes, adoptive transfer 
experiments were performed using differently induced phenotypes, described 
above. These experiments were performed employing a THP-1 as well as a 
melanoma cell line (mel624.38; HLA-A2+, HMMR+) as targets for TCR150-
modified lymphocytes. While the persistence of lymphocytes was not altered by 
the different phenotypes, tumor outgrowth was dramatically retarded when TEM or 
TCM phenotypes were transferred. In particular, the TEM-mediated effect was in 
concordance with the in vitro results discussed above. These observations are 
consistent with other studies using non-human primate or mouse model systems 
that revealed similar results using memory-like phenotypes for adoptive transfer 
(Berger et al. 2011; Wang et al. 2011). When both tumor cell lines were analyzed 
for growth retardation, the melanoma cell line was significantly more retarded in 
tumor outgrowth compared to THP-1. Possible reasons may include a different 
impact of the tumor microenvironment inhibiting TCR-positive lymphocytes to a 
different extent or due to variations in the immunogenicity of the cell lines. 
Further investigations are needed to resolve these discrepancies.   
Significant improvement could not be observed when conventional IL-2-treated 
lymphocytes were compared to Tc17-cultured lymphocytes. The discrepancy 
with published antitumor effects may be explained by the lack of an endogenous 
immune system in the NSG mouse model (Hinrichs et al. 2009a; Hinrichs et al. 
2009b; Garcia-Hernandez Mde et al. 2010). It is likely that the cytokine-producing 
Tc17 cells impact indirectly on the tumor cells, via activation of other 
compartments of the immune system. To bring these observations in line with 
other xenograft model systems, discrepancies may by due to shorter observation 
Discussion 
___________________________________________________________________ 
42 
periods, usage of higher cell doses or inadequate preincubation of effector and 
target cells (Klebanoff et al. 2005; Distler et al. 2008; Carpenito et al. 2009; 
Hinrichs et al. 2009b; Wang et al. 2011). Therefore, the results described here 
clearly demonstrate a potent antitumor effect, although all therapeutic 
approaches failed to eradicate solid tumors completely.  
Since reports postulate that administration of IL-15 over time would prolong 
the persistence of human lymphocytes in NSG mice, daily administration of IL-15 
was compared with two doses of DC vaccination (Wang et al. 2011). While 
vaccination with autologous DC did not result in a further deceleration of tumor 
outgrowth, IL-15 application resulted in a slight improvement of the rejection of 
the THP-1-mediated tumor. In contrast, tumor growth of mel624.38 appeared to 
increase. This may indicate that IL-15 is a growth factor for this cell line. 
Alternatively, infiltrations of TCR-modified cells may falsely appear as tumor 
growth (unpublished observations).  
To determine the potential impact of adoptively transferred lymphocytes on 
disseminated tumor, we utilized a bioluminescent non-invasive in vivo imaging 
method, developed by Dr. I. Jeremias (unpublished data). This method allows a 
precise and sensitive detection of luciferase-tagged tumor cells in living mice. 
Accordingly to the results discussed above, transfer of HMMR-specific TCR150-
modified TEM lymphocytes (4x105/mouse) led to significant retarded tumor 
growth, when compared to PBL transduced with an irrelevant TCR. 
Administration of IL-15 under these tumor conditions resulted in a slight 
enhancement of growth deceleration. More dramatic results could be observed 
when transfer of CD8-enriched TCR-positive T cells was combined with IL-15-
administrations. This combination of therapeutic agents resulted in a complete 
remission of the tumor, indicting that CD8+ effector memory T cells in 
combination with IL-15 have a prominent potential to retard leukemia expansion 
in this model.   
These results are of outstanding significance since other xenograft studies 
targeting disseminated human tumors, used increased cell doses for adoptive 
transfer (up to 1x107 lymphocytes) (Zhao et al. 2010). Comparison of per 
kilogram cell doses used in the experiments discussed above (4x105 cells 
/mouse (à 20g); equivalent to approx. 5x107 cells/kg) to doses applied in clinical 
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trials (1x109 to 1x1011) reveals that a minimum 2-log lesser cell dose was still 
sufficient to retard tumor outgrowth in this mouse model (Rosenberg et al. 2008).  
In conclusion, TCR150, targeting HMMR, was revealed to be a potent 
candidate for TCR gene-transfer into lymphocytes. In particular, when introduced 
in recipient cells with an IL-15-induced memory-like phenotype, TCR150 
demonstrated a promising antitumor effect in the NSG mouse model established 
in this project.  
 
3.3 Outlook 
Regarding future improvements of in vivo model systems for the evaluation of 
human DC-based vaccines, the utilization of an HLA-expressing mouse model 
would be of outstanding interest (Shultz et al. 2010). Such strains would likely 
enable the use of human hematopoetic stem cells for the reconstitution of mice, 
followed by autologous DC vaccination. Thereby, it is likely that GvHD effects 
can be reduced and multiple applications of DC, comparable to clinical settings, 
would be feasible. In addition, the NSG mouse model displays a helpful tool for 
resolving the importance of various administration routes for DC vaccines. 
Therefore, the induced immune responses following intravenous application, 
used in this study, could be compared to those induced after intradermal or 
intranodal injection, commonly used in clinical settings.  
A clear challenge of the CD137-mediated enrichment of antigen-specific T 
cells is their epitope identification. Since identification of the targeted peptide 
sequences for TCR150, as well as all other HMMR-specific T cell clones, has not 
yet proceeded, identification of those peptides entails one crucial component of 
future investigations. In particular, identification of the targeted epitopes by the 
other HMMR-specific T cell clones would probably reveal new and predominantly 
immunogenic epitopes within HMMR. Besides the selection of an appropriate 
source of peptide (e.g. ivt-RNA fragments, long overlapping peptides, nonamers), 
the screening cells create a major hindrance in solving this problem. Up to now, 
no HMMR-negative cell line with suitable properties for peptide loading has been 
found. As an alternative method artificial APC can be applied but the missing 
capacity for peptide-processing would dramatically limit the number of peptides 
screened.  
Discussion 
___________________________________________________________________ 
44 
As an additional interest, the differences between survivin and HMMR on the 
protein-level require further studies. First experiments using confocal microscopy 
revealed both antigens in activated PBL, but disclosed differences in the cellular 
distribution as well as the distribution throughout the cell population (data not 
shown). Moreover, preliminary in vivo killing experiments have pointed out that 
HMMR-specific as well as survivin-specific tgTCR-lymphocytes do not eliminate 
activated HLA-A2+ PBL in vivo. Additional optimization, for instance in 
combination with a peptide-specific vaccination strategy to induce clonal in vivo 
proliferation, is required to reinforce these observations.  
An unexpected aspect of this studie was found in the differences in tumor 
outgrowth of THP-1 and mel624.38 after adoptive transfer of TEM tgTCR150 
lymphocytes. Due to the many possible factors or factor combinations impacting 
on the transferred lymphocytes, several experiments for revealing potential 
differences between the tumor cells are required to resolve the discrepancy. 
These analyses should be related to the tumor microenvironment, expression of 
inhibitory molecules or other T cell inhibitory factors. Additionally, the 
identification of an induced “inhibited” T cell phenotype (e.g. anergic T cells, 
regulatory T cells) would give insight into the inhibitory mechanisms and should 
therefore be investigated in more detail. Nevertheless, these observations could 
be of high impact for the prediction of the clinical outcome of ATT therapy.   
Recent observations in clinical studies indicated a beneficial use of multiple 
TCR, targeting more than one antigen (Zhou et al. 2005). To solve this 
controversy the impact of either individually applied or combined therapy using 
HMMR- and tyrosinase-specific tgTCR-PBL can be assessed in the established 
xenograft melanoma mouse model.  
Besides stable TCR-gene transfer, transient TCR expression via ivt-RNA 
represents a feasible technology for in vitro analysis of TCR functionality and 
avidity. In particular high-through-put screening assays, as required for the 
epitope screening of the HMMR-specific T cell clones, are potential in vitro 
applications. The transient TCR expression could provide a safety mechanism in 
the ATT approach. As a first therapeutic step of engineered lymphocytes, the 
transfer of transient TCR expressing lymphocytes is under consideration. This 
approach would allow a first insight into possible autoimmune reactions as well 
as intended antitumor effects, without persistence of TCR expression in patients. 
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Therefore, by using the NSG in vivo model system, comparisons of transiently 
TCR expressing lymphocytes to stable TCR expressing cells could be 
addressed. Since the use of particularly non-activated T cell phenotypes (e.g. ex 
vivo use of sorted TCM) or clonal T cell populations (e.g. antiviral specific T cells) 
are under consideration (Stauss et al. 2008; Heslop et al. 2010). However, so far 
no adequate system has been able to assess these differences in detail. 
Transient TCR expression in T cell clones with a single specificity can limit the 
cross-reactivity and would allow a precise comparison of varying TCR using the 
same recipient cells. Furthermore, the introduction of TCR into varying 
phenotypes with minimal alterations of the native cells can be enabled by the 
usage of ivt-RNA for TCR gene transfer. These experiments could reveal insights 
into T cell biology and resolve the question of most suitable T cell phenotypes to 
retard tumors in vivo.    
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Generation of Th1-Polarizing Dendritic Cells Using the
TLR7/8 Agonist CL075
Stefani Spranger,*,1 Miran Javorovic,*,†,1 Maja Bu¨rdek,* Susanne Wilde,*
Barbara Mosetter,* Stefanie Tippmer,*,† Iris Bigalke,*,† Christiane Geiger,*
Dolores J. Schendel,*,‡,1 and Bernhard Frankenberger*,1
In this paper, we describe a new method for preparation of human dendritic cells (DCs) that secrete bioactive IL-12(p70) using
synthetic immunostimulatory compounds as TLR7/8 agonists. Monocyte-derived DCs were generated using a procedure that pro-
vided mature cells within 3 d. Several maturation mixtures that contained various cytokines, IFN-g, different TLR agonists, and
PGE2 were compared for impact on cell recovery, phenotype, cytokine secretion, migration, and lymphocyte activation. Mixtures
that included the TLR7/8 agonists R848 or CL075, combined with the TLR3 agonist polyinosinic:polycytidylic acid, yielded
3-d mature DCs that secreted high levels of IL-12(p70), showed strong chemotaxis to CCR7 ligands, and had a positive costimu-
latory potential. They also had excellent capacity to activate NK cells, effectively polarized CD4+ and CD8+ T cells to secrete
IFN-g and to induce T cell-mediated cytotoxic function. Thereby, mature DCs prepared within 3 d using such maturation
mixtures displayed optimal functions required for vaccine development. The Journal of Immunology, 2010, 185: 000–000.
D
endritic cells (DCs) are potent adjuvants for the induction
of tumor-specific helper and killer cells in cancer patients
(1, 2). DCs are the most important activators of naive
cells during development of T cell-mediated immunity. Cancer
immunotherapies using DC vaccination now preferably apply ma-
ture DCs (mDCs) loaded with tumor-associated Ags, which are
injected near or directly into lymph nodes where they interact with
naive T cells, thereby fostering activation and differentiation of
CD8+ CTLs. In addition, DCs can regulate cytokine polarization
of T cells, and some mDCs can activate NK cells, which contrib-
ute to innate immune responses that help to orchestrate long-term
Ag-specific memory T cell responses (3–6).
Various methods have been developed for preparation of mDCs
starting from PBMCs or other myeloid progenitor cells. The most
common method generates mDCs from monocytes over a period of
7 d (7). An alternative procedure allows mDCs to be produced
within 2 d (8–10). Monocytes can be isolated either from PBMCs
through plastic adherence, by isolation of CD14+ cells with mAbs,
or by using leukapheresis and elutriation. Isolated monocytes are
cultured in vitro with GM-CSF and IL-4 or IL-13 to produce
immature DCs (iDCs) (11–13). Thereafter, several alternatives
can be used to obtain mDCs, each of which yields cells with
somewhat different properties that must be clearly specified for
DC-based vaccine development. Jonuleit et al. (7) described a mat-
uration mixture containing TNF-a, IL-1b, IL-6, and PGE2 (here-
after designated as the four-component mixture [4C]) that
produced 7-d DCs with surface markers characteristic for mDCs,
and these cells could be easily recovered in sufficient numbers for
clinical application. This type of mDC has been used frequently in
early-phase clinical trials of DC vaccination in patients with var-
ious forms of malignancies. However, these mDCs do not produce
bioactive IL-12(p70), which is a critical cytokine for the induction
of Th1 cells and activation of NK cells.
Elegant studies in mice demonstrated that activation of TLR sig-
naling cascades could produce mDCs with Th1-polarizing capacity
(14). Human DC subsets express all known human TLRs, with the
most diverse expression pattern in monocyte-derived DCs and mye-
loid DCs (15). On the basis of these observations, a number of studies
explored the use of different TLR agonists to modulate DC function,
particularly with respect to cytokine secretion profiles (14, 16–25).
We previously described DCs that were matured in a 7-d proto-
col using a mixture that included the imidazoquinoline-like mole-
cule R848 as a TLR7/8 agonist (26). The resultant 7-d mDCs
produced substantial amounts of IL-12(p70) and displayed pheno-
typic and functional characteristics desired for clinical application,
including high cell recoveries. However, the 7-d culture period in
a good manufacturing practice facility is a strong hindrance for
clinical development. Therefore, we investigated approaches to
rapidly produce monocyte-derived mDCs that would display suit-
able characteristics for efficient use in vaccine development. The
studies reported in this paper show that maturation mixtures con-
taining the synthetic thiazoloquinoline immunostimulatory com-
pound CL075, or R848, as a TLR7/8 agonist, when combined
with polyinosinic:polycytidylic acid [poly(I:C)] as a TLR3 ligand,
yielded mDCs within 3 d that showed excellent profiles with re-
spect to recovery, phenotype, cytokine secretion, and migration, as
well as capacity to activate NK cells and CD8+ CTLs and to
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effectively polarize CD4+ and CD8+ T cells to secrete IFN-g.
Thereby, these 3-d mDCs are highly suited for development of
DC-based antipathogen or antitumor vaccines.
Materials and Methods
Leukapheresis and elutriation
We used a closed system of elutriation (ELUTRA; Gambro BCT, Lake-
wood, CO) to obtain monocytes as progenitor cells for generation of iDCs, as
described previously (26). In accordancewith the Declaration of Helsinki and
after approval by the Institutional Review Board of the Technical University
(Munich, Germany), healthy donors underwent 180min of leukapheresis with
the COBE Spectra cell separator (Gambro BCT, Hechingen, Germany) with
a modifiedMNC program (V6.1): separation factor was set to 700 with a col-
lection rate of 0.8 ml/min and a target hematocrit of only 1–2%. Resulting
blood cells were analyzed by automatic blood counter (ACT Dif; Beckman
Coulter, Krefeld, Germany) to set up conditions for the ELUTRA system.
Leukapheresis products were processed according to the manufacturer’s in-
structions by amethod of counterflowcentrifugal elutriation using a fixed rotor
speed (2400 rpm) and computer-controlled stepwise adjustment of media flow
rate, followed by rotor-off harvesting. Five liters of running buffer consisting of
RPMI 1640 medium with very low endotoxin (hereafter RPMI-VLE) (Bio-
chrom, Berlin, Germany) with 1.5% human serum (pool of AB-positive adult
males) (Institute of Transfusion Medicine, Suhl, Germany) was used for cell
separation. This process resulted in five fractions with enriched monocytes
present in the rotor-off fraction. The cellular composition of individual fractions
was characterized by automatic cell counting and flow cytometry.
Generation of mDCs from elutriated monocytes
Cells from the rotor-off fraction, subsequently designated as fraction 5, were
frozen in aliquots of 5 3 107 monocytes in freezing medium consisting of
human serum albumin (20% human serum albumin solution; Octalbine,
Octapharma, Langen, Germany), 20% DMSO (Merck, Darmstadt, Ger-
many), and 10% glucose (Braun, Melsungen, Germany). Monocytes were
thawed and washed with endotoxin-free PBS (Biochrom) at 1500 rpm for
10 min. Cells were resuspended and seeded at 4.5 3 107 per “nuncleon-
surface” flask (80 cm2) (Nunc, Wiesbaden, Germany) in 15 ml DC medium
containing RPMI-VLE and 1.5% human serum and cultivated for 50 min at
37˚C and 5% CO2 in a humidified atmosphere. Afterward, cells were
washed twice with RPMI-VLE, and 15 ml DC medium was added. On
day 0, cultures were supplemented with 100 ng/ml GM-CSF (Leukine;
Berlex, Richmond, VA) and 20 ng/ml recombinant human IL-4 (R&D
Systems, Wiesbaden, Germany) in 3 ml fresh DC medium per flask. Full
DC maturation was achieved by addition of various mixtures on day 2 (see
Table I). The components for the maturation mixtures were as follows:
TNF-a, IL-1b, and IL-6 (R&D Systems); poly(I:C), R848, and CL075
(InvivoGen, San Diego, CA); IFN-g (Boehringer Ingelheim, Ingelheim,
Germany); and PGE2 (Sigma-Aldrich, Deisenhofen, Germany). For the
induction of mDCs with a tolerogenic phenotype, rIL-10 (R&D Systems)
was added with a final concentration of 83.33 ng/ml. After incubation of
iDCs with maturation mixtures for 24 h, cells were harvested by washing
twice with PBS plus 0.5% human serum with light shaking and assessed
directly or cryopreserved as described above for fraction 5 monocytes.
Surface phenotyping of DCs
DCs were labeled with the following fluorescence-conjugated mAbs: CD14
(FITC, clone MFP9), CD86 (FITC, clone 2331 FUN-1), CD80 (PE, clone
L307.4), CD274 (B7-H1, FITC, clone MIH1) (all BD Biosciences, Heidel-
berg,Germany),HLA-DR (PE, cloneB8.12.2), andCD83 (PE, cloneHB15a)
(Immunotech, Marseille, France). CCR7 staining was performed with rat
hybridoma supernatantmedium (BLR-2, clone 8E8; E. Kremmer, Helmholtz
Zentrum Mu¨nchen, Munich, Germany) and compared with a rat hybridoma
isotype control (EBNA-A2, clone R3; E. Kremmer) by incubation of DCs in
culture supernatant for 60 min, followed by washing and detection with
secondary mouse Ab against rat IgG conjugated with cyanin-5 (Jackson
ImmunoResearch Laboratories,West Grove, PA). To test viability, DCswere
pelleted and resuspended for 20 min in 7-aminoactinomycin D (Sigma-
Aldrich) at a final concentration of 10 mg/ml in PBS with 2% FCS. After
washing, cells were analyzed by flow cytometry using FACSCalibur or LSR
II instruments (BD Biosciences). Postacquisition data analysis was per-
formed with FlowJo 8 software (Tree Star, Ashland, OR).
Signal 3 assay of cytokine secretion
mDCs were cocultured with CD40L-expressing cells as a mimic for interac-
tions with activated T cells, as described previously (23). Briefly, mDCs were
seeded in 96-well plates at concentrations of 2 3 104 cells/well and
coincubated with mouse fibroblasts stably transfected with human CD40L
at a concentration of 53 104 cells/well. DCs and CD40L fibroblasts cultured
in medium alone were used to assess cytokine secretion of individual cell
populations. After 24 h, plates were centrifuged, and supernatants of eight
replicate wells were pooled for analysis of IL-10 and IL-12(p70).
Migration assay
After harvesting and washing, mDCs were analyzed in a Transwell mi-
gration assay, as described previously (27). In brief, the lower culture
chamber of a 24-Transwell plate (Costar Corning, Corning, NY) was filled
with 600 ml migration medium, consisting of RPMI-VLE, 500 U/ml GM-
CSF, 250 U/ml IL-4, and 1% human serum, with or without chemokine
CCL19 at 100 ng/ml (R&D Systems). mDCs were seeded in the upper
chamber at 2 3 105 cells/well and incubated for 2 h at 37˚C in 5% CO2 in
a humidified atmosphere. DCs from the upper and lower chambers were
collected and counted using a Neubauer hemocytometer.
NK cell activation
NK cells were enriched from cryopreserved PBMCs using the Dynabeads
Untouched Human NK Cells Kit (Invitrogen, Karlsruhe, Germany),
according to themanufacturer’s instructions.NK cells (13 106)were seeded
in RPMI 1640 medium, supplemented with 200 mM L-glutamine, 100 mM
sodium pyruvate, 104 U/ml penicillin and streptomycin (all Invitrogen), and
10% pooled human serum. NK cells were stimulated with 1 3 105 autolo-
gous mDCs. After 24 h, supernatant was collected and analyzed using an
IFN-g ELISA. Cocultured cells were stained afterward with CD3 (FITC,
clone UCHT1; BD Biosciences), CD56 (allophycocyanin, clone N901;
Immunotech), and CD69 (PE, clone TP1.55.3; Immunotech) Abs to depict
the activated NK cell populations. After washing, cells were analyzed by
flow cytometry using an LSR II instrument (BD Biosciences).
Postacquisition data analysis was done with FlowJo 8 software (Tree Star).
Aliquots of activated NK cells were also cryopreserved and later evaluated
for cytotoxic function.
Activation of allogeneic T lymphocytes
Cryopreserved PBMCs isolated from HLA-A22 donors were cocultured
with allogeneic mDCs prepared from HLA-A2+ donors using 1 3 106
PBMCs and 1 3 105 mDCs in T cell medium (RPMI 1640 medium,
12.5 mM HEPES, 4 mM L-glutamine, and 100 U/ml penicillin and strep-
tomycin, supplemented with 10% pooled human serum). Following 7 d of
coculture, recovered lymphocytes were analyzed by flow cytometry for
intracellular cytokine staining.
Activation of Ag-specific T lymphocytes
mDCs were harvested and pulsed with 1 mg/ml peptide for 120 min at 37˚C
and 5% CO2 in a humidified atmosphere. For Ag-pulsing of DCs, a MART-
1/Melan-A nonamer (ELAGIGILT; Metabion, Martinsried, Germany) as
well as a peptide pool (CEF) comprising peptides of human CMV, EBV,
and influenza A virus (PANATecs, Tuebingen, Germany) were used. Cry-
opreserved PBMCs isolated from HLA-A2+ donors were cocultured with
autologous, peptide-pulsed mDCs using 1 3 106 PBMCs and 1 3 105
mDCs in T cell medium (RPMI 1640 medium, 12.5 mM HEPES, 4 mM
L-glutamine, and 100 U/ml penicillin and streptomycin, supplemented with
10% pooled human serum). Following 7 d of coculture, recovered lym-
phocytes were tested directly for cytotoxic activity. Recovered cells were
also restimulated using the same cryopreserved batch of peptide-pulsed
DCs for 24 h, at which time supernatants were collected for determination of
IFN-g content using a standard ELISA. Background activity in cytotoxic-
ity and secretion assays was determined using non–peptide-pulsed mDCs.
Multimer staining
PBLs obtained after 7 d of coculture with 3-d peptide-pulsed mDCs were
harvested, washed, and stained with MART-1/Melan-A25–36 (ELAGIGILT
peptide)–specific multimer. Control stainings were performed using a CMV
pp65-peptide495–503 multimer (both provided by Prof. Dr. D. Busch, Tec-
hnical University of Munich). Afterward, costaining of surface molecules
was performed as described above using the following Abs: CD3 (PerCP,
clone SK7; BD Biosciences); CD4 (FITC, clone 13B8.2; Immunotech); and
CD8 (allophycocyanin, clone SK1; BD Biosciences). Postacquisition data
analysis was done using FlowJo 8 software (Tree Star).
Intracellular cytokine staining
PBLs activated for 7 d with mDCs were harvested, washed, and stimulated
for 1 h at 37˚C with 1 ng/ml PMA and 250 ng/ml ionomycin (Sigma-
Aldrich). Afterward, brefeldin A (10 mg/ml) and monensin (50 mM) were
added, and the cells were incubated for an additional 4 h. Staining of
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surface molecules was performed as described above using the following
Abs: CD3 (PerCP, clone SK7; BD Biosciences); CD4 (PE, clone 13B8.2;
Immunotech); CD8 (allophycocyanin, clone SK1; BD Biosciences);
CD16 (APC, clone 3G4; Caltag Laboratories, Buckingham, U.K.); and
CD56 (PE, clone N901; Immunotech). Afterward, cells were fixed with
1% paraformaldehyde, washed twice, and permeabilized with 0.1% sa-
ponin solution (Sigma-Aldrich). Cells were incubated with IFN-g–
specific (FITC, clone 25723.11; BD Biosciences) and IL-4–specific
(PE, clone 3010.211; BD Biosciences) Abs in 0.35% saponin solution
in PBS for 20 min at 4˚C. After washing, cells were analyzed by flow
cytometry as described above. Postacquisition data analysis was
performed using FlowJo 8 software (Tree Star).
Cytokine secretion measurement by ELISA and multiplex
technology
Secretion of IL-12(p70) and IL-10 by mDCs in signal 3 assays as well as
secretion of IL-5, IL-13, and IFN-g by activated PBLs were detected by
standard ELISA, using pretested Ab duo sets for detection of IL-5, IL-10,
IL-12(p70), or IFN-g (BD Systems, Heidelberg, Germany) and IL-13
(R&D DuoSet, Wiesbaden, Germany), according to the manufacturer’s
instructions. Colorimetric substrate reaction with tetramethylbenzidine
and H2O2 was measured, after stopping the reaction with H3PO4, at 450
nm and wavelength correction at 620 nm and analyzed with “easy fit”
software (SLT, Crailsheim, Germany). Multiple cytokine and growth factor
secretion in culture supernatants of mDCs were quantified by multiplex
protein arrays (Human Grp I cytokine 17-Plex Panel; Bio-Rad, Hercules,
CA), according to the manufacturer’s instructions. In brief, microspheres
coated with cytokine-specific capture mAbs were incubated for 30 min at
room temperature with 50 ml supernatant medium. After three washing
steps, biotinylated detection mAbs were added and incubated for 30 min at
room temperature, followed by 10 min of incubation with streptavidin-PE.
A two-laser array reader (BioPlex System, Hercules, CA) simultaneously
quantified 17 different cytokines, chemokines, and growth factors. Stan-
dard curves and concentrations were calculated with BioPlex Manager
4.1.1 on basis of the five-parameter logistic plot regression formula.
Cytotoxicity assay
Cytotoxic activity of NK cells and T cells that were preactivated in DC
cocultures was analyzed in a standard 4-h chromium release assay. K562
cells were used as target cells in the NK assays combining 1.5 3 103
target cells and NK cells at E:T cell ratios of 10:1, 5:1, 2.5:1, and
1.25:1. Melanoma cell lines Mel624.38 (HLA-A2+, MART-1/Melan-A+)
and MelA375 (HLA-A2+; MART-1/Melan-A2) (28) were used as target
cells for activated T cells at E:T of 20:1, 10:1, 5:1, or 2.5:1. Specific lysis
was determined as described previously (29). The percentage of specific
lysis was calculated as 100 3 (experimental release 2 spontaneous re-
lease)/(maximum release2 spontaneous release). Spontaneous release was
assessed by incubating target cells in the absence of effector cells and was
generally ,15%.
Western blotting
mDCs were stimulated with the maturation mixture for an additional 2 h,
harvested and washed with PBS, and lysed in lysis buffer (20 mMTris-HCl,
150 mM NaCl [pH 7.4], 150 mM CHAPS, 1 mM PMSF, 1 mM Na3VO4,
1 mM NaF, and 13 Complete). Protein concentration was detected using
the BCA Protein Assay Kit (Pierce Chemical Co., Rockford, IL), accord-
ing to the manufacturer’s instructions. Western blotting was performed
following the instructions of the NuPAGE System (Invitrogen). For spe-
cific phospho-STAT (pSTAT) staining, polyclonal anti-pSTAT Abs were
used (STAT1-pTyr701 and STAT6-pTyr641; Cell Signaling Technologies,
Danvers, MA), b-actin was stained using a polyclonal Ab from Sigma-
Aldrich (A5060), and detection was performed using a polyclonal anti-
rabbit IgG Ab (Cell Signaling Technologies).
Results
mDCs can be efficiently generated in 3 d
Monocytes were obtained by elutriation of leukapheresis products
of healthy donors. These cells were used for the in vitro generation
of iDCs usingGM-CSFand IL-4 in a fast protocol lasting 2 d (8). DC
maturation was induced on day 2, creating different populations of
3-d mDCs, using mixtures summarized in Table I. 4C represented
the well-characterized 4C that did not include any TLR ligands (7).
5C+R848 was used previously to prepare 7-d mDCs (26). It in-
cluded the synthetic ligand R848 (resiquimod), which is an
imidazoquinoline-like molecule that interacts with TLR7/8 recep-
tors. It also included the TLR3 agonist poly(I:C). Poly(I:C) is
known also to bind to the MDA-5 receptor that belongs to the
family of cytosolic helicase pattern recognition receptors (30). It
is accepted that TLR3 detects extracellular viral dsRNA internal-
ized into the endosomes, whereas RIG-I/MDA-5 detects intra-
cellular viral dsRNA (31, 32). The synthetic thiazoloquinoline-
derivative type immune response modifying compound CL075
can also induce signals via TLR7/8 in some cells, but its impact
on DC maturation and function has not been reported to date (16,
17). Therefore, we also assessed this substance for its impact on DC
maturation. However, a few experiments used mixture 5C alone,
which did not include a TLR7/8 agonist but did contain poly(I:C) as
a TLR3 agonist. Mixtures 5C, 5C+R848, and 5C+CL075 also dif-
fered from 4C in the inclusion of IFN-g, the exclusion of IL-6,
and a 4-fold reduction in the concentration of PGE2.
Mixtures induce mature surface marker phenotypes on iDCs
mDCs were prepared from three or four healthy donors, applying
the various maturation mixtures for 24 h. After a total 3-d culture
period, mDCs were recovered from the culture vessels, and percen-
tages of cell recovery were compared. The mDC recoveries ranged
from 7.9 to 9%, and there were no significant differences noted
among the three groups (Supplemental Table I). The three mDC
populations, as well as iDCs from two donors, were then analyzed
by flow cytometry for expression of surface markers that are char-
acteristic for iDCs and mDCs. In addition to determining the per-
centages of positive cells, the levels of surface marker expression
were also compared (Table II). The mDCs displayed the expected
shift to high percentages of cells, expressing substantial levels of
CD80, CD83, and CCR7. There were no substantial differences
noted among the different mixtures with respect to the various
surface markers that were upregulated on the mDCs.
Production of IL-12(p70) is superior by DCs matured using
TLR7/8 agonists and poly(I:C)
Our goal in creating TLR-containing maturation mixtures was to
generate a population of optimized DCs for clinical studies that
could secrete bioactive IL-12(p70) while producing no or only
low levels of IL-10 to obtain cells that would polarize Th cells
in a Th1 direction (14). Furthermore, for vaccine development,
it is important to assure that mDCs retain the capacity to secrete
IL-12(p70) upon encounter with T cells in lymph nodes. This
capacity was assessed in a so-called signal 3 assay, in which
mDCs were cocultured with a murine fibroblast cell line that
expresses human CD40L and thereby mimics an encounter of
mDCs with CD40L+ T cells. Signal 3 assays were performed
with mDC populations that were prepared from multiple inde-
pendent donors. After coculture of 3-d mDCs with CD40L-
expressing fibroblasts for 24 h, amounts of IL-12(p70) and
IL-10 released into the culture medium were determined by stan-
dard ELISA. The results are shown in Fig. 1 as mean values of
IL-12(p70) and IL-10 in picograms per milliliter. The DC4C pop-
ulations secreted only low amounts of IL-12(p70), whereas
DC5C+R848 and DC5C+CL075 produced very high amounts of IL-
12(p70) upon stimulation via CD40, which were significantly
different from those of DC4C. In contrast, the mDC populations
secreted only very low amounts of IL-10, with no significant
differences among the three groups.
mDCs show chemotaxis to CCL19 signals
If mDCs are considered for use in vaccine development it is im-
portant to demonstrate that they have an adequate potential to
migrate to lymph node sites. This is primarily governed by
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expression of the chemokine receptor CCR7, which mediates
a chemotactic response to the chemokines CCL19 and CCL21 that
are expressed in the lymph nodes (33, 34). On the basis of the
assessment of CCR7 phenotype, it was apparent that mDCs pro-
duced with mixtures 5C+R848 and 5C+CL075 were comparable
to those matured with 4C, both with respect to percentages of
positive cells and levels of expression. Although substantial
numbers of cells displayed this critical chemokine receptor, this
does not necessarily equate directly with migratory responses to
CCR7 chemokine signals. Therefore, Transwell migration assays
were used to assess the spontaneous migration of the mDC pop-
ulations, as well as their migratory responses to CCL19 as a che-
moattractant. As illustrated in Fig. 2, low percentages of mDC
populations showed spontaneous migration in the absence of
chemoattractant, but substantially higher percentages of mDCs
showed Transwell chemotaxis to CCL19 chemokine, with an
overall significant difference to spontaneous migration in each
group (p = 0.03). However, there were no significant differences
among the three groups of mDCs.
mDCs prepared using TLR7/8 agonists strongly activate NK
cells
According to phenotype, cytokine secretion, and migratory ca-
pacity, it was clear that CL075 and R848 had comparable impacts
on the development of mDCs. We next addressed the capacity of
DC5C+R848 and DC5C+CL075 to activate various lymphocyte pop-
ulations as compared with DC4C, which have been used most
extensively in clinical studies.
It was expected that mDCs that secrete bioactive IL-12(p70)
would be superior to DC4C populations in the activation of NK
cells. This was clearly demonstrated when enriched NK cells pre-
pared from multiple unrelated donors were incubated for 24 h with
mDCs and analyzed for secretion of IFN-g as one parameter of
NK cell activation. Only low levels of IFN-g were secreted by NK
cells stimulated with DC4C, whereas NK cells released sub-
stantially more IFN-g following contact with DC5C+R848 or
DC5C+CL075 (Fig. 3A).
As a second parameter for NK cell activation, we measured
upregulation of the activation marker CD69 on NK cells after
24-h activation with mDCs. Results of NK cells from one represen-
tative donor are shown in Fig. 3B. NK cells expressing this marker
after exposure to DC4C cells did not differ substantially from NK
cells cultured in medium alone. Strong changes were seen for NK
cells activated with DC5C+R848 or DC5C+CL075, showing substan-
tially increased expression of CD69. Notably, DC5C+R848 and
DC5C+CL075 stimulation had a strong impact on CD69 expression
by both the CD56dim and CD56bright NK cells.
As a third parameter, the killing capacity of activated NK cells
was determined after activation with mDCs for 24 h. Effector cells
were tested in a standard 4-h chromium release assay using the K562
cell line as the target cell. NKcells culturedwithDC4Cdisplayed only
slightly enhanced killing activity at high E:T when compared with
NK cells not exposed to DC stimulation (Fig. 3C). In contrast, NK
cells activated by either DC5C+R848 or DC5C+CL075 showed greater
killing at all E:T compared with NK cells activated with DC4C.
mDCs prepared using TLR7/8 agonists polarize allogeneic
CD4 and CD8 T cells
To analyze the effect on T cell polarization, we stimulated PBMCs
containing mixtures of CD4+ and CD8+ T cells with allogeneic
3-d mDCs generated using either 4C, 5C+R848, or 5C+CL075
mixtures. After 1 wk of T cell-DC coculture, the allostimulated
T cells were harvested, washed, and activated with PMA and
ionomycin for 5 h to induce intracellular cytokine expression.
The lymphocytes were then analyzed by flow cytometry for ex-
pression of CD3, CD4, and CD8 surface markers. In parallel, the
fractions of cells producing IFN-g and IL-4 were determined us-
ing intracellular cytokine staining. PBMCs cultured for the same
time period in the absence of DCs served as a background control
of unstimulated cells.
Table I. Composition of mixtures used for DC maturation
Mixture Population Inflammatory Cytokines/IFNs Other Additives TLR Ligands
4C DC4C TNF-a, IL-1b, IL-6 PGE2
5C DC5C TNF-a, IL-1b, IFN-g PGE2 Poly(I:C)
5C+R848 DC5C+R848 TNF-a, IL-1b, IFN-g PGE2 Poly(I:C), R848
5C+CL075 DC5C+CL075 TNF-a, IL-1b, IFN-g PGE2 Poly(I:C), CL075
The following concentrations were used in the individual mixtures (bold): 4C, 10 ng/ml TNF-a, 10 ng/ml IL-1b, 1000 ng/ml
PGE2, and 15 ng/ml IL-6; 5C, 10 ng/ml TNF-a, 10 ng/ml IL-1b, 250 ng/ml PGE2, 5000 U/ml IFN-g, and 20 ng/ml poly(I:C);
5C+R848, 10 ng/ml TNF-a, 10 ng/ml IL-1b, 250 ng/ml PGE2, 5000 U/ml IFN-g, 20 ng/ml poly(I:C), and 1 mg/ml R848; 5C+
CL075, 10 ng/ml TNF-a, 10 ng/ml IL-1b, 250 ng/ml PGE2, 5000 U/ml IFN-g, 20 ng/ml poly(I:C), and 1 mg/ml CL075.
Table II. Expression of typical DC surface markers
CD14 CD80 CD83 CD86 HLA-DR CCR7
% Positive cells
iDCs 25 ± 5a 29 ± 20 22 ± 3 99 ± 0 100 ± 0 8 ± 0
4Cb 3 ± 0 98 ± 1 95 ± 4 100 ± 0 98 ± 4 75 ± 2
5C+R848 3 ± 1 99 ± 0 97 ± 1 98 ± 3 77 ± 24c 72 ± 6
5C+CL075 3 ± 1 99 ± 0 97 ± 1 98 ± 3 95 ± 8 83 ± 2
MFIs
iDCs 19 ± 0d 16 ± 2 14 ± 1 144 ± 31 497 ± 124 25 ± 7
4C 20 ± 6 76 ± 12 86 ± 28 760 ± 107 732 ± 203 56 ± 8
5C+R848 14 ± 5 143 ± 33 61 ± 19 946 ± 286 542 ± 151 48 ± 10
5C+CL075 12 ± 2 144 ± 25 48 ± 5 842 ± 369 496 ± 158 58 ± 6
aData represent mean percentages of positive-stained cells ± SEs for three to four independent donors.
bDCs matured in mixtures shown in Table I.
cSignificant differences between 5C+R848 and 5C+CL075.
dData represent MFIs ± SEs for three to four independent donors.
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In a representative example, ∼6% of CD4+ T cells cultured in
medium alone were positive for IFN-g, and 1.5% expressed
IL-4 (Fig. 4A). These values increased to ∼25% of CD4+ T cells
with IFN-g and 6.5% with IL-4 after activation for 1 wk with
DC4C cells. In contrast, around twice as many CD4+ T cells
expressed IFN-g after coculture with DC5C+R848 or DC5C+CL075,
whereas CD4+ T cells producing IL-4 remained at the background
levels of unstimulated PBMCs. Similar effects were seen on po-
larization of CD8+ T cells, with higher percentages of cells pro-
ducing IFN-g (Fig. 4B), without alterations in percentages of
IL-4–stained cells (data not shown), following coculture with
DC5C+R848 or DC5C+CL075, as compared with DC4C.
IL-5 and IL-13 represent additional Th2 cytokines of impor-
tance. To determine the amount of IL-5 and IL-13 secreted by cells
cultured for 7 d with allogeneic mDCs, we restimulated CD4-
enriched T cells or PBLs for 24 h with allogeneic PBMCs. The
levels of cytokines secreted into the supernatant medium were an-
alyzed using standard ELISA. Neither T cells activated with DC4C
nor T cells stimulated with DC5C+R848 or DC5C+CL075 secreted
appreciable amounts of IL-5 and IL-13 (data not shown).
DCs matured with TLR7/8 agonists prime better Ag-specific
T cell responses
The capacity of DCs to prime naive CD8+ cells to specific Ags is of
particular importance for development of efficient antitumor
immune responses. To address this capacity of mDC populations,
we cocultured PBLs from HLA-Ap0201 donors for 1 wk with
autologous mDCs that were pulsed with the ELA-peptide epitope
of the MART-1/Melan-A Ag, which is a tumor-associated protein
that is overexpressed by a large number of melanomas. In addi-
tion, the capacity of the mDCs to reactivate antiviral immune
responses was assessed using the CEF pool of HLA-A2–
restricted peptides from three common viruses that re-
present immunodominant epitopes to which many adult healthy
donors show immune reactivity. After the 7-d stimulation phase,
PBLs were restimulated for 24 h using peptide-pulsed DCs as well
as unpulsed mDCs of the same origin to detect background
FIGURE 2. Migratory capacity of mDCs to CCR7 ligands. Depicted are
data of five independent Transwell migration assays using CCL19 as
a chemoattractant for DC4C, DC5C+R848, or DC5C+CL075. Pore size of the
membrane was 5 mm; chemokine concentration of CCL19 was 100 ng/ml.
Shown are mean values with SEM on a log10 scale. Statistical analyses
were performed using the Mann-Whitney U test.
FIGURE 1. Cytokine secretion assessed by a signal 3 assay. DC pop-
ulations were matured using the 3-d protocol. Independent experiments
were performed with a number of n = 4–6 donors for DC4C, DC5C+R848,
or DC5C+CL075, respectively. CD40L-transfected mouse fibroblasts were
used as stimulators for mDCs, mimicking the encounter with T cells that
express CD40L. Supernatants were collected after 24 h of coculture. Cyto-
kines were measured by standard ELISA. Shown are the mean values with
minimum and maximum values (on a log10 scale) of IL-12(p70) and IL-10
detected in the supernatant. Significance was ascertained using the two-
tailed Mann-Whitney U test.
FIGURE 3. Activation of NK cells by mDCs. NK cells were prepared
from several unrelated donors and incubated for 24 h with washed DCs
that were matured in mixtures 4C, 5C+R848, and 5C+CL075. A, Secretion
of IFN-g was quantified by a standard ELISA and shown as individual
values on a log10 scale (4C, 5C+CL075: n = 7; 5C+R848: n = 4; line
represents mean value; Mann-Whitney U test was applied for statistical
analyses). B, Cocultured cells were stained for CD3, CD56, and CD69
expression. Depicted is a representative specific staining of CD56 versus
CD69 of the CD32 population (n = 4). C, Cytotoxic activity of NK cells
assessed in a standard 4-h chromium release assay against K562 target
cells at the varying effector to target cell ratios indicated on the x-axis.
Data are derived using cells from two independent donors and shown as
mean with SEM.
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activation. PBLs stimulated with ELA- or CEF-pulsed mDC5C+CL075
secreted noticeably higher amounts of IFN-g compared with PBLs
cocultured with peptide-pulsed mDC4C (data not shown).
To assess the killing capacity of T cells primed with different
mDC populations, PBLs were cocultured with ELA-pulsed mDCs
for 7–10 d. Staining with a MART-1/Melan-A26–35 multimer was
performed on day 10. In a representative example, nonstimulated
CD8+ cells contained 0.3% multimer-positive T cells, which
were not increased by coculture with DC4C (Fig. 4C). In contrast,
the multimer-positive fraction increased through coculture with
DC5C+R848 or DC5C+CL075 to 1.7 and 2.4%, respectively, clearly
demonstrating the superior capacity of DCs matured with these
mixtures to induce Ag-specific CTLs.
Primed CTLs were analyzed in a standard 4-h chromium release
assay using MelA624.38 (HLA-A2+ and MART-1/Melan-A+) and
MelA375 (HLA-A2+ and MART-1/Melan-A2) as target cells.
CTL primed with peptide-pulsed DC4C showed cytotoxic acti-
vity somewhat greater than effector cells cultured without any
DCs, whereas CTLs primed with peptide-pulsed DC5C+R848 or
DC5C+CL075 showed substantially greater cytotoxic activity, which
was specific for melanoma cells coexpressing MART-1/Melan-A
and HLA-A2 (Fig. 4D).
DCs matured using 5C+CL075 display a prominent positive
costimulatory profile and STAT1 activation
In addition to IL-12(p70) secretion, we observed several other dif-
ferences between DC4C and DC5C+CL075 that may impact on lym-
phocyte activation and function. For example, differences were
found with respect to expression of the positive costimulatory
molecule CD80 (B7.1) versus the negative costimulatory molecule
CD274 (B7-H1). A preponderance of CD80 compared with
CD274 seems to be important for transmission of positive costi-
mulatory signals to T cells. Fig. 5A shows mean fluorescence in-
tensity (MFI) values of CD80 and CD274 on DCs matured using
mixtures 4C or 5C+CL075, with or without addition of IL-10.
Expression of CD80 was highest on DC5C+CL075 and significantly
different to DC4C. DC5C+CL075+IL-10 was generated by addition of
IL-10 to the maturation mixture as a tolerogenic control. Treat-
ment with IL-10 has been shown to reduce the stimulatory capac-
ity of DCs, resulting in anergized T cells (35, 36). IL-10–
stimulated DCs showed a reciprocal relationship of CD80 to
CD274, with lower CD80 and higher CD274 expression. Similar
observations were made with DC5C+R848 (data not shown).
On a molecular level, STAT molecules are important tran-
scription factors in the downstream signaling pathways of TLRs
and IFN-gRs. DCs matured with 4C and 5C+CL075 were assessed
for the activation status of the STAT proteins 1 (pTyr701), 2
(pTyr690), 3 (pSer727 and pTyr705), 5 (pTyr694), and 6 (pTyr641).
STAT1, STAT3, and STAT6 were found to be activated in the
mDCs based on their phosphorylation status (data not shown),
but differences between DC4C and DC5C+CL075 were only found
for STAT1 and STAT6 (Fig. 5B). DC5C+CL075 displayed strongly
increased STAT1 phosphorylation that was only marginal in DC4C.
Activation of STAT1 has been demonstrated previously for DCs
matured in mixtures containing R848 (24).
DCs matured with a TLR3 agonist are inferior to those matured
with TLR3 and TLR7/8 signals
Clearly mDCs prepared using a combination of TLR3 and
TLR7/8 agonistswere superior toDCsmaturedwithmixture 4C that
lacked TLR signaling capacity. However, the impact of the TLR3
signal alone was not clear. Therefore, comparisons of DC5C and
DC5C+CL075 were made to ascertain the role of TLR3 stimulation in
the absence of TLR7/8 activation (Fig. 6). Mixture 5C induced
a maturation phenotype similar to 5C+CL075, albeit with some-
what lower levels of CD80, CD83, and CCR7 (Fig. 6A). DC5C
secreted high levels of bioactive IL-12(p70) in signal 3 assays that
were comparable to DC5C+CL075 and substantially greater than
DC4C (Fig. 6B). Coculture of NK cells with DC4C and DC5C for
24 h yielded comparable percentages of activated NK cells express-
ing CD69, but these were less than half the value obtained through
activation by DC5C+CL075 (Fig. 6C). Furthermore, secretion of
FIGURE 4. Activation of T cells by mDCs.
PBMCs from HLA-A22 donors were stimulated
with mDCs derived from an HLA-A2+ donor for
7 d. After 5 h of stimulation with PMA and
ionomycin, intracellular IFN-g and IL-4 were
analyzed using flow cytometry. A, Shown is
a representative example of gated CD4+ cells
with double staining of intracellular IFN-g and
IL-4. B, IFN-g–positive cells are depicted as
percentages of CD4+ cells (gray) and CD8+
cells (black), respectively. Shown are mean
values with SEM; significance was analyzed
using an ANOVA test in combination with a
Bonferroni posttest (pp , 0.01; ppp , 0.001;
each compared with unstimulated control or
compared with CD8+ T cells stimulated with
DC4C). C, Autologous PBLs of HLA-A2+
donors were stimulated with MART-1/Melan-A
(ELA-) peptide-pulsed mDCs for 7–10 d, fol-
lowed by a staining with a MART-1/Melan-A
multimer and CD8-specific Ab on day 10. D,
Killing was assessed on day 7 in a standard
4 h chromium-release assay using Mel624.38
(HLA-A2+, MART-1/Melan-A+) and MelA375
(HLA-A2+, MART-1/Melan-A2) tumor cell
lines as positive and negative target cells,
respectively. Shown are two independent
donors as mean values with SEM.
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IFN-g by T cells primed and restimulated with mDCs was much less
for DC4C and DC5C compared with DC5C+CL075 (Fig. 6D). Killing
capacity of MART-1/Melan-A–specific CTL primed over 7 d was
comparable for peptide-pulsed DC4C and DC5C and somewhat
greater than T cells cultured in the absence of mDC. In contrast,
T cells stimulated with peptide-pulsed DC5C+CL075 displayed much
higher levels of killing of tumor cells coexpressing MART-1/
Melan-A and HLA-A2 (Fig. 6E). These results demonstrated that
DCs matured using only TLR3 signals were functionally inferior in
activation of both NK cells and T cells to DCs matured using the
combination of TLR3 and TLR7/8 agonists.
Discussion
In DC-based vaccination, mDCs are essential to induce effective
immune responses; therefore, the first generation vaccine trials that
applied iDCs may not have achieved adequate in vivo maturation to
allow induction of optimal immune responses. The second gener-
ation of vaccines using mDCs provided cells that were more pro-
ficient at delivering signal 1 to T cells through abundant MHC class
I and class II expression and were capable of delivering signal 2
through an improved expression of costimulatory molecules, but
they did not express a cytokine profile that would foster induction
of optimal antitumor responses. The discovery that TLR signaling
in murine DCs could activate the NF-kB pathway opened the door
for inclusion of synthetic TLR agonists in maturation mixtures to
modulate the cytokine profile of mDCs (37).
AvarietyofTLRsare expressedbyhumanmonocyte-derivedDCs
(38). Signaling through different TLRs, including TLR3, TLR7,
and TLR8, also causes activation of the NF-kB pathway in
human cells, with subsequent induction of several immuno-
modulatory genes (14, 24, 25). This leads to production of cyto-
kines and chemokines, such as TNF-a, IFN-g, IL-6, IL-10, IL-12,
and MIP-1a, in various cell types (16, 17). The availability of
synthetic ligands for several TLRs, including imiquimod (R837),
resiquimod (R848), S-27609, CL097, CL075 (3M-002), CL087, or
loxoribone, has enabled the impact of TLR activation to be assessed
in various cell types (18, 22). On the basis of these observations,
mixtures containing various synthetic TLR agonists have been used
to prepare human mDCs. Mailliard et al. (23) described a matura-
tion mixture composed of TNF-a, IL-1b, IFN-a, IFN-g, and the
TLR3 agonist poly(I:C), which enhanced the production of
bioactive IL-12(p70) in 7-d mDCs but gave only low cell yields.
This could be a limiting factor in obtaining sufficient numbers of
mDCs for clinical studies if vaccination protocols do not entail
direct intralymphatic injection (clinical trial ID UPCI 03-118;
http://clinicaltrials.gov/ct2/show/NCT00390338) but rely instead
on migration of a small proportion of mDCs to neighboring lymph
nodes after s.c. or intradermal injection (39, 40). An alternative
approach included only the TLR7/8 ligand resiquimod (R848) for
stimulation of iDCs; however, this yielded DCs lacking several
phenotypic characteristics of fully mature DCs desired for clinical
use (41). Dauer et al. (10) recently incorporated TLR4 and
TLR7/8 ligands in their maturation mixture to obtain 2-d mDCs
secreting bioactive IL-12(p70). This study revealed that TLR
ligands enhanced IL-12(p70) secretion in mDCs as well as stimu-
latory capacity; however, the maturation status and migratory ca-
pacity were lower than mDCs produced with mixture 4C.
We previously described DC maturation mixtures including
R848 and poly(I:C) as respective agonists for TLR7/8 and TLR3, in
combination with additional cytokines within a 7-d-protocol (26).
CL075 is a synthetic small molecule thiazoloquinoline immuno-
stimulatory compound that is a preferential activator of TLR8,
resulting in downstream activation of NK-kB and other trans-
cription factors. It is also involved in transcriptional activation
of numerous genes encoding cytokines, chemokines, and costimu-
latory molecules (17). So far, the impact of CL075 on DC matu-
ration has not been reported. We found in this study that mDCs
prepared with maturation mixtures using CL075 displayed pheno-
types and functions suitable for antitumor vaccine development.
Comparison of mDCs prepared without TLR agonists versus
those stimulated with TLR3 [poly(I:C)], alone or in combination
with TLR7/8 agonists (R848/CL075), revealed that all populations
of mDCs were similar with respect to percentages of positive cells
expressing costimulatory molecules. Some variations in HLA-DR
and CCR7 were noted and mixture 5C+CL075 provided the highest
percentages of mDCs expressing these two molecules. The good
expression of CCR7 was paralleled by a strong spontaneous migra-
tory capacity of the mDCs as well as positive chemotactic re-
sponses to CCL19 chemokine signals.
As expected, TLR signaling altered the cytokine secretion profile
of mDCs, leading to high production of bioactive IL-12(p70). DCs
prepared with mixtures including only a TLR3 signal or in com-
bination with a TLR7/8 agonist induced high levels of IL-12
(p70) secretion in signal 3 assays that mimic DC encounters with
T cells. These findings are supported by a study of Larange` et al.
(42), which demonstrated that signaling through TLR8 had a high
impact on secretion of IL-12(p70).
The modulated cytokine profile of mDCs achieved through
combined TLR3 and TLR7/8 signaling had a strong impact on
functional activation of NK cells, as seen by upregulation of CD69
on both CD56dim and CD56bright NK cell subpopulations, as well
as on the levels of IFN-g secretion and killing capacity by NK
cells after a 24-h exposure to mDCs. A recent study also showed
that IL-12(p70) secreted by DCs influences NK activation, in
FIGURE 5. Costimulatory profile and STAT activation in mDCs. mDCs
were generated with the 3-d-protocol. A, Shown is the expression level of
the costimulatory molecules CD80 and CD274 (B7-H1) detected by flow
cytometry as mean values of six individual experiments (three independent
donors) with SEM. As a tolerogenic control, mDCs were prepared using 10
ng/ml IL-10 incorporated into mixture 5C+CL075. Statistical analysis was
performed using an ANOVA test in combination with a Bonferroni post-
test. B, Shown is a Western blot stained for pSTAT1 and pSTAT6; b-actin
was stained as a control. Exposure times were 3 min, 30 s, and 3 s for 4C,
5C+CL075, and b-actin staining, respectively.
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particular IFN-g secretion, in a cell-contact–dependent manner
(6), as also found in our studies. Thus, DCs matured with 5C+
CL075 or R848 should support innate responses that can lead to
direct killing of tumor cells by activated CD56dim NK cells as well
as through the capacity of CD56bright NK cells to support devel-
opment of adaptive immune responses by cytokine and chemokine
secretion (43).
TLR7/8 signaling with CL075 or R848 had a positive impact on
the ability of CD4+ and CD8+ T cells to produce IFN-g. Although
some CD4+ and CD8+ allogeneic T cells were polarized to Th1
and Th2 cells using DC4C cells, substantially higher percentages
of IFN-g–polarized T cells were obtained using TLR-activated
mDCs. In addition, these mDCs were able to induce greater num-
bers of CTLs that displayed specific killing capacity for tumor
cells. We also observed that the levels of CD80 were significantly
higher on DC5C+CL075 compared with DC4C, whereas levels of
CD274 were not significantly different. Therefore, it would be
expected that such TLR-activated mDCs would have a superior
capacity for T cell activation. This is in accordance with recent
findings by Selenko-Gebauer et al. (44), who nicely showed that
the expression levels of positive costimulatory molecules pre-
vailed over low expression of inhibitory molecules in T cell acti-
vation, whereas a reverse profile resulted in poor T cell
stimulation. In addition, they postulated that inhibitory molecules
had a greater influence when the overall expression of costimula-
tory molecules was low.
The molecular mechanisms responsible for these phenotypic and
functional differences in DCs matured by 4C and 5C+CL075 were
indicated by the strong differences in STAT1 activation. In par-
ticular, pSTAT1-Tyr701 was strongly increased in DC5C+CL075
compared with DC4C. This activation is known to result in an
altered expression profile of downstream STAT1-dependent genes,
including cytokines and costimulatory molecules (42, 45). Phos-
phorylated STAT1 can bind to an IFN-g–activated sequence or an
IFN-stimulated response element in DNA. In both cases, this leads
to increased expression of IFN-stimulated genes (46). Moreover,
IFN-stimulated response element binding sites are present in the
promoter regions of CD80 and CD274 (47, 48), likely explaining
FIGURE 6. Comparison of TLR3 and TLR3 with TLR7/8 agonists for DC maturation. A, Depicted is a representative surface staining of CD80, CD83,
and CCR7 on DCs matured with mixture 5C (open histograms) and 5C+CL075 (dark gray histograms). Unstained controls are shown in light gray. MFI
values are indicated within the histograms. Data are representative for two independent donors (n = 2). B, Signal 3 assays were performed with n = 2–6
donors for DC4C, DC5C, or DC5C+CL075. Assays were performed as described in Fig. 1, and supernatant media were collected after 24 h of coculture with
CD40L-expressing fibroblasts. Cytokines were measured by standard ELISA. Shown are the mean values with minimum and maximum values (on a log10
scale) of IL-12(p70) and IL-10. C, NK cells of two individual donors were cocultured with mDCs for 24 h. Activated NK cells were stained for CD3, CD56,
and CD69 expression. Depicted is specific staining of CD56 versus CD69 of the CD32 population (n = 2). D, Autologous PBLs were stimulated with
MART-1/Melan-A (ELA-) peptide-pulsed mDCs for 7 d, followed by specific restimulation for 24 h using peptide-pulsed mDCs. Unpulsed mDCs were
used to measure background responses. The amount of secreted IFN-g was assessed by a standard ELISA and corrected by subtraction of background
values of T cells stimulated with unpulsed mDCs. Shown are two independent donors as mean values with SEM. E, Autologous PBLs were stimulated with
MART-1/Melan-A (ELA-) peptide-pulsed mDCs for 7 d, and killing was assessed in a standard 4-h chromium release assay using Mel624.38 (HLA-A2+,
MART-1/Melan-A+) and MelA375 (HLA-A2+, MART-1/Melan-A2) tumor cell lines as positive and negative target cells, respectively. Shown are two
independent donors as mean values with SEM.
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the significantly enhanced expression of these molecules on DCs
matured with 5C+CL075. Others found that phosphorylation of
STAT1 was induced in DCs by the TLR7/8 agonist R848 and that
decreased IL-12(p70), CD40, and CD83 expression was seen fol-
lowing inhibition of the STAT1 signaling pathway in studies using
7-d mDCs (24, 42).
Altogether, maturation mixtures including CL075 or R848 as
TLR7/8 agonists, together with a TLR3 agonist, allowed mDCs to
be produced in 3 d that had superior characteristics, when compared
with DCs matured in the absence of TLR signals or activated by
only a TLR3 signal. The production of mDCs in 3 d rather than 7 d
provides a great cost reduction for DC vaccine generation, because
cell cultures must not be resupplemented with cytokines during the
short culture period. Furthermore, occupancy time of clean room
facilities is greatly reduced. This allows rapid generation of mDCs
that can be used for development of antipathogen and antitumor
vaccines.
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Abstract
Background: Antigen-loaded dendritic cells (DC) are capable of priming naïve T cells and therefore represent an
attractive adjuvant for vaccine development in anti-tumor immunotherapy. Numerous protocols have been
described to date using different maturation cocktails and time periods for the induction of mature DC (mDC)
in vitro. For clinical application, the use of mDC that can be generated in only three days saves on the costs of
cytokines needed for large scale vaccine cell production and provides a method to produce cells within a standard
work-week schedule in a GMP facility.
Methods: In this study, we addressed the properties of antigen uptake, processing and presentation by monocyte-
derived DC prepared in three days (3d mDC) compared with conventional DC prepared in seven days (7d mDC),
which represent the most common form of DC used for vaccines to date.
Results: Although they showed a reduced capacity for spontaneous antigen uptake, 3d mDC displayed higher
capacity for stimulation of T cells after loading with an extended synthetic peptide that requires processing for
MHC binding, indicating they were more efficient at antigen processing than 7d DC. We found, however, that 3d
DC were less efficient at expressing protein after introduction of in vitro transcribed (ivt)RNA by electroporation,
based on published procedures. This deficit was overcome by altering electroporation parameters, which led to
improved protein expression and capacity for T cell stimulation using low amounts of ivtRNA.
Conclusions: This new procedure allows 3d mDC to replace 7d mDC for use in DC-based vaccines that utilize
long peptides, proteins or ivtRNA as sources of specific antigen.
Background
The benefit of dendritic cells (DC) as adjuvants to
induce tumor-specific cytotoxic T cells as well as helper
T cells has been demonstrated in animal experiments
and initial human trials [1,2]. In different tumor vac-
cines that were successfully applied in mice, mature DC
(mDC) were used that were loaded with tumor antigens,
supplied in various forms, including tumor extracts,
short peptides or antigen-encoding RNA [3,4]. Several
clinical trials using DC as tumor-vaccines have also
been performed, where an increased T cell response
against tumor-associated antigens could be observed [5].
DC are the most potent antigen-presenting cells for
the stimulation of naïve T cells [6]. Immature DC (iDC)
patrol peripheral tissues and take up antigens via macro-
pinocytosis, phagocytosis or receptor-mediated endocy-
tosis. After uptake of antigen, iDC process and present
antigen-derived peptides on their MHC molecules. Since
DC have the ability for cross-presentation, exogenous
antigens can be presented on MHC-II as well as on
MHC-I molecules [7]. Presentation of antigens by iDC
leads to T cell anergy, deletion of T cells or the induc-
tion of IL-10-secreting T regulatory cells [8,9]. Following
antigen uptake, iDC convert to a mature phenotype,
characterized by the upregulation of different cell sur-
face molecules, such as CD40, CD80 and CD83 [10].
These mDC also show higher expression of the chemo-
kine-receptor CCR7, which plays an important role for
DC homing to lymph nodes [11]. Upon arrival in the
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lymph nodes, antigen-loaded mDC are able to prime
naïve T cells, which then exit the lymph nodes after
antigen-encounter. The primed effector T cells can
recognize and eliminate specific target cells in the
periphery.
Different protocols for the generation of DC have
been described to date. In vitro, DC can be developed
from CD34+ precursor cells or CD14+ monocytes
[10,12]. Monocytes can be enriched from peripheral
blood mononuclear cells (PBMC) via plate adherence,
by the use of anti-CD14 antibodies or by elutriation of
leukapheresis products. iDC are usually induced by sti-
mulation with GM-CSF and IL-4 [13,14]. It has also
been shown that IL-4 could be replaced by IL-15, lead-
ing to the differentiation of monocytes into cells with
properties of Langerhans cells [15-17]. Furthermore, DC
can also be induced in the presence of IFN-b and IL-3
[18,19]. The induction of mDC can be initiated by sev-
eral different stimuli, including microbial components
(e.g. LPS as a Toll-like receptor 4 ligand), proinflamma-
tory cytokines, viral-like stimuli [e.g. poly (I:C)] or
T cell-derived molecules (e.g. CD40L) [16,18,20-24].
Depending on the composition of the maturation cock-
tails, mDC show different stimulatory and polarizing
capacities on naïve T cells.
Most protocols for the generation of mDC require
approximately one week of cell culture. As such, Jonuleit
and colleagues induced mDC on day five to six of a
seven-day culture period by adding a four-component
maturation cocktail (hereafter 4C cocktail), containing
TNF-a, IL-1b, IL-6 and PGE2 [22], that is commonly
used for the induction of DC maturation. It has been
shown that mDC could also be generated within two
days [25,26]. These “fast DC” were generally able to
prime naïve T cells or stimulate effector cells [25,27,28].
The faster development of mDC may better reflect the
situation in vivo [29].
In this study, we performed a systematic comparison
of 3d and 7d mDC in terms of phenotype, chemokine-
directed migration, antigen uptake and subsequent sti-
mulation of cytotoxic T lymphocytes (CTL) after incu-
bation with exogenous peptides or loading with antigen
via electroporation. Because different forms of antigen
are considered for use in DC-based vaccine develop-
ment, it was important to demonstrate that mDC pre-
pared in a three-day protocol would have antigen
processing capacity comparable to the well known prop-
erties of 7d mDC.
Materials and methods
Peptides, antibodies and reagents
The short MART-1/Melan-A26-35 peptide (ELAGI-
GILTV) (purchased from Metabion, Martinsried,
Germany) and the long MART-1/Melan-A peptide
(GSGHWDFAWPWGSGLAGIGILTV) (purchased from
Biosyntan, Berlin, Germany) were reconstituted in 50%
DMSO containing water at a concentration of 1 mg/ml
and 20 mg/ml, respectively. Further dilutions were
performed in medium. Monoclonal antibodies specific
for DC surface molecules were directly labelled and
purchased from Becton Dickinson (Heidelberg,
Germany). The unlabelled CCR7 (clone 2H4) antibody
(Becton Dickinson) and the MART-1/Melan-A antibody
(clone A103; Dako Cytomation, Hamburg, Germany)
were detected with the additional use of secondary
antibodies [Cy5-coupled F(ab’)2-antibody (Dianova,
Hamburg, Germany) and biotinylated F(ab’)2-antibody
(Becton Dickinson)] and streptavidin-PE (Dianova).
FITC-dextran from Sigma-Aldrich (Deisenhofen,
Germany) and CCL19 from R&D Systems (Wiesbaden,
Germany) were used. IL-1b, IL-4, IL-6 and TNF-a were
purchased from R&D Systems, IL-2 from Chiron Behr-
ing (Marburg, Germany), GM-CSF (Leukine®) from
Berlex (Seattle, USA) and PGE2 from Sigma-Aldrich.
Tumor cell lines and CTL
The melanoma cell lines Mel-93.04A12 (HLA-A2+,
Melan-A+; gift from P. Schrier, Department of Immuno-
hematology, Leiden University Hospital, Leiden, the
Netherlands), Mel A375 (HLA-A2+, Melan-A-; CRL-
1619; ATCC) and SK-Mel-29 (HLA-A2+; gift from T.
Wölfel, Third Department of Medicine, Hematology and
Oncology, Johannes Gutenberg University of Mainz,
Mainz, Germany) were cultured in RPMI 1640 medium
supplemented with 10% fetal calf serum, 2 mM L-gluta-
mine, 1 mM sodium pyruvate and non-essential amino
acids. AK-EBV-B cells (gift from T. Wölfel) were cul-
tured in RPMI 1640, containing 10% fetal calf serum.
The HLA-A2-restricted, MART-1/Melan-A26-35 specific
CTL A42 (gift from M. C. Panelli, National Institutes of
Health, Bethesda, MD) were cultured in RPMI 1640
supplemented with 10% human serum (Lonza, Walkers-
ville, USA), 2 mM L-glutamin, 1 mM sodium pyruvate,
100 IU penicillin/streptomycin, 0.5 μg/ml mycoplasma
removal agent (MP Biomedicals, Eschwege, Germany)
and 125 IU/ml IL-2. 5 × 105 CTL were restimulated
every two weeks using 1 × 105 SK-Mel 29 and 2 × 105
AK-EBV-B (both irradiated with 100 Gy) in 1.5 ml A42
CTL medium per well of a 24-well plate. On the day of
restimulation, 500 IU/ml IL-2 were added to the culture.
A42 CTL were used for coculture experiments 8 days
after restimulation.
Generation and culture of 3d DC and 7d DC
Monocytes were enriched from heparinized blood by
Ficoll density gradient centrifugation and subsequent
plate adherence or from a leukapheresis product via elu-
triation, as described previously [30]. For freezing of
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multiple aliquots, 2-4 × 107 monocytes per ampule were
resuspended in VLE (very low endotoxin) RPMI supple-
mented with 5% human serum albumin (20% Octalbin®,
Octapharma, Langenfeld, Germany) and mixed 1:1 with
freezing medium, containing VLE RPMI, 10% human
serum albumin and 20% DMSO. After thawing, 15 ×
106 monocytes were plated in a Nunclon™flask (80 cm2;
Nunc, Wiesbaden, Germany) in VLE RPMI medium
supplemented with 1.5% human serum. For inducing
the development of 2d iDC, 20 ng/ml IL-4 and 100 ng/
ml GM-CSF were added to the medium immediately
after plating the monocytes. On day two, 2d iDC could
be harvested for study. For maturation, the 2d iDC were
cultured with the four component cocktail, containing
10 ng/ml IL-1b, 15 ng/ml IL-6, 10 ng/ml TNF-a and
1000 ng/ml PGE2 in addition to 100 ng/ml GM-CSF
and 20 ng/ml IL-4 [22]. After 24 h, the 3d mDC were
harvested for study. To generate 7d DC, the culture
medium was supplemented with 20 ng/ml IL-4 and 100
ng/ml GM-CSF on days 1 and 3 after plating the mono-
cytes. On day 6, the maturation cocktail (as for 3d
mDC) was added to the culture of 6d iDC and 7d mDC
where harvested for study after 24 h. Prior to freezing,
DC were resuspended in 20% human serum albumin
and mixed with equal amounts of freezing medium,
containing 20% human serum albumin, 20% DMSO and
10% glucose (Braun, Melsungen, Germany).
Generation of MART-1/Melan-A ivtRNA
The mMESSAGEmMACHINE™Kit from Applied Biosys-
tems (Darmstadt, Germany) was used for the production
of MART-1/Melan-A ivtRNA. The linearized vector
pcDNAI/Amp/Aa1 (gift from T. Wölfel), encoding the
MART-1/Melan-A cDNA, served as a template for in
vitro transcription. To increase the stability of the RNA,
a poly-A tail was added to the ivtRNA with the aid of
the Poly(A) Tailing Kit™(Applied Biosystems). The kits
were used according to the manufacturers’ instructions.
Cell surface staining of DC
The expression of cell surface molecules on DC was
detected using specific monoclonal antibodies [CD14
(clone M5E2), CD83 (clone HB15e), CD209 (clone
DCN46), CD40 (clone 5C3), HLA-DR (clone G46-6),
CCR7 (clone 2H4), CD86 (clone 2331), CD80 (clone
L307.4) and CD274 (clone M1H1), all Becton Dickin-
son] and measured by flow cytometry. 5 × 104 DC were
washed with ice-cold PBS supplemented with 1% FCS
and incubated for 30 min with the appropriate antibody
(1:25 dilution). If the first antibody was directly linked
to a fluorochrome, the cells were washed once again, as
described above, and resuspended in 200 μl PBS con-
taining 1% FCS. If use of a secondary antibody was
necessary, the cells were washed and incubated with the
secondary antibody for an additional 20 min, washed
again and resuspended as described above. The DC
were analyzed using either FACS Calibur™or LSR-II™in-
struments (BD Biosciences, Heidelberg, Germany).
Results were evaluated using the CellQuest™(BD Bios-
ciences) or FloJo™(Tree Star, Inc., Ashland, OR)
software.
Intracellular staining of DC
For the detection of intracellular MART-1/Melan-A
protein, 3 × 105 DC were fixed in PBS containing 1%
paraformaldehyde (PFA) for 30 min on ice. After fixa-
tion, cells were washed with ice-cold PBS containing 1%
FCS and resuspended in 500 μl 0.1% saponin in PBS
(Sigma-Aldrich) to enable permeabilization of the cell
membrane. The cells were centrifuged and the cell pellet
subsequently resuspended in 0.25% saponin in PBS. The
MART-1/Melan-A antibody was added to the cell sus-
pension (dilution 1:20) and incubated for 1 h at room
temperature. After incubation, the cells were washed
twice in 0.1% saponin in PBS. Incubation with the sec-
ondary, Cy5-coupled antibody (dilution 1:100) was per-
formed in 0.25% saponin in PBS for 30 min at room
temperature. Before being resuspended in PBS with 1%
FCS, the cells were washed in 0.1% saponin in PBS once
again. The MART-1/Melan-A expression was analyzed
by flow cytometry, as described for cell surface staining.
Phagocytosis assay
The phagocytosis capacity of DC was tested via uptake
of FITC-dextran. 2 × 105 DC were resuspended in 400
μl VLE RPMI containing 1.5% human serum, supple-
mented with 10 μg/ml FITC-dextran for 1 h at 37°C
and 5% CO2. As controls, the same concentrations of
DC were incubated in medium without FITC-dextran
for 1 h at 37°C or in medium supplemented with 10 μg/
ml FITC-dextran for 1 h on ice. After incubation, the
cells were washed 3-4 times with ice-cold PBS contain-
ing 1% human serum and 0.1% NaN3. The cells were
resuspended in PBS containing 1% human serum and
analyzed by flow cytometry.
Peptide-loading of DC
3-4 × 106 DC were incubated with different concentra-
tions of the long or short MART-1/Melan-A peptides in
a six-well-plate in VLE RPMI with 1.5% human serum.
The incubation duration for the long peptide was 24 h
and for the short peptide 2 h or 24 h. After incubation
the DC were washed to remove excess peptide.
Electroporation of DC
Electroporation of DC was performed with the Gene
Pulser Xcell™from Biorad (München, Germany) in
0.4 cm electroporation cuvettes (Biorad). Prior to
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electroporation, DC were washed twice in ice-cold Opti-
MEM I medium (Invitrogen, Karlsruhe, Germany). 2-3
× 106 DC were resuspended in 200 μl OptiMEM I, pre-
incubated on ice for three min and mixed with the
MART-1/Melan-A ivtRNA (or the long MART-1/
Melan-A peptide) in the electroporation cuvette. DC
were pulsed with either 250 V, 150 μF or 300 V, 300 μF
(exponential protocol). DC electroporated with H2O
were used as controls. Directly after pulsing, the cells
were transferred into a six-well-plate, containing VLE
RPMI with 1.5% human serum, and incubated at 37°C
and 5% CO2 for 24 h.
Migration assay
A standard migration assay [31] was performed to deter-
mine the migratory capacity of DC. 2 × 105 DC were
resuspended in 100 μl migration medium (RPMI 1640
supplemented with 1% human serum, 500 U/ml GM-
CSF and 250 U/ml IL-4) and incubated in the upper
chamber of a 24-trans-well-plate (Costar/Corning, USA)
for 2 h at 37°C and 5% CO2. To determine chemokine-
directed migration, the lower chambers contained 600
μl migration medium supplemented with 100 ng/ml
CCL19 (R&D Systems). For detection of spontaneous
migration and cell chemokinesis, the migration medium
in the lower chamber either contained no CCL19 or
CCL19 was present in both the upper and lower cham-
bers. After 2 h of incubation the cells from the upper
and lower chambers were harvested and cell counts
determined with the aid of the CellTiter-Glo® Lumines-
cent Cell Viability Assay (Promega).
Induction of antigen-specific T lymphocytes
3d and 7d mDC were harvested and pulsed with 10 μg/
ml MART-1/Melan-A26-35 peptide (ELAGIGILTV) for
120 min at 37°C, 5% CO2 in a humidified atmosphere.
Cryopreserved autologous PBMC isolated from HLA-A2
+ donors were cocultured with autologous, peptide-
pulsed mDC using 1 × 106 PBMC and 1 × 105 mDC in
T cell medium (RPMI 1640, 12.5 mM HEPES, 4 mM
L-glutamine, 100 U/ml penicillin and streptomycin, sup-
plemented with 10% pooled human serum). After 7 days
of coculture, recovered lymphocytes were restimulated
using the same cryopreserved batch of peptide-pulsed
DC for 24 h, at which time supernatants were collected
for determination of IFN-g content via a standard
ELISA using the OptEIA™Human IFN-g ELISA Kit from
BD Biosciences (Heidelberg, Germany) according to the
manufacturers’ protocol.
Restimulation of effector CTL
A42 CTL were stimulated with tumor cells or antigen-
loaded DC at a ratio of 2 × 104 CTL and 4 × 104 tumor
cells/DC per 96-well in 200 μl A42 CTL medium. The
coculture was set up 24 h after peptide-loading or pul-
sing of the DC with ivtRNA, if not otherwise indicated.
The stimulation period was 24 h. Coculture superna-
tants were stored at -80°C for later analyses. The IFN-g
release of the stimulated A42 CTL was measured in the
supernatant media by ELISA, as above.
Results
Morphology and FITC-dextran uptake of 3d mDC and 7d
mDC
Immature and mature DC were generated in vitro using
either elutriated monocytes or monocytes obtained via
plate adherence of freshly isolated PBMC of healthy
donors. In all experiments, the 4C described by Jonuleit
and colleagues was used for DC maturation [22]. Standard
7d mDC were induced within one week, whereas 3d mDC
were generated within 72 hours. The different DC types
were analyzed via flow cytometry and light microscopy
and compared in terms of size and morphology (Fig. 1A
and 1B). It was noticeable that 3d mDC were much smal-
ler and showed a lower granularity than 7d mDC. 3d
mDC were similar in size to 2d iDC, whereas 7d mDC
were clearly larger than 6d iDC (Fig. 1A and 1B). Further-
more, 3d mDC displayed a higher yield and viability com-
pared to 7d mDC (Table 1). All four DC types displayed
capacity for macropinocytosis, following incubation with
10 μg/ml FITC-dextran for 1 h at 37°C. As controls, DC
were incubated without FITC-dextran under the same
conditions or with FITC-dextran for 1 h at 4°C. Subse-
quently, FITC-dextran expression was analyzed by flow
cytometry (Fig. 1C). As expected, 2d iDC and 6d iDC
showed greater FITC-dextran uptake and 6d iDC achieved
a higher mean fluorescence intensity compared with 2d
iDC, although comparable percentages of positive cells
were seen. A somewhat lower FITC-dextran uptake was
usually detected in 3d mDC compared with 7d mDC.
Nevertheless, immature and mature DC from both proto-
cols displayed capacity to take up particles (e.g. antigens)
from their surroundings.
Phenotype of immature and mature DC
After 2, 3, 6 and 7 days, respectively, fast DC and stan-
dard DC were stained with monoclonal antibodies speci-
fic for cell surface molecules typically expressed on iDC
and mDC and subsequently analyzed via flow cytometry.
2d iDC and 6d iDC displayed no CD83 and only very
low expression of CD80, which is typical for iDC. Differ-
ences between 2d iDC and 6d iDC were seen in the
expression pattern of CD14, CD209 (DC-SIGN), CD86
and CCR7 in various donors (n = 3). 3d and 7d mDC
showed the expected mature phenotypes, with high
expression of CD83 and no expression of CD14. Both
also expressed high levels of costimulatory molecules,
like CD80, CD86 and CD40, as well as other cell surface
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molecules that are important for the function of mDC,
including CD209 (DC-SIGN), HLA-DR and CCR7 (Fig.
2A and 1B). Despite the shorter culture time, 3d mDC
often expressed higher levels of CD209, CD40 and
HLA-DR as compared to 7d mDC. Whereas higher
expression of these molecules on 3d mDC varied among
different donors, HLA-DR was consistently seen to be
better expressed on 3d mDC in different donors (n = 3).
In contrast, expression of the inhibitory molecule
CD274 (B7-H1) was consistently lower on 3d than on
7d mDC. This difference was even more striking when
the expression of the positive costimulatory molecule
CD80 and the inhibitory molecule CD274 was directly
compared. Thus, 3d mDC displayed a stronger positive
costimulatory phenotype, with higher expression of
CD80 compared to CD274, whereas 7d mDC showed a
lower level of CD80 compared to CD274 (Fig. 2C).
Despite variability in levels of expression among differ-
ent donors, these data may suggest that 3d mDC might
have a slight advantage in the expression pattern of
costimulatory molecules and thereby may display a
higher stimulatory capacity for T cells compared to 7d
mDC.
Migratory capacity of 3d mDC and 7d mDC
One of the key features of DC, besides their ability to
take up antigens in the periphery, is to migrate to the
lymph nodes in order to present antigenic peptides to
T cells. Both 3d and 7d mDC showed a high expression
of CCR7 (Fig. 2A), which is an important receptor for
homing of DC to lymph nodes. To test migratory capa-
city, iDC and mDC were examined using a standard
migration assay. DC were incubated in the upper cham-
ber of a trans-well-plate at 37°C for 2 h. The lower
chambers contained migration medium, with or without
the chemokine CCL19. As an additional control for cell
chemokinesis, CCL19 was placed in both the upper and
lower chambers. Since CCL19 is a specific ligand for
the CCR7 receptor, migration of DC towards medium
containing CCL19 reveals a directed migratory capacity,
whereas migration towards medium alone or in the pre-
sence of chemokine in both chambers corresponds to
Figure 1 Morphology and FITC-dextran uptake of 3d mDC and 7d mDC. The size and the morphology of immature and mature 3d DC and
7d DC were analyzed by (A) flow cytometry and (B) light microscopy. (C) DC were incubated without or with 10 μg/ml FITC-dextran at 37°C or
at 4°C for 1 hour. The cells were then washed three times in ice-cold PBS with 1% FCS. The uptake of FITC-dextran was analyzed by flow
cytometry. Data are representative for three independent experiments. The left-most open histograms represent medium only controls, the open
grey curves indicate mDC incubated with FITC-Dextran at 4°C and the filled histograms at 37°C.
Bürdek et al. Journal of Translational Medicine 2010, 8:90
http://www.translational-medicine.com/content/8/1/90
Page 5 of 13
spontaneous, undirected migratory capacity and a more
random movement of the DC (Fig. 3). Neither 2d iDC,
nor 6d iDC showed an ability to migrate, even though
some expression of CCR7 was detected on these imma-
ture DC (Fig. 2A). In contrast, 3d mDC showed a
higher directed migration compared with spontaneous
migration. Strikingly, 7d mDC showed reduced directed
migration compared to 3d mDC in all five donors
tested, although the CCR7 expression on 3d mDC and
7d mDC was nearly the same (Fig. 2A). However, the
differences in the directed migratory capacity between
3d and 7d mDC were not statistically significant.
MART-1/Melan-A peptide recognition on DC by A42 CTL
Next, 3d and 7d mDC were tested for their stimulatory
capacity of CD8+ effector T cells. Fast and standard
mDC prepared from HLA-A2+ donors were loaded exo-
genously with short MART-1/Melan-A26-35 peptide
(ELAGIGILTV) for 2 h or 24 h. Because this peptide is
only 10 amino acids long it can bind directly to HLA-
A2 molecules. The peptide-loaded DC were cocultured
for another 24 h with the MART-1/Melan-A-specific
effector CTL A42 which recognize the MART-1/Melan-
A26-35 peptide presented by HLA-A2 molecules. Activa-
tion of CTL A42 was measured by IFN-g release. The
MART-1/Melan-A-negative melanoma cell line Mel
A375 and the MART-1/Melan-A-positive melanoma cell
line Mel-93.04A12 were used as controls (Fig. 4A). A42
CTL showed IFN-g release after stimulation with either
3d or 7d mDC. The amount of IFN-g was higher in
cocultures using DC that had an increased duration of
peptide loading, indicating that 24 h of peptide loading
provided DC with higher amounts of HLA-A2-peptide
ligand, resulting in better stimulatory capacity. The 3d
mDC were comparable to 7d mDC in their capacity to
restimulate effector CTL after exogenous peptide load-
ing for 24 h.
Uptake of long MART-1/Melan-A peptide by 3d mDC and
7d mDC
The ability of 3d and 7d mDC to take up, process and
present antigen was also tested. For this purpose, a long
MART-1/Melan-A peptide, consisting of 23 amino
acids, was used. This peptide is too long to be exogen-
ously loaded directly onto HLA-A2 molecules. There-
fore, it has to be processed by the DC, including
cleavage by the proteasome and transport to the endo-
plasmic reticulum for binding on MHC and export to
the cell surface, where it can be recognized by CTL. 3d
and 7d mDC were incubated with different amounts of
long peptide for 24 h, washed and cocultured with A42
CTL for an additional 24 h. IFN-g release by the CTL
was measured via ELISA (Fig. 4B). Again, both mDC
types showed capacity to stimulate CTL after incubation
with the long peptide, revealing that adequate uptake of
peptide occurred and both DC types were able to intra-
cellularly process and present the correct epitope.
Electroporation of 3d mDC and 7d mDC with peptide or
ivtRNA
To bypass the lower spontaneous uptake of antigen by
mDC, it is possible to use electroporation to introduce
either peptide or ivtRNA into DC. We compared 3d
and 7d mDC that were electroporated according to
optimal parameters that were previously established for
7d mDC [32]. After introduction of 1 μg, 5 μg or 10
μg of long peptide, the mDC were incubated at 37°C
for 24 h and then cocultured with A42 CTL. Once
again, 3d mDC showed capacity comparable to 7d
mDC for stimulation of IFN-g release by the CTL
(Fig. 5A). Use of ivtRNA is an attractive source of anti-
gen that can be easily and cheaply generated from any
antigen-encoding cDNA. To analyze this as a source of
antigen, immature and mature DC were electroporated
with 24 μg of ivtRNA encoding MART-1/Melan-A,
using the same electroporation conditions as applied
with the long peptide. After 24 h of incubation at
37°C, the electroporated DC were cocultured with A42
CTL for another 24 h. Whereas 2d iDC were unable to
stimulate A42 CTL, 3d mDC showed a weak but
detectable stimulatory capacity. In contrast, A42
CTL responded very well to stimulation with ivtRNA-
transfected 7d mDC (Fig. 5B).
Table 1 Yield, purity and viability of immature and
mature DC
2d iDC 6d iDC 3d mDC 7d mDC
Donor 1
Yield* n.d.+ n.d.+ 8% 4%
Purity # n.d.+ n.d.+ 39% 34%
Viability $ n.d.+ n.d.+ 94% 78%
Donor 3&
Yield* 12%§ 6%§ 18% 9%
Purity# 57% 58% 60% 70%
Viability$ 93% 84% 95% 86%
Donor 4&
Yield* n.d.+ n.d.+ 4% 3%
Purity# 32% 30% 42% 60%
Viability$ 85% 76% 86% 81%
* Yield: from PBMC with the starting population set at 100%.
+ n.d.: not determined.
# Purity: SSC/FSC.
$ Viability: propidium iodide (PI) stain.
&Donors 3 and 4 are identical with donors 3 and 4 in Table 2 and Table 3.
§ These values are lower compared to 3d and 7d mDC due to cell loss from
strong adherence of iDC.
Bürdek et al. Journal of Translational Medicine 2010, 8:90
http://www.translational-medicine.com/content/8/1/90
Page 6 of 13
Since the electroporation conditions used in this
experiment were originally established for 7d mDC, it
was possible that they might be suboptimal for 3d mDC.
It was seen, for example, that the stimulatory capacity of
3d mDC could be improved by using higher amounts of
ivtRNA with these electroporation parameters (data not
shown). This, however, was a poor solution for clinical
application of mDC since it would increase costs for
production of ivtRNA. Therefore, alternate electropora-
tion conditions for 3d mDC were explored in order to
improve the efficiency of ivtRNA transfer. After testing
several variations of electroporation, modified para-
meters of 300 V and 300 μF (exponential protocol) were
found that facilitated optimal eGFP expression in 3d
mDC after transfer of ivtRNA (data not shown).
Based on these observations, protein expression and
stimulatory capacity were again compared in 3d and 7d
mDC that were loaded with MART-1/Melan-A ivtRNA,
applying both the old and modified parameters. Hereby,
3d and 7d mDC were electroporated with 12 μg ivtRNA,
incubated for 24 h and then cocultured with A42 CTL
for an additional 24 h. Three hours after electropora-
tion, the MART-1/Melan-A protein expression was
assessed in 3d and 7d mDC via intracellular staining
using a MART-1/Melan-A-specific antibody and flow
cytometry (Fig. 5C). With the modified parameters
(300 V, 300 μF), 3d mDC showed a higher percentage
of positive cells (88% vs. 79%) and a nearly five-fold
increase in MFI (361 vs. 74) compared with 3d mDC
electroporated according to the older conditions. In
contrast, the percentage of MART-1/Melan-A positive
cells remained similar with only a slight increase in MFI
(1.5-fold) in 7d mDC. Under both conditions, 7d mDC
displayed a poor recovery rate 24 h after electroporation,
using either the old or modified parameters (34% and
25%, respectively) compared to 3d mDC (77% and 60%,
respectively). Furthermore, 3d mDC showed a higher
viability after electroporation compared to 7d mDC
(Table 2). The improved MART-1/Melan-A expression
in 3d mDC correlated with a substantial increase in
Figure 2 Phenotype of immature and mature DC. The expression of cell surface molecules on 2d iDC, 6d iDC, 3d mDC and 7d mDC was
detected with specific antibodies and analyzed by flow cytometry. The open histograms correspond to the isotype controls, whereas the grey
and black histograms display the specific binding of FITC- or PE-coupled antibodies. (A) Expression of CD14, CD83, CD209, CD40, HLA-DR and
CCR7. (B) Expression of the B7-family-members CD86, CD80 and CD274. (C) Comparison of the expression of the costimulatory molecule CD80
and the inhibitory molecule CD274 on 3d mDC and 7d mDC. Data are representative for three independent experiments.
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stimulatory capacity (Fig. 5D). This was detected as a
three-fold higher IFN-g release from A42 CTL. 7d mDC
also showed a somewhat higher stimulatory capacity,
corresponding to their higher level of protein
expression.
Recoveries of 3d mDC and 7d mDC after freezing and
thawing
For use in clinical application, it is important that large
lots of antigen-loaded mDC can be prepared and cryo-
preserved in multiple aliquots for individual applications
over time. To determine cell recovery after freezing and
thawing, 3d and 7d mDC were frozen, without or 3 h
after electroporation. After several days of storage, the
DC were thawed and cell recoveries were determined
(Table 2). In the absence of electroporation, the recov-
eries of both 3d and 7d mDC after cryopreservation and
thawing were equal (68% vs. 70%, respectively). In con-
trast, 3d mDC displayed a greater robustness after elec-
troporation and cryopreservation, leading to substantially
higher cell recoveries compared with 7d mDC (41% vs.
18%) and to higher cell viabilities (Table 3).
Stimulation of naïve T cells
Since it is essential for DC-based vaccines to enable
de novo priming of new T cell responses, we also
Figure 3 Migratory capacity of immature and mature DC. 2d
iDC, 6d iDC, 3d mDC and 7d mDC were compared for their
migratory capacity towards migration medium containing (+) or
lacking (-) CCL19 in a trans-well migration assay. To measure
directed migration, the medium in the lower chamber of the trans-
well plate was supplied with 100 ng/ml CCL19, spontaneous
migratory capacity was detected using medium that did not
contain CCL19 in the lower chamber and random cell chemokinesis
was determined by adding CCL19 to both the upper and the lower
chambers. 2 × 105 DC were added in the upper chamber and
incubated at 37°C and 5% CO2 for 2 h. Afterwards, DC numbers in
the lower chambers were determined. Shown are three
independent donors as mean values with standard errors of the
mean (SEM). Statistical analyses were performed using the Mann
Whitney test (n.s.: not significant).
Figure 4 Recognition of MART-1/Melan-A peptide on 3d mDC and 7d mDC by MART-1/Melan-A-specific CTL. (A) 3d mDC and 7d mDC
were exogenously loaded with 10 μg/ml short MART-1/Melan-A26-35 peptide for 2 h or 24 h at 37°C and 5% CO2. After washing, the peptide-
loaded DC were cocultured with MART-1/Melan-A-specific A42 CTL for 24 h at 37°C and 5% CO2. MART-1/Melan-A-positive tumor cells (Mel-
93.04A12) and MART-1/Melan-A-negative tumor cells (Mel A375) served as controls and were cocultured with A42 CTL at the same time points
as the DC (2 h and 24 h). The IFN-g release of A42 CTL was measured by IFN-g-ELISA. The columns show mean values of triplicates with
standard deviations. Data are representative for two experiments. (B) 3d mDC and 7d mDC were incubated with different amounts of long
MART-1/Melan-A peptide for 24 h at 37°C and 5% CO2. The DC were cocultured with A42 CTL for additional 24 h. The IFN-g release of A42 CTL
was measured by IFN-g-ELISA. The columns show mean values of duplicates with standard deviations. The data for 2.5 μg/ml are representative
for two independent experiments (n.d.: not detected).
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Figure 5 Electroporation of 3d mDC and 7d mDC with long MART-1/Melan-A peptide and MART-1/Melan-A-encoding ivtRNA. (A) 3d
mDC and 7d mDC were electroporated (250 V, 150 μF) with 1 μg, 5 μg and 10 μg long MART-1/Melan-A peptide. After 24 h incubation at 37°C
and 5% CO2, the DC were cocultured with A42 CTL for 24 h. (B) 2d iDC, 3d mDC and 7d mDC were electroporated (250 V, 150 μF) with 24 μg
MART-1/Melan-A ivtRNA, incubated at 37°C for 24 h and cocultured with A42 CTL for 24 h (n = 3). (C) 3d mDC and 7d mDC were
electroporated with 12 μg MART-1/Melan-A ivtRNA at different electroporation conditions (250 V, 150 μF and 300 V, 300 μF), respectively. 3 h
after electroporation, mDC were stained intracellularly with a MART-1/Melan-A-specific antibody and analyzed by flow cytometry (n = 2). (D) 24
h after electroporation with MART-1/Melan-A ivtRNA, DC were cocultured with A42 CTL for 24 h (n = 2). The IFN-g release of the A42 CTL was
measured by IFN-g-ELISA. The bars in A, B and D show mean values of triplicates with standard deviations (Rec.: recovery; n.d.: not detected).
Table 2 Viability after electroporation, cryopreservation and thawing
3d mDC 7d mDC
w/o EP 300 V 300 μF 250 V 150 μF w/o EP 300 V 300 μF 250 V 150 μF
Donor 3 Before freezing
Cell counts (× 106) 1.4 0.5 0.8 0.7 0.5 0.4
Viability* 94% 90% 91% 75% 52% 74%
After thawing
Cell counts (× 106) 0.5 0.2 0.2 0.2 0.1 0.2
Viability* 86% 79% 78% 51% 26% 55%
Donor 4 Before freezing
Cell counts (× 106) 1.1 1.4 1.3 0.7 0.7 0.6
Viability* 89% 85% 88% 59% 58% 62%
After thawing
Cell counts (× 106) 1.0 0.9 0.8 0.6 0.4 0.5
Viability* 90% 90% 89% 86% 79% 84%
* Viability: PI stain.
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analyzed the capacities of MART-1/Melan-A peptide-
loaded 3d and 7d mDC to stimulate naïve T cells in
autologous cocultures. PBL were primed for seven days
using either MART-1/Melan-A peptide-loaded 3d or 7d
mDC. At this time the primed cells were recovered and
restimulated with either melanoma tumor cell lines or
with the same batches of peptide-pulsed 3d and 7d
mDC that were cryopreserved and thawed before use as
stimulating cells. The levels of IFN-g secretion were
detected by standard ELISA. When the primed T cells
were restimulated with MART-1/Melan-A-expressing
tumor cells they showed low levels of cytokine release
which increased substantially upon restimulation with
MART-1/Melan-A peptide-pulsed 3d mDC (Fig. 6). In
contrast, the IFN-g secretion of PBL stimulated with
MART-1/Melan-A peptide-pulsed 7d mDC was much
weaker. As described previously for DC that were
matured with 4C cocktail, we did not detect any IL-
12p70 secretion after stimulation of DC using CD40-
ligand expressing cells from either 3d or 7d mDC (data
not shown).
Discussion
Since several different protocols for the generation of
mDC using monocytes have been described to date, the
aim of our study was to compare standard 7d mDC
with 3d mDC in terms of phenotype, processing and
presentation of antigen after transfection of either pep-
tide or ivtRNA and stimulation of effector CTL. If 3d
mDC display the same key characteristics as 7d mDC,
they would be preferred for DC-vaccine development
because of savings in time and costs.
In 2003, Dauer and colleagues published a protocol
for the rapid generation of mDC in vitro [25,26]. These
so called “fast DC” were induced from monocytes within
48 hours and showed typical phenotypic characteristics
of mDC. We modified this procedure somewhat by add-
ing the 4C maturation cocktail, designed by Jonuleit and
colleagues [22], to the cultures of immature DC on the
second day, thereby yielding mDC after three days of
culture.
First, we observed that 3d mDC retained a smaller size
and lower granularity compared to 7d mDC, as
described for fast DC generated in 48 h [25,26,33]. This
difference in morphology raised the issue whether 3d
mDC would differ from 7d mDC in terms of antigen
uptake, processing and presentation of antigen-derived
peptides on the cell surface. Indeed, 3d mDC showed a
lower capacity for spontaneous uptake of FITC-dextran
from their surroundings, compared to 7d mDC. The
Table 3 Recoveries of 3d mDC and 7d mDC after cryopreservation and thawing
3d mDC - EP* 7d mDC - EP* 3d mDC + EP* 7d mDC + EP*
counts
(× 106)
% counts
(× 106)
% counts
(× 106)
% counts
(× 106)
%
Donor 1
Before EP* 2.0 100 2.0 100
Before freezing 1.6 100 1.2 100 1.4 70 1.3 65
After thawing 0.9 59 0.9 73 0.9 43 0.5 26
Donor 2
Before EP* 1.5 100 1.5 100
Before freezing 1.2 100 0.5 100 1.0 65 0.3 23
After thawing 1.0 83 0.5 98 0.7 47 0.3 17
Donor 3
Before EP* 2.0 100 2.0 100
Before freezing 1.4 100 0.7 100 0.5 25 0.5 25
After thawing 0.5 37 0.2 23 0.2 11 0.1 3
Donor 4
Before EP* 1.5 100 1.5 100
Before freezing 1.1 100 0.7 100 1.4 93 0.7 45
After thawing 1.0 91 0.6 86 0.9 61 0.4 27
mean % after thawing ± SD+ 68 ± 24 70 ± 33 41 ± 21 18 ± 11
* EP: electroporation.
+ SD: standard deviation.
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phenotyping of 3d and 7d mDC revealed that both types
of mDC expressed comparable levels of many important
surface molecules. Nevertheless, some differences were
observed in the levels of costimulatory molecules that
play an important role in interactions with T cells.
Thus, differences in the intensity of expression of the
inhibitory molecule CD274 were detected, which may
impact on the costimulatory capacities of 3d and 7d
mDC for T cells. CD274 (B7-H1, PD-L1) on DC inter-
acts with PD-1 on T cells and transmits an inhibitory
signal [34,35]. Therefore, DC that express a preponder-
ance of CD274 might inhibit rather than foster T cell
activation. We observed that 7d mDC expressed higher
levels of CD274 compared to the costimulatory mole-
cule CD80. In contrast, 3d mDC showed a reciprocal
lower expression of CD274 compared to CD80 (Fig. 2).
These results indicate that 3d mDC may be more effec-
tive in activating T cells compared to 7d mDC, which
would be advantageous for priming of naïve T cells.
Nevertheless, when 3d and 7d mDC were loaded exo-
genously with short MART-1/Melan-A peptide, both
DC types showed comparable capacities to stimulate
A42 CTL (Fig. 4A). These findings indicated that the
higher ratio of CD274 to CD80 in 7d mDC did not
impair their capacity to stimulate primed effector cells
(Fig. 2B and 1C). While DC loading with short peptide
led to comparable stimulation of CTL, 3d and 7d mDC
revealed different capacities to stimulate effector T cells
after incubation with long peptide. IFN-g release from
T cells after stimulation with standard mDC loaded with
long peptide was previously noted to be much higher
than stimulation with standard mDC loaded with short
peptide [36]. This may be due to maintenance of a per-
sisting pool of long peptide within the DC that could be
processed and presented for a longer period after
uptake. In our studies 3d mDC showed equal or better
stimulatory capacity for T cells after incubation with
long peptide compared to 7d mDC, indicating that pro-
cessing may have been more efficient in 3d mDC, since
the spontaneous uptake of exogenous material was
lower in 3d mDC, as evidenced by FITC-dextran uptake.
After introduction of the long peptide by electropora-
tion, comparable stimulatory capacities were found
between 3d and 7d mDC. Since levels of IFN-g release
by T cells were in general lower after stimulation with
DC that were electroporated with peptide compared
with spontaneous peptide uptake, we speculate that
electroporation might diminish somewhat the antigen
processing capacity of the DC.
Next, we analyzed protein expression in 3d and 7d
mDC after electroporation of ivtRNA, alongside their sti-
mulatory capacity for CTL. As shown previously, anti-
gen-loaded fast DC were clearly able to stimulate T cells
[25,27]. However, we extended these observations by
comparing the stimulatory capacities of 3d and 7d mDC
side-by-side after electroporation of MART-1/Melan-A
ivtRNA. Using previously established electroporation
conditions, we noted that 3d mDC showed diminished
stimulatory capacity compared to 7d mDC in repeated
experiments with multiple donors. This was likely due to
lower protein expression in 3d mDC after introduction of
ivtRNA. The low protein expression in 3d mDC could be
overcome by using greater amounts of ivtRNA (data not
shown). However, based on the differences in morphol-
ogy and size, we speculated that the more compact 3d
mDC might be more robust and that more intense elec-
troporation conditions might improve ivtRNA transfer,
yielding better protein expression after transfer of lower
amounts of ivtRNA. Indeed, alteration of the electropora-
tion parameters yielded an improved protein expression
in 3d mDC, which subsequently showed a much better
stimulatory capacity for CTL. Thus, once 3d and 7d
mDC expressed comparable levels of protein, they
showed comparable stimulatory capacities for CTL.
When testing the migratory capacities of immature
and mature 3d or 7d DC, we observed that immature
DC displayed neither spontaneous nor chemokine-
directed migration. This was also found by Dauer and
colleagues for immature DC prepared in 24 h from
monocytes [37]. 3d mDC appeared to have somewhat
better migratory capacity than 7d mDC in multiple
donors, which might be related to a less terminally-
differentiated status. Since effective migration of DC is
essential for the priming of naïve T cells in the lymph
nodes, this characteristic supports use of 3d mDC for
vaccine development.
Figure 6 Stimulation of naïve T cells with MART-1/Melan-A
peptide-pulsed 3d and 7d mDC. Autologous PBL were stimulated
with MART-1/Melan-A peptide-pulsed 3d and 7d mDC for 7 days,
followed by specific restimulation for 24 h using peptide-pulsed
mDC and Melan-A-positive tumor cells. The IFN-g release of the PBL
was measured by IFN-g-ELISA. Shown are two independent donors
as mean values with SEM (n.d.: not detected).
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Because 3d mDC were smaller than 7d mDC and
seemed more resistant to electroporation, we speculated
that they were more robust cells. Indeed, 3d mDC load-
ing of ivtRNA required a stronger electroporation pulse
to achieve similar protein expression to 7d mDC. Like-
wise, when recoveries of 3d mDC and 7d mDC were
examined after cryopreservation and thawing, 3d mDC
showed higher cell recoveries when the mDC were elec-
troporated prior to cryopreservation. Furthermore, 3d
mDC displayed higher cell viabilities after electropora-
tion and cryopreservation when compared to 7d mDC.
Thus, 3d mDC yielded higher cell recoveries and
thereby would be superior to 7d mDC for clinical appli-
cation if a DC vaccine strategy entails electroporation
with antigenic proteins or antigen-encoding ivtRNA, fol-
lowed by cryopreservation of multiple aliquots for thaw-
ing and immediate application to patients.
Since it is important that mDC are able to stimulate
naïve T cells in a vaccine setting, we analyzed the stimu-
latory potential of MART-1/Melan-A peptide-pulsed 3d
and 7d mDC on autologous PBL. Under short-term
priming conditions of only seven days, we failed to
detect any tumor-specific killing of MART-1/Melan-A-
expressing tumor cells nor did we detect enrichment of
MART-1/Melan-A-multimer-positive T cells (data not
shown). Nevertheless, PBL stimulated with peptide-
pulsed 3d mDC showed a higher IFN-g release when
restimulated with peptide-loaded 3d mDC compared to
PBL that were primed and restimulated with 7d mDC.
It has been shown previously by others, that fast DC
generated in 48 h had an equal or greater capacity to
stimulate naïve T cells compared to 7d mDC [28,33].
The failure to detect cytotoxic activity and detectable
numbers of MART-1/Melan-A-multimer-positive T cells
in our experiments is likely related to the use of 4C
cocktail for DC maturation and the absence of IL-2 or
IL-7 in the culture medium. It has already been
described that DC matured with 4C cocktail do not pro-
duce bioactive IL-12p70, which is important for optimal
polarization of naïve T cells for tumor recognition
[30,38]. Improved stimulatory capacity of naïve T cells is
achieved if mDC are generated using a cocktail that
enables their production of IL-12p70. Recently, we
showed indeed that 3d mDC, matured with TLR-ligand
containing maturation cocktails display a much higher
stimulatory capacity for naïve T cells than 3d mDC
matured with 4C cocktail [38].
Conclusions
Here we show that 3d mDC displayed similar character-
istics to 7d mDC concerning phenotype and capacity to
stimulate CTL after exogenous pulsing with short pep-
tide. We observed that 3d mDC also had good capacities
to stimulate CTL after uptake and processing of long
peptide and they displayed a strong chemokine-directed
migration. The 3d mDC were more robust and thereby
required altered conditions for introduction of RNA-
encoding antigen via electroporation, however this char-
acteristic likely accounts for higher cell recoveries after
electroporation and cryopreservation compared to 7d
mDC. Thus, 3d mDC offer a suitable alternative to 7d
mDC for use in clinical trials, thereby saving time and
costs for cell production.
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2 
Abstract 
 
Here we describe a new method to compare vaccination with different 
preparations of mature human dendritic cells (DC) in a xenograft mouse model. 
NOD/scid IL2Rgnull (NSG) mice reconstituted with human peripheral blood 
mononuclear cells (PBMC) were vaccinated with autologous human-derived 
mature DC prepared using different protocols. First, two reconstitution regimes 
were evaluated for engraftment rates, leading to selection of 4-week engraftment 
for vaccine evaluation. NSG recipients of human PBMC were vaccinated twice 
with DC generated in vitro for 3 or 7 days. DC cultured for 3 days were better at 
inducing antigen-specific immune responses in vivo. We then compared DC 
matured using two different maturation cocktails. Consistent with in vitro 
observations, vaccination using mature DC activated with a Toll-like receptor 
(TLR) 7/8 agonist resulted in enhanced immune responses. To date, appropriate in 
vivo systems for comparing human cell-based vaccines have been lacking: this 
humanized mouse model system provides an approach to compare characteristics 
of new DC-based vaccine strategies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
Introduction 
 
Dendritic cell (DC) vaccines hold high therapeutic potential for induction of 
antitumor immunity in cancer patients [1,2]. Current cancer vaccines focus on 
mature DC (mDC) loaded with tumor-associated antigens (TAA) and injected 
intradermally to activate CD8+ cytotoxic T lymphocytes (CTL) and natural killer 
(NK) cells.  
Various methods have been developed for preparation of mDC for clinical 
studies; mostly these rely on a 6-day protocol using IL-4 and GM-CSF to induce 
immature DC (iDC), followed by a 24 h maturation phase [3]. Published studies 
demonstrated that DC generated over 2 or 3 days give comparable [4] or enhanced 
[5] immune responses to 7-day mDC. Most clinical trials rely on a four-
component cocktail (4C) containing IL-1, IL-6, TNF- and PGE2 [6]. The 
discovery that TLR agonists can optimally activate murine DC to secrete IL-12 
[7] led to studies of the impact of TLR agonists on human mDC cytokine 
production [8-10]. We have described maturation cocktails using quinoline-like 
molecules, R848 or CL075, in 3-day and 7-day mDC [11,12]. DC matured with 
TLR7/8 agonists, with or without poly (I:C) as a TLR3 agonist, resulted in 
substantial secretion of bioactive IL-12(p70) and high potential to activate innate 
and adaptive immune responses [11,12].  
Humanized mouse models could provide a useful tool for in vivo 
assessment of DC vaccines [13] but reports characterizing immune responses after 
DC-based vaccination are rare [14]. Engraftment of human peripheral blood 
lymphocytes (PBL) in mice has been reported using two NOD/scid strains, one 
with a truncated mutation (NOG) and one with a null mutation (NSG) of the IL-2-
receptor -chain [15,16].  
In this study, we used NOD/scid IL2Rgnull (NSG) mice to engraft human 
PBMC and perform vaccination experiments using 3- and 7-day mDC. 
Additionally, we compared cocktail 4C with our maturation cocktail containing 
R848 as a TLR7/8 agonist (5C+R848). We demonstrate here that 3-day mDC are 
superior to 7-day mDC in vivo. Furthermore, DC matured with the 5C+R848 
cocktail induced enhanced antitumor immunity compared to 4C-matured DC.  
 
 
4 
Methods 
 
Preparation of PBMC for engraftment of NSG mice and ex vivo generation of 
mDC 
Peripheral blood of healthy donors was prepared as described [12]. Afterwards 
PBMC were used directly for engraftment or as sources of mDC, as described 
[5,12]. In brief, monocytes were isolated via flask adhesion and cells were 
cultured for 2- or 6-days with IL-4 and GM-CSF. Afterwards, maturation 
cocktails were added as described [12] using 4C and 5C+R848 cocktails. See 
Supplementary Table 1 for cytokine concentrations. DC were harvested after 24 h, 
loaded with antigen and incubated for an additional 6 h before injection into 
human PBMC reconstituted mice.   
 
Engraftment PBMC in NSG mice 
All animal experiments were approved by the local authorities according to the 
legal regulations. For the 9-week reconstitution protocol, mice were irradiated 
with a sub-lethal dose of 100 cGy one day before intravenous injection of 1x106 
human PBMC, while the 4-week protocol used a single intravenous injection of 
10x106 PBMC, without irradiation. Mice were vaccinated on day 42 or day 14 
after reconstitution, respectively (see also workflow shown in Fig. 1A and 1B). 
 
Electroporation of mDC and vaccination of humanized mice 
Specific antigen was introduced to DC in the form of in vitro-transcribed-RNA 
(ivt-RNA), as described [5]. Electroporation of mDC was performed using 
varying amounts of ivt-RNA (shown for each experiment), prepared from 
linearized T7-promotor-containing plasmids, with the mMESSAGE mMACHINE 
T7 kit (Ambion) following the manufacturer’s instructions. We used the plasmid 
pCDM8HLA-A2 encoding HLA-A*0201 (gift from E. Weiß, Ludwig-
Maximilians-University, Munich) and the plasmid pcDNAI containing MART-1 
and WT-1 cDNA. Electroporation was performed as described in [5] and mDC 
were cultured 6 h following electroporation. Afterwards, mDC were injected 
immediately or cryopreserved for later vaccination. DC (1x106) were given twice 
intravenously, with a one-week interval between injections. After 7 to 14 days 
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mice were sacrificed and spleen cell suspensions prepared for in vitro 
characterization of immune responses.  
 
Functional analysis and flow cytometry 
Spleen cells were cultured in RPMI 1640 medium supplemented with 10% fetal 
calf serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 1 mM non-essential 
amino acids and 5 M beta mercaptho-ethanol, either overnight or over a 7-day 
period, in the presence of 50 IU/ml IL-2 and 0.1 g/ml OKT-3, prior to 
chromium-release assays. Cytotoxic assays were performed as described [12]. 
Tumor cell lines used as targets were cultured as described [12,17]. For flow 
cytometry, cells were stained using a MART-1/MelanA25-36-specific multimer 
(peptide sequence: ELAGIGILT; PE-conjugated; kindly provided by D. Busch, 
Technical University of Munich) for 20 minutes, followed by washing and 
staining with specific CD3 (PerCP; clone SK7, BD) and CD8 (APC; clone SK1, 
BD) or with directly labeled CD3, CD4 (PE; clone 13B8.2, Immunotech), CD8, 
CD62L (FITC; clone SK11, BD) antibodies. Measurement was performed using a 
LRSII machine and FlowJo software for analyses.   
 
Results 
 
Engraftment of human PBMC in NSG mice 
 
To analyze the ability of human mDC to induce immune responses in vivo, we 
used NSG mice xenografted with human PBMC. Initially we compared two 
published engraftment methods, with minor modifications [14,18]. As shown in 
Figure 1A and B, the protocols differed in the length of the engraftment period of 
9 weeks (9-wk) (Fig. 1A) or 4 weeks (4-wk) (Fig. 1B). For the 9-wk protocol, 
mice were irradiated with a sub-lethal dose of 100 cGy, 24 h prior to injection of 
1x106 human PBMC. The mice were immunized with the DC vaccines 6 weeks 
later. For the 4-wk protocol non-irradiated recipients received 10x106 PBMC and 
were immunized after two weeks. Vaccination of mice in each group consisted of 
two intravenous injections of 1x106 mDC, with a one-week interval between 
them. Freshly prepared mDC from autologous donors were used for the first 
vaccination and cryopreserved mDC for the second.  
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FACS analysis of vaccinated mice showed a mean of 55.7% human CD3+ 
T cells using the 9-wk protocol, while the 4-wk engraftment protocol resulted in a 
mean of 26.0% human T cells (Fig. 1C and 1D). When the CD4 and CD8 
fractions were compared within the human CD3+ T cells, we detected an increased 
mean percentage of CD8 (58.4 %; CD4 34.3 %) cells using the 9-wk protocol, 
while the CD8 (48.6 %, in mean) to CD4 (40.7 %, in mean) distribution after the 
4-wk engraftment reflected more the normal situation in humans (Fig. 1C and 
1D). Additionally, we observed that the CD62L-positive fraction of naïve cells 
and the level of expression, assessed as mean fluorescent intensity (MFI), were 
decreased using the 9-wk versus the 4-wk protocol (Fig. 1C and 1D). 
Furthermore, we observed signs of graft-versus-host-disease (GvHD) 
approximately 5 weeks after engraftment with the 9-wk protocol (not shown). 
Mice showed a strong loss of weight, fur loss and thin red skin. Based on these 
observations, we selected the 4-wk procedure for DC vaccination studies.  
 
Induction of allo-specific responses using DC pulsed with HLA-A2-encoding 
RNA 
 
To assess if mDC were able to induce immune responses in vivo, we used an 
allogeneic approach employing DC of an HLA-A2- donor. To create allo-
restricted peptide ligands for T cell recognition [19], we electroporated mDC with 
ivt-RNA encoding HLA-A2 (24 g) and MART-1/MelanA ivt-RNA (48 g) as a 
source of antigen. In parallel, PBMC and DC from the same donor were 
cocultured in vitro. Priming efficiency of in vitro and in vivo activated PBL were 
compared in a chromium-release assay using THP-1 (HLA-A2+, MART-1-) and 
mel624.38 (HLA-A2+, MART-1+) cell lines as target cells. Only low killing 
activity was detected after in vitro priming but responses were greater against the 
melanoma tumor, indicating a component of antigen-specific recognition (Fig. 2A 
left) and lysis of both targets was enhanced when T cells were primed in vivo (Fig. 
2A right). T cells primed with 7-day DC matured using 4C, in vitro and in vivo, 
resulted in only low specific recognition of tumor cells. In contrast, mDC 
generated using the 3-day protocol induced increased responses, in both cases. In 
particular we observed that T cells obtained from mice vaccinated in vivo with 
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5C+R848 matured-DC showed enhanced specific lysis of both target cells (Fig. 
2A right). 
 
MART-1/MelanA-specific immune responses in an autologous setting 
 
To verify these findings in an autologous setting, we utilized the model antigen 
MART-1/MelanA for priming. For these experiments DC prepared from an HLA-
A2+ donor were electroporated with RNA encoding MART-1/MelanA (48 g). 
Seven days after vaccination of mice, reconstituted with HLA-A2+ PBMC from 
the same donor, splenocytes were analyzed by FACS using a MART-1-specific 
multimer to determine the numbers of antigen-specific cells within the human T 
cell fractions. 7-day cultured DC failed to induce any multimer-positive cells 
above the background of non-vaccinated mice, while 3-day DC derived using 
either 4C or 5C+R848 induced multimer-positive cells (Fig. 2B, 2C). Not all mice 
in a group yielded multimer-positive cells; one mouse in each group of four 
displayed no positive cells (not shown).  
We isolated and cultured splenocytes from the vaccinated mice for one-
week in vitro stimulation with anti-CD3 antibody and human IL-2 to enrich 
human T cells before assaying for function. A chromium-release assay assessed 
specific responses using mel624.38 cells as positive target cells and THP-1 cells 
as negative controls. None of the T cell fractions showed reactivity against THP-1 
(not shown). As indicated by the multimer-staining results (Fig 2B), splenocytes 
from mice immunized with 7-day DC (4C) showed no specific lysis of tumor cells 
in vitro. In contrast, 3-day DC matured with 5C+R848 induced MART-1-specific 
responses in three of four mice. In mice immunized with 3-day DC matured by 
4C, only one mouse showed specific lysis of the MART-1+-cell line, although 
three of the four mice were positive for multimer staining. To account for 
variations in CD8+ T cells, we calculated the percentage relative lysis, normalizing 
to the percentage of CD8+ T cells. An additional experiment using MART-
1/MelanA in combination with WT-1 as a second targeted antigen was also 
included into this analsyis (Fig. 2D, 2E and not shown). In both experiments 3-
day DC matured with 5C+R848 were superior in capacity to induce antigen-
specific CD8+ CTL.  
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Discussion 
 
DC vaccines in vitro can potently reactivate human patient T cell responses [20]. 
In particular, DC have the capacity to activate antigen-specific CTL-driven 
immune responses. Recently published studies in humans indicate that the 
commonly used 4C cocktail is suboptimal in its capacity to activate mDC to guide 
antitumor responses, whereas murine DC matured with TLR agonists resulted in 
more effective antitumor responses [7]. Few papers describe the use of humanized 
mice to assess the efficacy of human DC-vaccines [14,21]. The ability to carry out 
in vivo comparisons of new DC vaccine preparations would be of substantial 
interest for design of clinical trials. 
We have developed a rapid and simple system to investigate various 
human DC-based cellular therapeutics. We were able to engraft NSG mice with 
human PBMC within two weeks. Although engraftment of human cord blood-
derived stem cells would result in higher engraftment rates and reduced GvHD, 
the feasibility of obtaining stem cells and DC from the same donor is limited. In 
addition, testing patient-derived DC with lymphocytes of healthy HLA-matched 
donors is also difficult.  
By adapting a 4-wk engraftment protocol of 10x106 PBMC followed by 
two vaccinations with 1x106 DC, we were able to induce and detect allo-reactive 
as well as antigen-specific responses in donor T cells from humanized NSG mice. 
In these settings, 7-day DC failed to induce potent immune responses, while DC 
generated in a 3-day period induced good responses using the 4C cocktail. 
Furthermore, DC matured with the TLR7/8 agonist R848 not only gave enhanced 
immune responses in individual mice, but also increased the numbers of positive 
responders within a cohort. It is not known whether failure to induce immune 
responses in some mice is due to deficiencies in vaccination or reflects variation 
between mice, for example, in qualitative or quantitative levels of reconstitution. 
In experiments reported here we did not inject DC into or near lymph nodes, a 
strategy commonly used in clinical protocols. Further studies will show the 
potential of varying the immunization route on vaccine efficacy.  
In conclusion, the humanized mouse model system developed here enables 
investigation of therapeutic cell reagents in an in vivo setting, which hopefully 
reflects the situation in humans. In addition, this method allows to assess the 
9 
potential of human in vitro prepared DC to activate autologous T cells in an in 
vivo setting, using NSG mice reconstituted with responder cells. In particular, this 
model allows comparisons to be made among different vaccine strategies and 
comparison of the immunogenicity of selected tumor-associated antigens in vivo, 
prior to use in clinical studies.  
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Figure legends 
Fig.1: Efficacy of engraftment of human PBMC in NSG mice 
(A) Schema of 9-wk engraftment protocol. Mice were irradiated 24 h prior to i.v. 
injection of 1x106 human PBMC. Vaccination using 1x106 mDC occurred on day 
42 and day 49 and spleens were isolated on day 63. (B) Schema of 4-wk 
engraftment protocol starting with i.v. injection of 10x106 human PBMC on day 
1. Injection of 1x106 mDC was performed on day 14 and day 21 and spleens were 
isolated on day 28. (C) Representative examples for CD3 vs. SSC, CD4 vs. CD8 
and CD62L expression (from left to right) of flow cytometry analysis comparing 
engraftment efficacy of 9-wk (left of each block) and 4-wk (right of each block). 
(D) Statistical analysis of engraftment efficacy comparing 9-wk and 4-wk 
protocol and vaccinated using 7 day- 4C (circles), 3 day- 4C (squares) or 3 day-
5C+R848 (triangles) mDC. Statistical analyses were performed using a two-tailed 
Mann-Whitney test and p<0.05 were considered significant. 
 
Fig. 2: In vivo priming efficiency using DC-based vaccination 
(A) Chromium-release assay using in vitro (left) and in vivo (right) allogeneic 
primed T cells. DC from an HLA-A2- donor were pulsed with RNA encoding 
HLA-A2 and MART-1 prior to stimulation of autologous PBMC. 2x103 THP-1 
(HLA-A2+, MART-1-) or mel624.38 (HLA-A2+, MART-1+) target cells were 
tested in combination with various numbers of effectors (E:T). Data for in vivo 
primed T cells are depicted as means of four individual mice. (B) MART-1-
specific multimer staining versus CD8 staining of in vivo-primed human T cells. 
Differently matured DC of an HLA-A2+ donor, pulsed with MART-1 RNA, were 
used for vaccination. Staining was performed on day of spleen isolation. (C) 
Killing capacity (% specific lysis) of ex vivo cultured CTL populations tested 
individually in a chromium-release assay. 2x103 mel624.38 target cells were 
incubated with varying numbers of splenocytes (E:T). Responses of non-
immunized mice are shown as open circles while filled circles represent responses 
of immunized mice. Filled squares represent responses of individual mice shown 
in (B). (D) Relative specific lysis of individual vaccinated mice shown in (C). 
Values at an E:T of 20:1 were adjusted as follows: % rel. specific lysis = % spec. 
lysis/ (% CD8/ 100). (E) Relative lysis of isolated, ex vivo activated splenocytes 
against 2x103 mel624.38 (HLA-A2+, MART-1+) or 2x103 K562-A2 (HLA-A2+, 
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WT-1+) target cells at an E:T of 20:1. Mice were previously immunized twice 
with autologous mDC, electroporated with ivt-RNA encoding for MART-1 and 
WT-1. Given are means with SEM of 4 mice for 3d-DC (4C) and 3d-DC 
(5C+R848), 3 mice for 7d-DC (4C) and 1 mouse without vaccination.   
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Suppl. Table 1. Composition of cocktails used for DC maturation 
 
Cocktail  
 
Population 
Inflammatory 
cytokines/interferons 
Other 
additives TLR-ligands 
     
4C DC4C      TNF-a, IL-1β, IL-6 PGE2  
5C + R848 DC5C+R848      TNF-a, IL-1β, IFN-γ PGE2 poly(I:C), R848 
The following concentrations were used in the maturation cocktails: 
4C: TNF-a (10 ng/ml); IL-1β (10 ng/ml); PGE2 (1000 ng/ml); IL-6 (15 ng/ml) 
5C + R848: TNF-a (10 ng/ml); IL-1β (10 ng/ml); PGE2 (250 ng/ml); IFN-γ (5000 U/ml);  
poly (I:C) (20 ng/ml); R848 (1 µg/ml) 
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Adoptive transfer of T cells expressing
transgenic T-cell receptors (TCRs) with
antitumor function is a hopeful new
therapy for patients with advanced tu-
mors; however, there is a critical bottle-
neck in identifying high-affinity TCR spe-
cificities needed to treat different malig-
nancies. We have developed a strategy
using autologous dendritic cells cotrans-
fected with RNA encoding an allogeneic
major histocompatibility complex mole-
cule and a tumor-associated antigen to
obtain allo-restricted peptide-specific
T cells having superior capacity to recog-
nize tumor cells and higher functional
avidity. This approach provides maxi-
mum flexibility because any major histo-
compatibility complex molecule and any
tumor-associated antigen can be com-
bined in the dendritic cells used for prim-
ing of autologous T cells. TCRs of allo-
restricted T cells, when expressed as
transgenes in activated peripheral blood
lymphocytes, transferred superior func-
tion compared with self-restricted TCR.
This approach allows high-avidity T cells
and TCR specific for tumor-associated
self-peptides to be easily obtained for
direct adoptive T-cell therapy or for isola-
tion of therapeutic transgenic TCR se-
quences. (Blood. 2009;114:2131-2139)
Introduction
T-cell responses against tumors are often directed against self-
major histocompatibility complex (MHC) molecules presenting
peptides derived from overexpressed self-proteins. In general,
high-avidity T cells specific for self-peptide/self-MHC ligands are
eliminated by negative selection to prevent autoimmunity. The
T-cell receptor (TCR) affinity of remaining T cells specific for
self-ligands is normally low; however, high-avidity T cells are
needed to effectively eradicate tumors. Because negative selection
is limited to self-MHC molecules, T cells that recognize allogeneic
MHC molecules have not undergone negative selection. Thus,
peptides presented by allogeneic MHC molecules can stimulate
high-avidity T cells specific for tumor-associated ligands derived
from overexpressed self-proteins.1 T cells that recognize allogeneic
MHC molecules irrespective of specific peptide can be distin-
guished from peptide-specific T cells at the clonal level and
excluded.2
Several approaches have been used to obtain allo-restricted
peptide-specific cytotoxic T lymphocytes (CTLs). For example,
peptide-loaded T2 cells were used to generate HLA-A2 allo-
restricted T cells.3,4 This system is normally limited to HLA-A2
and CTLs induced with exogenous peptides often fail to effectively
kill tumor cells.5 Activated B cells coated with allogeneic peptide-
MHC (pMHC) monomers were also used to prime allo-restricted
CD8 T cells.6 For broad application, this method would require
development of many different pMHC monomers. Furthermore,
allo-restricted peptide-specific T cells were obtained using T cells
and stimulating cells derived from HLA partial-mismatched do-
nors.7 Here, necessary donor pairs that differ by single HLA
allotypes are rare. Therefore, each of these methods has strong
limitations.
We developed an approach that provides maximum flexibil-
ity to obtain allo-restricted peptide-specific T cells using
RNA-transfected dendritic cells (DCs) as stimulating cells. The
use of DCs as antigen-presenting cells is particularly valuable
because of their superior capacity to prime naive lymphocytes.
In this approach, T cells are stimulated with autologous DCs
cotransfected with RNA that encode an allogeneic MHC mole-
cule and a tumor-associated antigen (TAA), bypassing the need
to search for appropriate HLA-mismatched donors for the DC
source. These DCs coexpress both proteins and present allo-
pMHC complexes that activate allo-restricted peptide-specific
T cells. In this approach, high-avidity T cells that recognize
self-peptides are more readily found because they were not
subjected to negative selection in vivo.
Selected allogeneic high-avidity T cells can be used directly for
adoptive T-cell therapy in HLA-haploidentical stem cell transplan-
tation.8 Alternatively, their TCR sequences can be used to develop
designer lymphocytes.4,9,10 Thereby, autologous T cells from tumor
patients in general, or from MHC-matched donors in the case of
stem cell transplantation, can be used for TCR transduction,
bypassing the need for direct transfer of allogeneic T cells.
Improved ability to isolate T cells with high-affinity TCR recogniz-
ing common tumor-associated ligands will allow quicker develop-
ment of this therapy for more patients.
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Methods
Cell lines and effector CTLs
The human melanoma cell lines, Mel-A375 (HLA-A2, tyrosinase;
CRL-1619, ATCC), Mel-93.04A12 (HLA-A2, tyrosinase; gift of P.
Schrier, Department of Immunohematology, Leiden University Hospital,
Leiden, The Netherlands), Mel-624.3811 and SK-Mel-23 (HLA-A2,
tyrosinase; gift of M. C. Panelli, National Institutes of Health, Bethesda,
MD), SK-Mel-28 (HLA-A2, tyrosinase; MTB-72; ATCC), SK-Mel-29
(HLA-A2, tyrosinase, gift of P. Rieber, Institute of Immunology,
Technical University Dresden, Dresden, Germany), WM-266-4 (HLA-A2,
tyrosinase; CRL-1676; ATCC) and primary cultures of a human mela-
noma (passage 6-12) and MaCa1 (HLA-A2, tyrosinase, gift of Dr R.
Wank, Immunotherapy Center, Munich, Germany), stable HLA-A*0201
transfectant of MaCa1 (MaCa1/A2; HLA-A2, tyrosinase, gift of E.
Noessner, Institute of Molecular Immunology, Helmholtz Zentrum Mu¨nchen,
Munich, Germany), RCC-2612 (HLA-A2, tyrosinase), PancTu1 (HLA-
A2, tyrosinase, gift of P. Nelson, Department for Biological Chemistry,
University Hospital LMU Munich, Munich, Germany), UTS CC 1588
(HLA-A2, tyrosinase, gift of M. Schmitz, Institute of Immunology,
Technical University Dresden, Dresden, Germany) as well as the lymphoid
cell line T2 (CRL-1992; ATCC) were cultured in RPMI 1640 medium
supplemented with 12% fetal bovine serum, 2 mM L-glutamine, and 1 mM
sodium pyruvate and nonessential amino acids.
The HLA-A2 allo-reactive CTL JB4,13 the HLA-A*0201–restricted
tyrosinase peptide-specific CTL Tyr-F8,14 which were primed using stimu-
lating cells pulsed with exogenous peptide (gift of P. Schrier, Department of
Immunohematology, Leiden University Hospital, Leiden, The Nether-
lands), the HLA-A*0201–restricted tyrosinase peptide-specific, melanoma
patient–derived IVS-B15 CTLs (gift of T. Wo¨lfel, Third Department of
Medicine, Hematology, and Oncology, Johannes Gutenberg-University of
Mainz, Mainz, Germany), and the HLA-A*0201–restricted melan-Apeptide–
specific A4211 CTLs (gift of M. C. Panelli) were cultured as described.11,13-15
Production of tyrosinase, melan-A, and HLA-A2 ivt-RNA
The plasmid pCDM8-HLA-A2 with HLA-A*0201 cDNA (gift of E. Weiß,
Department of Biology II, Ludwig-Maximilians-University, Munich, Ger-
many), pZeoSV2/huTyr with tyrosinase cDNA (gift of I. Drexler, Institute
of Molecular Virology, Helmholtz Zentrum Mu¨nchen, Munich, Germany),
and pcDNAI/Amp/Aa1 with melan-A cDNA (gift of T. Wo¨lfel) were
linearized and used as in vitro transcription templates to produce RNA with
the aid of the mMESSAGE mMACHINE T7 kit (Ambion) according to the
manufacturer’s instructions.
Fluorescence-activated cell sorter analysis
HLA-A2 molecules were stained with BB7.2 monoclonal antibody (HB82;
ATCC) followed by a secondary antibody conjugated with phycoerythrin
(PE; goat anti–mouse IgG; Jackson ImmunoResearch Laboratories). The
intracellular tyrosinase expression in RNA-transfected DCs was detected
using tyrosinase-specific primary monoclonal antibody (clone T311; Novo-
castra Laboratories) and Cy5-conjugated secondary antibody (rat anti–
mouse IgG; Jackson ImmunoResearch Laboratories) as described.16
De novo priming of T cells with RNA-pulsed DCs
Blood samples from healthy donors were collected with donors’ informed
consent in accordance with the Declaration of Helsinki and after approval
by the Institutional Review Board of the University Hospital of the
Ludwig-Maximilians-University. Donor HLA types are listed in Table 1.
Mature DCs were prepared from adherent monocytes and transfected with
in vitro transcribed (ivt)–RNA via electroporation as previously de-
scribed.16 DCs of HLA-A2 donors were loaded with 24 g tyrosinase
ivt-RNA, and DCs of HLA-A2 donors were cotransfected with 24 g
tyrosinase ivt-RNA and 48 g HLA-A2 ivt-RNA. On the same day,
autologous CD8 T lymphocytes were enriched from peripheral blood
mononuclear cells (PBMCs) via negative selection using a commercial kit
according to the manufacturer’s instructions (CD8 T Cell Isolation Kit II
[human]; Miltenyi Biotec). Cocultures were initiated 10 hours after DC
electroporation in 24-well plates (Techno Plastic Products) by adding 105
RNA-pulsed DCs to 106 CD8 T cells in RPMI 1640, supplemented with
10% heat-inactivated human serum, 4 mM L-glutamine, 12.5 mM N-2-
hydroxyethylpiperazine-N-2-ethanesulfonic acid, 50 M -mercaptoethanol,
and 100 U/mL penicillin/streptomycin (T-cell medium). Interleukin-7
(IL-7, 5 ng/mL; Promokine) was added on day 0 and 50 U/mL IL-2 (Chiron
Behring) after 2 days and then on every third subsequent day. Addition of
IL-2 was delayed to decrease proliferation of nonspecific CD8 T cells.17
The second stimulation of primed T cells was made after 7 days using
freshly prepared RNA-pulsed DCs.
HLA multimer sorting
Seven days after the second stimulation of CD8-enriched T cells with
RNA-pulsed DCs, HLA-A2–restricted tyrosinase-specific T cells were
stained with a PE-labeled HLA-A2 tyrosinase369-377 (A2-tyr) multimer,18
CD8-specific antibody (clone RPA-T8; BD Pharmingen) and propidium
iodide (2 g/mL) for sorting. Up to 5  106 cells were incubated with
12 g multimer in 100 L phosphate-buffered saline plus 0.5% human
serum. Allophycocyanin-labeled, CD8-specific antibody was then added for
an additional 25 minutes. After staining, cells were washed and sorted on a
FACSAria cell sorter (BD Biosciences) as described.19
Culture of peptide-specific CTLs
Multimer-sorted T cells were cloned by limiting dilution in round-bottom
96-well plates (TPP). IL-2 (50 IU/mL) was supplemented every 3 days with
5 ng/mL IL-7 and 10 ng/mL IL-15 (PeproTech) every 7 days. CTLs were
stimulated nonspecifically with CD3-specific antibody (0.1 g/mL; OKT-3;
gift of E. Kremmer, Institute of Molecular Immunology, Helmholtz
Zentrum Mu¨nchen, Munich, Germany) and provided with 105 feeder cells
per 96-well, consisting of irradiated (50 Gy) PBMCs derived from a pool of
5 unrelated donors and 104 irradiated (150 Gy) Epstein-Barr virus–
transformed allogeneic B-lymphoblastoid cell line every 2 weeks. Prolifer-
ating T cells were cultured in 24-well plates (TPP) in T-cell medium plus
cytokines and feeder cells. Clonality was determined by TCR–-chain
receptor analysis, as described.20
Peptide loading of T2 cells, PBMCs, and tumor cells
For exogenous peptide pulsing, 106 T2 cells were incubated at 37°C and 5% CO2
for 2 hours with 10 g/mL human 2-microglobulin (Calbiochem) and titrating
amounts, ranging from 105 M to 1011 M, of the tyrosinase peptide YMD
(tyrosinase369-377 YMDGTMSQV; Metabion). T2 cells pulsed with 105 M
influenza peptide GIL (flu: influenza matrix protein58-66 GILGFVFTL; Meta-
bion) served as the negative control. PBMCs were loaded with tyrosinase peptide
as for T2 cells with titrating amounts ranging from 106 to 1011 M. Tumor cells
were loaded with either 105 M flu peptide or 105 M tyrosinase peptideYMD as
described for T2 cells. After washing, peptide-loaded T2 cells, PBMCs, or tumor
cells were used as target cells in cytotoxicity or as stimulating cells in interferon-
(IFN-) release assays.
IFN- release assay
To demonstrate the stimulatory capacity of RNA-pulsed DC 10 hours after
electroporation, 100 L of JB4, Tyr-F8, IVS-B, or A42 T-cell suspensions
(2 104 cells in 100 L) was added to RNA-loaded DCs (4 104 cells in
100 L) in round-bottom 96-well plates. T cells with mock-transfected DCs and
Table 1. HLA types of donors used in these studies
Donor Antigen HLA types
A Tyr HLA-A*01/*02, -B*08/*44, -Cw*05/*07
D Tyr HLA-A*02/*03, -B*35/*37, -Cw*04/*06
T Tyr HLA-A*01/*26, -B*07/*57, -Cw*06/*07
E Tyr HLA-A*24/*26, -B*07/*44, -Cw*07/*16
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without stimulator cells served as controls and showed negligible IFN-
secretion.
For investigation of specificity, CTLs (2 103 cells in 100 L) were
incubated with various tumor cell lines (104 cells in 100 L), with or without
peptide pulsing, as described in “Peptide loading of T2 cells, PBMCs, and tumor
cells.” Culture supernatants were harvested after 24 hours of coculture and
assessed by a standard enzyme-linked immunosorbent assay (ELISA) using the
OptEIA Human IFN- Set (BD Biosciences). Data represent mean values with
corresponding mean deviations calculated from duplicate determinations. For the
calculation of percentage relative IFN- release, the maximum IFN- release was
set to the reference value of 100% and corresponding values were calculated
corresponding to this reference.
Cytotoxicity assay
Cytotoxic activity of CTLs was analyzed in a standard 4-hour chromium
release assay. Melanoma cell lines and peptide-loaded T2 cells were used as
target cells. T cells were cocultured with 103 melanoma target cells/well at
effector cell to target cell (E:T) ratios of 5:1 or 10:1. For determination of
functional avidity, 104 T cells were added to 103 peptide-pulsed T2 cells
loaded with titrated amounts of peptide, giving a constant E:T of 10:1.
The percentage of specific lysis was calculated as: 100  (experimental
release  spontaneous release)/(maximum release  spontaneous release).
Spontaneous release was assessed by incubating target cells in the absence
of effector cells and was generally less than 15%. For the calculation of
percentage relative lysis, the maximum percentage specific lysis was set to
the reference value of 100%, and corresponding values were calculated
corresponding to this reference. To determine half-maximum lysis, percent-
age relative lysis was plotted against peptide concentration. The peptide
concentration at which the curve crossed 50% relative lysis was taken as the
value of half-maximum lysis.21
Retroviral TCR gene transfer
For TCR identification of tumor-specific CTLs, regions of the TCR–- and
TCR–-chains encoding CDR3 were amplified by polymerase chain
reaction using a panel of TCRV- and TCRV- primers in combination with
respective constant region primers as described.22 The full TCR–- and
TCR–-chain genes of CTL clones T58 and D115 were amplified by
polymerase chain reaction using cDNA as template. Primer sequences will
be provided on request. The constant regions of both TCR chains were
exchanged by the murine counterparts to increase the stability of the TCR.23
The TCR chains were linked by a 2A peptide linker (TCR--P2A-TCR-
),24 codon-optimized (Geneart),25 and cloned into the retroviral vector
MP71PRE via NotI and EcoRI restriction sites.24 Retroviral vector plasmids
were cotransfected into 293T cells with expression plasmids encoding
Moloney MLV gag/pol and MLV-10A1 env gene, respectively, to produce
amphotropic MLV-pseudotyped retroviruses as described.24 Ten days after
Figure 1. De novo priming of CD8 T cells with RNA-pulsed
DCs. (A) Coexpression of HLA-A2 and tyrosinase proteins was
detected by flow cytometry in DCs of an HLA-A2 donor trans-
fected with 24 g tyrosinase ivt-RNA (left histograms) and DCs of
an HLA-A2 donor transfected with 48 g HLA-A2 and 24 g
tyrosinase ivt-RNA (right histograms). Stained samples are repre-
sented by filled curves and corresponding controls by empty
curves. Data are representative of 9 independent experiments,
demonstrating that all DCs used for T-cell priming coexpressed
both proteins. (B) Columns represent the amount of IFN-
(picograms per milliliter) secreted by a tyrosinase-independent
HLA-A2 allo-reactive T-cell clone (JB4) and an HLA-A2–restricted
tyrosinase peptide–specific T-cell clone (Tyr-F8) after coincuba-
tion with RNA-pulsed DCs, 10 hours after electroporation. IFN-
was quantified in culture supernatants by ELISA. Mean values
and mean deviations represent duplicates. n.d. indicates not
detectable. (C) DCs of an HLA-A2 donor were transfected with
HLA-A2 (48 g) and tyrosinase (24 g) or melan-A (48 g)
ivt-RNA alone and in combination and used for coincubation with
the HLA-A2 allo-reactive CTL clone (JB4), 2 HLA-A2–restricted
tyrosinase peptide–specific CTL clones (Tyr-F8 and IVS-B), and
an HLA-A2–restricted melan-A peptide–specific CTL clone (A42)
10 hours after electroporation. IFN- was quantified in culture
supernatants by ELISA and presented as picograms per milliliter.
Mean values and mean deviations represent duplicates. n.d.
indicates not detectable.
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the second transduction, peripheral blood lymphocytes (PBLs) were stained
using PE-labeled A2-tyr multimer and fluorescein isothiocyanate-labeled
CD8-specific antibody. Multimers presenting peptides derived from cyto-
megalovirus pp65 were used as controls: PE-labeled HLA-B7 pp65417-427
(B7-pp65) multimers served as the HLA control, and HLA-A2 pp65495-503
multimers as a peptide-specificity control. On day 15, an IFN- release
assay was performed using T2 cells or autologous PBMCs loaded with
graded amounts of tyrosinase peptide (1012 M to 105 M) and the tumor
cell lines MaCa1, SK-Mel-28, Mel-A375, RCC-26, PancTu 1, MaCa1/A2,
UTS CC 1588, Mel-624.38, Mel-93.04A12, SK-Mel-23, SK-Mel-29, and
WM-266-4 as stimulating cells at an E:T of 2:1.
Statistical analysis
The nonparametric, 2-tailed Mann-Whitney U test was used to evaluate
statistical differences between datasets derived from self- and allo-
restricted CTLs in cytotoxicity and IFN- release assays. For statistical
analysis of differences between paired datasets obtained from either self- or
allo-restricted CTLs in cytotoxicity and IFN- release assays, the nonpara-
metric, 2-tailed Wilcoxon signed rank test was used. Values of P less than
.05 were considered statistically significant. All analyses were performed
using the SPSS statistical software (Version 15.0; SPSS Inc).
Results
Activation of CD8 T cells with RNA-pulsed DCs
The first step in generating CTLs was the preparation of stimulating
DCs that coexpressed allogeneic HLA molecules and a selected
TAA. For proof of principle, mature DCs were loaded with
Figure 2. Recognition of peptide-loaded Mel-A375 and exem-
plary screening data from the DC priming. (A) HLA-
A2tyrosinase Mel-A375 were exogenously loaded with irrel-
evant flu peptide, the tyrosinase-peptide YMD, and compared
with HLA-A2tyrosinase Mel-93.04A12 for capacity to stimulate
CTLs. IFN- secretion of the tyrosinase-independent HLA-A2
allo-reactive T-cell clone (JB4), 2 HLA-A2–restricted tyrosinase
peptide–specific T-cell clones (Tyr-F8 and IVS-B), and an HLA-A2–
restricted melan-A peptide–specific T-cell clone (A42) was mea-
sured by ELISA and given as picograms per milliliter. (B) Exem-
plary screening data of clones derived from a priming using DCs
derived from an HLA-A2 donor loaded with HLA-A2 and tyrosi-
nase RNA. Cytotoxic activity was assessed in a standard 4 hours
chromium release assay using HLA-A2tyrosinase Mel-A375
and HLA-A2tyrosinase Mel-93.04A12 melanoma cells as tar-
get cells at different E:T ratios. Data are given as percentage-
specific lysis.
Table 2. Overview of specificity of CTL from 2 HLA-A2 and
2 HLA-A2 donors
Reactivity
Self-restricted (HLA-A2
donors), no. (%)
Allo-restricted (HLA-A2
donors), no. (%)
No reactivity* 21 (55) 8 (16)
Allo-A2† 0 (0) 27 (53)
A2-tyrosinase‡ 17 (45) 16 (31)
Total no. 38 (100) 51 (100)
*Clones failed to recognize HLA-A2-tyrosinase ligands.
†Clones recognized HLA-A2 without peptide.
‡Clones recognized HLA-A2-tyrosinase-peptide ligands.
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ivt-RNA for HLA-A2 and tyrosinase via electroporation, as
described.16 Tyrosinase ivt-RNA was transferred alone into HLA-
A2 DCs or in combination with HLA-A2 ivt-RNA into HLA-A2
DCs. Protein coexpression was detected by flow cytometry with
specific monoclonal antibodies (Figure 1A). Uniform surface
expression of endogenous HLA-A2 molecules was detected on
DCs of HLA-A2 donors, whereas transgenic HLA-A2 expression
was variable on DCs of HLA-A2 donors, with some strongly
positive DCs. Both DC populations coexpressed intracellular
tyrosinase protein at comparable levels. Such DCs were tested for
their capacity to stimulate effector CTL to secrete IFN-: JB4 cells
recognize allogeneic HLA-A2 molecules irrespective of specific
peptide,13 whereas Tyr-F8 cells recognize tyrosinase369-377 peptide
presented by HLA-A2.14 JB4 and Tyr-F8 cells released IFN- in an
HLA-A2–dependent manner because mock-transfected DCs of
HLA-A2 but not HLA-A2 donors activated JB4, whereas Tyr-F8
only recognized DCs expressing both HLA-A2 and tyrosinase
(Figure 1B). Further analysis of CTL activation by RNA-pulsed
DCs loaded with HLA-A2 and a selected TAA (tyrosinase or
melan-A) is depicted in Figure 1C. JB4 recognized DCs that were
loaded with HLA-A2 RNA alone and they also could respond to
DC coexpressing either tyrosinase or melan-A RNA, demonstrat-
ing their allo-specificity for HLA-A2. In contrast, Tyr-F8 and
IVS-B T cells, both of which recognize HLA-A2-tyrosinase369-377
peptide complexes, only responded specifically to DCs coexpress-
ing HLA-A2 and tyrosinase RNA. Antigen specificity was demon-
strated with A42 cells, which recognize a melan-A–derived peptide
presented by HLA-A2; these CTLs only responded to DCs
coexpressing the 2 corresponding RNA.
The DCs shown in Figure 1A-B were used to prime purified
autologous CD8 T cells using 2 rounds of stimulation with freshly
prepared DCs. Peptide-specific T cells were sorted using specific
HLA-A2 tyrosinase369-377 multimer (A2-tyr multimer),26 cloned in
limiting dilution cultures and expanded using antigen-independent
stimulation.17
Superior function of HLA-A2 allo-restricted T cells
Isolated clones were analyzed in IFN- release and cytotoxicity
assays for function and specificity. Initial screening was done using
the Mel-A375 (HLA-A2 tyrosinase) and Mel-93.04A12 (HLA-
A2 tyrosinase) tumor cell lines as negative and positive controls,
respectively. The capacity of these tumor lines to specifically
stimulate JB4, Tyr-F8, IVS-B, and A42 is shown in Figure 2A,
demonstrating that both lines can be recognized by HLA-A2
allo-specific CTL (ie, JB4 cells). However, Mel-A375 cells could
not activate Tyr-F8 and IVS-B CTL unless they were pulsed with
tyrosinase peptide, whereas Mel-93.04A12 cells, which expressed
both endogenous tyrosinase and melan-A proteins, could activate
Tyr-F8, IVS-B, and A42 directly. Screening results for exemplary
clones primed against DCs derived from an HLA-A2 donor are
shown in Figure 2B, depicting either tyrosinase-independent allo-
reactivity for HLA-A2 or presumed specificity for HLA-A2-tyrosinase–
derived ligands. In total, 38 self-restricted clones from 2 HLA-A2
donors were screened: 21 clones had no reactivity, no clones recognized
HLA-A2 without tyrosinase peptide, and 17 clones recognized HLA-A2-
tyrosinase-peptide ligands (Table 2). Of 51 clones isolated from
2 HLA-A2 donors, 8 were nonreactive; 27 were allo-reactive, recogniz-
ing HLA-A2 independent of tyrosinase, and 16 were specific for
HLA-A2-tyrosinase ligands.
After discarding clones with tyrosinase-independent, HLA-A2
allo-reactivity, a set of strongly proliferating allo-restricted clones
with presumed tyrosinase-derived peptide specificity was further
analyzed compared with HLA-A2 self-restricted clones. All se-
lected clones showed cytotoxic activity and IFN- release directed
against Mel-93.04A12 (HLA-A2tyrosinase) but not Mel-A375
Figure 3. CTL clones from multimer-sorted cells of HLA-A2 and
HLA-A2 donors primed with RNA-pulsed DCs. (A) Cytotoxic
activity of 5 CTL clones from HLA-A2 and 7 CTL clones from
HLA-A2 donors is shown against Mel-A375 (HLA-A2tyrosinase)
and Mel-93.04A12 (HLA-A2tyrosinase) melanoma lines at E:T of
5:1. CTL clones showed significant differences in lysis of HLA-
A2tyrosinasevsHLA-A2tyrosinasemelanoma lines (nonparamet-
ric Wilcoxon signed rank test, *P	 .05). Allo-restricted clones dis-
played greater mean percentage-specific lysis than self-restricted
clones (52.8% vs 28.5%; nonparametric Mann-Whitney U test;
*P	 .05). The patient-derived IVS-B clone showed 22.5% specific
lysis (), and the peptide-primed CTL clone Tyr-F8 showed 14.4%
specific lysis (Œ). (B) IFN- secretion (picograms per milliliter) by the
same clones after coculture with Mel-A375 (HLA-A2tyrosinase)
and Mel-93.04A12 (HLA-A2tyrosinase) lines was measured by
ELISA. Allo-restricted clones showed higher mean IFN- secretion
than self-restricted clones (1639 pg/mL vs 561 pg/mL; nonparametric
Mann-Whitney U test; **P	 .005). The IVS-B clone () released 106
pg/mL IFN- and Tyr-F8 (Œ) released 129 pg/mL. (C) IFN- secretion
(picograms per milliliter) by 7 allo-restricted (F) and 3 self-restricted
(E) T-cell clones in coculture with a panel of tumor cell lines shown
from left to right: abreast carcinoma lineMaCa1(HLA-A2tyrosinase);
a melanoma line SK-Mel-28 (HLA-A2tyrosinase); Mel-A375 (HLA-
A2tyrosinase), a renal cell carcinoma line RCC-26 (HLA-
A2tyrosinase), a pancreas carcinoma line PancTu 1 (HLA-
A2tyrosinase), a stable HLA-A*0201 transfectant of MaCa1/A2
(HLA-A2tyrosinase), and a tongue carcinoma line UTS CC 1588
(HLA-A2tyrosinase); and the melanoma cell lines Mel-624.38,
Mel-93.04A12, SK-Mel-23, SK-Mel-29, and WM-266-4 (all HLA-
A2tyrosinase). The leftmost values designated with T show the
background levels of cytokine secreted by the CTL in the absence of
stimulating cells. (D) The HLA-A2tyrosinase tumor cell lines Mel-
A375, RCC-26, and MaCa1/A2 were exogenously loaded with either
105 M irrelevant flu peptide (f) or 105 M tyrosinase peptide YMD (t)
and IFN- secretion was measured by ELISAand given as picograms
per milliliter.
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(HLA-A2tyrosinase) melanoma cell lines (Figure 3A-B). The
allo-restricted CTLs had a significantly higher mean level of
specific lysis than the self-restricted CTLs (52.8% vs 28.5%) and a
significantly higher mean level of IFN- secretion (1639 pg/mL vs
561 pg/mL), demonstrating their general superior function. The
self-restricted melanoma patient-derived CTLs IVS-B and the
self-restricted peptide-primed Tyr-F8 CTLs were included for
comparison and showed low-intermediate killing (22.5% and
14.4%, respectively) and very low IFN- release (106 pg/mL and
129 pg/mL, respectively). A majority of these clones were further
analyzed for IFN- release after coculture with a panel of tumor
lines derived from several different tumor types (Figure 3C).
Although all the clones failed to recognize HLA-A2 and HLA-
A2tyrosinase tumor cells, most clones secreted detectable
amounts of IFN- after stimulation with the 5 HLA-A2tyrosinase
melanoma tumor lines. Furthermore, the allo-restricted peptide-
specific CTLs showed higher levels of IFN- secretion compared
with the self-restricted CTLs after stimulation with each of these
5 melanoma cell lines (range, 317-3417 pg/mL vs 43-1065 pg/mL).
HLA-A2tyrosinase tumor cell lines could be recognized after
exogenous pulsing with specific tyrosinase YMD peptide but not
with irrelevant flu peptide (Figure 3D). Again, more IFN- was
released by allo-restricted CTL compared with self-restricted
CTLs (range, 494-3693 pg/mL vs 55-655 pg/mL, respectively,
Figure 3D).
Functional T-cell avidity for tyrosinase-peptide recognition was
measured in a 51Cr-release assay using HLA-A2 T2 cells pulsed
with graded amounts of exogenous tyrosinase peptide as target
cells. The peptide concentration needed for 50% relative lysis
defined the value of half-maximal lysis.21 Self-restricted clones had
half-maximal values near 108 M (mean 
 1.1  108 M; Figure
4A,C). Allo-restricted clones displayed a range of values and
several clones responded to significantly less peptide
(mean 
 2.5  109 M; Figure 4B-C). This value differed signifi-
cantly from self-restricted clones (Figure 4C). The patient-derived
IVS-B clone and the Tyr-F8 clone required the most peptide
(3.0  108 M and 1.0  107 M, respectively; Figure 4A,C).
One self-restricted T-cell clone (D115) and 1 allo-restricted
T-cell clone (T58) were selected for further characterization based
on their highest rank in killing of melanoma cell lines (data not
shown). Responses to peptide-pulsed T2 cells showed that they
localized to the middle of their respective groups with relative
half-maximal lysis at lower peptide concentrations (T58: 6  1010
M vs D115: 108 M; Figure 4A-B).
A side-by-side comparison of the patient-derived IVS-B CTL
with self-restricted D115 and allo-restricted T58 CTL revealed that
IVS-B showed the poorest response, whereas D115 showed
intermediate and T58 the best recognition of HLA-A2 tumor cells
that endogenously expressed tyrosinase (Figure 5A). Although all
3 CTLs failed to recognize native HLA-A2tyrosinase tumor cell
lines, these tumor lines were recognized after exogenous pulsing
with specific tyrosinase YMD peptide but not with irrelevant flu
peptide (Figure 5B).
To answer the question whether allo-restricted T58 CTL would
also show superior recognition of primary melanoma cells, they
were compared with D115 CTL and patient-derived IVS-B CTLs.
Early passage tumor cells expressing tyrosinase from an HLA-A2
melanoma patient were transfected with HLA-A2 ivt-RNA to
create a pair of matched cell lines, with and without the specific
pMHC ligand (Figure 5C). ELISPOT assays of IFN- and perforin
showed a hierarchy similar to that observed with established
melanoma cell lines, with poor recognition by IVS-B CTLs,
intermediate recognition by D115 CTLs, and the strongest IFN-
and perforin secretion by T58 CTLs (Figure 5D-E). Recognition
was HLA-A2–restricted because the primary tumor cells that were
not transfected with HLA-A2 ivt-RNA were not recognized.
Mel-A375 (A2tyr) were not recognized, and Mel-93.04A12
(A2tyr) were recognized by the 3 CTL clones.
Allo-restricted transgenic TCRs confer superior function
It was important to demonstrate that the superior functional avidity
of allo-restricted T cells resided directly in the TCR; therefore, the
TCR cDNA of D115 and T58 CTLs was isolated, modified for
optimal expression, and introduced by retrovirus transfer into
human PBLs of healthy donors. Multimer staining of untransduced
PBLs was not seen (0.1%, data not shown). After transduction, no
notable multimer staining could be detected with the irrelevant
multimers B7-pp65 and A2-pp65 (0.2%-0.6%), and equal numbers
Figure 4. Comparisons of self-restricted and allo-restricted CTLs. (A-B) The
cytotoxic activity of individual CTL was measured against T2 cells loaded with graded
amounts of tyrosinase peptide (1011 M to 105 M) at an E:T of 10:1. Peptide
concentration and percentage relative lysis are displayed on the x- and y-axes,
respectively. Shown are (A) patient-derived CTL IVS-B (°), CTL Tyr-F8 derived via
T2 peptide priming (Œ°), and the 5 DC-primed self-restricted CTL and (B) DC-primed
allo-restricted CTL. Bold lines represent CTL D115 and T58 in panels A and B,
respectively. (C) Relative values of half-maximal lysis are presented for CTL IVS-B,
Tyr-F8, self-restricted CTLs (n 
 5), and allo-restricted CTLs (n 
 7). Means are
represented as black bars. Significant differences were found between the 2 groups
(nonparametric Mann-Whitney U test; *P 	 .05).
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of CD8 PBLs bound the specific A2-tyr multimer (TCR-D115,
10.9%; and TCR-T58, 10.9%; Figure 6A). The TCR-transduced
PBLs were tested without enrichment for IFN- release after
stimulation with peptide-pulsed T2 cells, whereby PBLs express-
ing TCR-T58 required 100-fold less peptide for half-maximal
release compared with PBL expressing TCR-D115 (Figure 6B).
Untransduced PBLs showed no specific IFN- secretion (data not
shown). The PBLs with TCR-T58 also released substantially
higher amounts of cytokine compared with PBLs with TCR-D115
and the concentration of peptide required to induce release of 2000
pg/mL IFN- differed by more than 15 000-fold (TCR-T58:
2.2  1010 M vs TCR-D115: 3.5  106 M; Figure 6C). Because
T2 cells have a genetic defect in peptide loading, they fail to
present most endogenous peptides in their endogenous HLA-A2
molecules; thus, they express highly uniform pMHCs after exog-
enous loading of tyrosinase peptide. To analyze the sensitivity of
TCR recognition of specific pMHC ligands within a heterogeneous
pMHC setting, which occurs in cells not having defects in
endogenous peptide loading, we created new stimulating cells
using autologous HLA-A2 PBMCs loaded with graded amounts
of tyrosinase peptide. In this case, tyrosinase peptide can only
displace some endogenous peptides in HLA-A2 molecules, thereby
strongly limiting these specific pMHC ligands on PBMCs. After
coculture with these PBMCs, TCR-T58 PBLs secreted consider-
ably higher amounts of IFN-. In addition, the lowest amount of
peptide required to induce IFN- secretion above background
levels differed substantially from TCR-D115 PBL (1010 M vs
107 M; Figure 6D). Specificity was retained in the 2 TCR-
transduced PBL populations, which only recognized HLA-
A2tyrosinase tumor cell lines after pulsing with specific YMD
but not irrelevant flu peptide. Furthermore, HLA-A2tyrosinase
tumor cell lines, but not HLA-A2 or HLA-A2tyrosinase tumor
lines led to specific activation of both CTLs (Figure 6E-F),
whereby PBL-T58 secreted significantly higher amounts of IFN-.
Thus, by all these parameters, the allo-restricted TCR-T58 was
found to be far superior to self-restricted TCR-D115 in its capacity
to recognize MHC-tyrosinase-peptide complexes.
Discussion
This systematic comparison of self-restricted and allo-restricted
peptide-specific CTLs clearly demonstrated that DCs that coex-
pressed allogeneic MHC molecules and tumor-associated antigen
induced allo-restricted peptide-specific T cells with superior antitu-
mor activity. Three features of the procedure are of particular
relevance. First, we took advantage of the well-documented
knowledge that allo-restricted T cells can express high-affinity
TCR specific for peptide ligands of self-proteins because they were
not deleted by negative selection.1,2 Thereby, T cells that more
effectively recognized tumor cells were more readily obtained.
Second, we used T cells of healthy donors, taking advantage of the
Figure 5. Tyrosinase peptide-specific CTL recognition of
tumor cell lines and primary melanoma tumor cells. (A) Col-
umns represent the amount of IFN- (picograms per milliliter)
secreted by patient-derived IVS-B CTL, self-restricted D115 CTL,
and allo-restricted T58 CTL in coculture with a panel of tumor cell
lines from left to right: MaCa1 (HLA-A2tyrosinase); SK-Mel-28
(HLA-A2tyrosinase); Mel-A375, RCC-26, PancTu 1, MaCa1/
A2, and UTS CC 1588 (all HLA-A2tyrosinase); Mel-624.38,
Mel-93.04A12, SK-Mel-23, SK-Mel-29, and WM-266-4 (all HLA-
A2tyrosinase). T indicates CTL without stimulating cells. (B) The
HLA-A2tyrosinase tumor cell lines Mel-A375, RCC-26, and
MaCa1/A2 were exogenously loaded with either 105 M irrelevant
flu peptide (f) or 105 M tyrosinase peptide YMD (t), and IFN-
secretion was measured by ELISA and given as picograms per
milliliter. (C) HLA-A2 expression on primary tumor cells (pas-
sage 12) of an HLA-A2 melanoma patient after transfection
with 50 g HLA-A2 ivt-RNA and on established melanoma
cell lines Mel-93.04A12 (HLA-A2tyrosinase), and Mel-A375
(HLA-A2tyrosinase) was measured by flow cytometry after
staining with HLA-A2–specific monoclonal antibody. Histo-
grams represent stained samples (filled curves) and control
samples (empty curves): control curves show untransfected
primary tumor cells stained with HLA-A2–specific monoclonal
(left histogram) or isotype control antibodies used with the
melanoma cell lines (middle and right histograms). HLA-A2
expression on primary tumor cells was detected 10 hours after
electroporation. (D) The capacity of the patient-derived CTLs
(IVS-B), the representative self-restricted CTLs (D115), and
the representative allo-restricted CTLs (T58) to secrete IFN-
or (E) release perforin in coculture with the melanoma cells
shown above was measured in ELISPOT assays. n.d. indicates
not detectable.
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optimal priming capacity of DCs for naive cells. This allowed us to
avoid use of patient lymphocytes, which often show poor proliferation
and function. Third, we used ivt-RNA as the source of both allogeneic
MHC molecules and TAAs. This provided maximum flexibility for
creating allo-ligands specific for any MHC class I allele and any selected
antigen. Furthermore, priming was not limited to known peptides
because the whole TAA was available for processing and presentation
within the DCs.27 Here we used HLA multimers to isolate peptide-
specific T cells, but alternative methods are available to select a broader
array of T cells, such as the IFN- capture assay.28 Indeed, CTLs that
released high levels of IFN- after tumor cell stimulation often had the
best killing capacity. It should also be noted that this same strategy can
probably be extended to identify high-avidity allo-restricted CD4
T cells by providing DCs with ivt-RNA encoding MHC class II alleles
in combination with TAAs. In this case, the ivt-RNA for TAAs can be
modified to shuttle the proteins into the endosomal pathway to allow
better peptide loading of class II molecules.27
Significant tumor regression can occur after adoptive transfer
of T cells with antitumor specificity.29 However, patient-derived
T cells may have suboptimal activity, as seen with IVS-B CTLs of a
melanoma patient. Furthermore, most self-restricted T cells with
high-affinity TCR specific for self-peptides have undergone nega-
tive selection, and remaining T cells may be negatively controlled
in the periphery. For these reasons, CTLs with appropriate specific-
ity and function are often missing in patients with rapidly
progressing tumors. Therefore, there is current interest in using
precharacterized TCR genes to create designer lymphocytes for
adoptive cell therapies.4,9 Expression of TCR transgenes in acti-
vated PBLs could imbue recipient lymphocytes with antitumor
activities comparable with the original CTLs,4,9 as seen here with
TCR-D115 and TCR-T58. Furthermore, some transgenic TCRs can
displace endogenous TCRs, yielding lymphocytes with monoclo-
nal TCRs.10,30 If more TCRs with this feature can be identified, the
safety of adoptive cell therapy would be improved.
Our studies comparing self-restricted and allo-restricted CTL clones
specific for the same MHC-tyrosinase ligand revealed that there were
inherent differences in the TCR themselves. Far superior recognition of
peptide-pulsed cells was seen with PBLs expressing the allo-restricted
TCR-T58 compared with the self-restricted TCR-D115. The improved
capacity of TCR-T58 PBLs to respond to substantially lower amounts of
peptide indicates that these T cells should be better able in vivo to
effectively recognize tumor cells that express only limited amounts of
Figure 6. Transfer of antigen specificity by retroviral transfer of
TCR-D115 and TCR-T58. (A) PBLs of a healthy donor were transduced
with TCR-D115 or TCR-T58. Unsorted TCR-transduced PBLs were
analyzed on day 10 for transgenic TCR expression using irrelevant
B7-pp65 and A2-pp65 multimers and specific A2-tyr multimers. Untrans-
duced PBLs showed no multimer binding (0.1%, data not shown).
Percentages of multimerCD8 T cells are displayed in the top right
quadrant. (B-C) The IFN- release of unsorted TCR-transduced PBLs
after stimulation with T2 cells loaded with graded amounts of tyrosinase
peptide (1012 M to 105 M) at a ratio of 2:1. (B) The relative IFN- release
is displayed in percentage. (C) The specific IFN- release is presented as
picograms per milliliter. (D) Functionality of unsorted TCR-transduced
PBLs was measured by IFN- release using autologous HLA-A2 PBMCs
loaded with tyrosinase peptide (1011 M to 106 M) as stimulating cells at
ratio of 2:1. Untransduced PBLs (Œ) showed no peptide-specific IFN-
release. (E) The HLA-A2tyrosinase tumor cell lines Mel-A375, RCC-26,
and MaCa1/A2 were exogenously loaded with either 105 M irrelevant flu
peptide (f) or 105 M tyrosinase peptide YMD (t) and IFN- secretion was
measured by ELISA and given as picograms per milliliter. (F) Specificity of
recognition was assessed by IFN- release after coculture with the tumor
cell lines from left to right: MaCa1 (HLA-A2tyrosinase); SK-Mel-28
(HLA-A2tyrosinase); Mel-A375, RCC-26, PancTu 1, MaCa1/A2, and
UTS CC 1588 (all HLA-A2tyrosinase); Mel-624.38, Mel-93.04A12,
SK-Mel-23, SK-Mel-29, and WM-266-4 (all HLAA2tyrosinase).
T indicates CTL without stimulating cells.
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specific pMHC ligand. This is supported by the far superior recognition
of melanoma tumor cell lines by PBL-T58.
The first clinical trials of adoptive transfer of TCR-transgenic T cells
in melanoma patients achieved clinical responses in a number of patients
with advanced disease.31,32 These results demonstrated the therapeutic
potential of this approach. It would be an advantage to provide patients
with mixtures of TCR-transgenic lymphocytes that target their tumors
via several different pMHC ligands to avoid immune selection of tumor
cell variants that lack expression of individual TAAs. Our priming
strategy should allow better access to high-avidity CTLs specific for
different TAAs that are prevalent in melanomas and other tumors, which
could serve as sources of therapeutic TCR sequences. Future adoptive
therapy of more patients will be feasible if useful TCR sequences are
available as “off-the-shelf” reagents. Our approach helps to close the
technologic gap in identifying suitable TCR with specificity for com-
mon TAA ligands that have sufficient affinity to effectively recognize
tumor cells.
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The	apoptosis	inhibitor	protein	survivin	is	overexpressed	in	many	tumors,	making	it	a	candidate	target	
molecule	for	various	forms	of	immunotherapy.	To	explore	survivin	as	a	target	antigen	for	adoptive	T	cell	
therapy	using	lymphocytes	expressing	survivin-specific	transgenic	T	cell	receptors	(Tg-TCRs),	we	isolat-
ed	HLA-A2–allorestricted	survivin-specific	T	cells	with	high	functional	avidity.	Lymphocytes	expressing	
Tg-TCRs	were	derived	from	these	T	cells	and	specifically	recognized	HLA-A2+	survivin+	tumor	cells.	Surpris-
ingly,	HLA-A2+	but	not	HLA-A2–	lymphocytes	expressing	Tg-TCRs	underwent	extensive	apoptosis	over	time.	
This	demise	was	caused	by	HLA-A2–restricted	fratricide	that	occurred	due	to	survivin	expression	in	lympho-
cytes,	which	created	ligands	for	Tg-TCR	recognition.	Therefore,	survivin-specific	TCR	gene	therapy	would	
be	limited	to	application	in	HLA-A2–mismatched	stem	cell	transplantation.	We	also	noted	that	lymphocytes	
that	expressed	survivin-specific	Tg-TCRs	killed	T	cell	clones	of	various	specificities	derived	from	HLA-A2+	
but	not	HLA-A2–	donors.	These	results	raise	a	general	question	regarding	the	development	of	cancer	vac-
cines	that	target	proteins	that	are	also	expressed	in	activated	lymphocytes,	since	induction	of	high-avidity	
T	cells	that	expand	in	lymph	nodes	following	vaccination	or	later	accumulate	at	tumor	sites	might	limit	
themselves	by	self-MHC–restricted	fratricide	while	at	the	same	time	inadvertently	eliminating	neighboring	
T	cells	of	other	specificities.
Introduction
Several recent developments have converged to improve adop-
tive T cell therapy of cancer. First, expression of TCRs as trans-
genic proteins in peripheral blood lymphocytes (PBLs) enables 
T cells with defined specificities to be generated in high num-
bers for patient-individualized therapy (TCR gene therapy), 
bypassing the  laborious process of  isolating and expanding 
specific T cells for individual patients (1). Second, high-affinity 
TCRs specific for peptides presented by different major histo-
compatibility complex molecules (hereafter, pMHC ligands) can 
be selected and employed as generic “off-the-shelf ” reagents, 
enabling future application of small repertoires of therapeutic 
Tg-TCRs to achieve greater clinical efficacy (2, 3). Third, selec-
tion of recipient lymphocytes and manipulation of the micro-
environment can enhance T cell survival, expansion, and long-
term function after adoptive transfer in vivo (4). In addition, 
tumor-associated antigens (TAAs) have been elucidated that 
may serve as suitable target structures on tumor cells, guiding 
the selection of TCR specificities.
A pilot project of the National Cancer Institute (NCI) pri-
oritized a group of TAAs for T cell therapy and vaccine devel-
opment (5). These TAAs represent mutant, overexpressed, or 
abnormally expressed proteins in cancer cells, as well as viral 
proteins present in virus-associated malignancies. The role of 
candidate proteins in oncogenicity was an important ranking 
factor, based on the consideration that T cell–mediated immune 
selection would be limited if tumor survival was dependent 
on TAA expression. For example,  survivin, a well-character-
ized inhibitor of apoptosis (6, 7), is an attractive candidate for 
immunotherapy, since  it  is not expressed  in most adult  tis-
sues but is overexpressed by many tumors (8). Furthermore, 
survivin-specific T cells were reported by several investigators 
(9–18). Survivin received a top score for oncogenicity, and it was 
ranked 21 among the 75 prioritized TAA (5).
High-affinity TCRs that efficiently recognize tumor cells are 
needed for effective TCR gene therapy (19, 20). However, T cells 
recognizing peptides of self-proteins presented by self-MHC mol-
ecules (hereafter designated self-restricted T cells) will often be 
missing or display only low functional avidity due to deletional 
tolerance (9, 21, 22). In contrast, HLA-allorestricted T cells can 
be obtained with high functional avidity for self-peptides (23). 
Advancing upon the original concept of Stauss and coworkers 
(24), we recently described a versatile strategy to derive allor-
estricted peptide-specific T  cells  as  sources  of high-affinity 
TCR, using DCs that were loaded with in vitro transcribed RNA 
(ivt-RNA) as a source of antigen to prime naive T cells (25). For 
example, DCs prepared from HLA-A2– donors can be loaded with 
ivt-RNA encoding allogeneic HLA-A2 molecules and a self-pro-
tein, such as survivin, for use as APCs. Because tolerance is MHC 
restricted, the corresponding autologous T cells of HLA-A2– indi-
viduals were not subjected to negative selection by HLA-A2 and 
can give rise not only to HLA-A2–alloreactive T cells but also to 
peptide-specific T cells that recognize survivin-derived peptides 
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presented by HLA-A2. We applied this strategy to isolate high-
affinity survivin-specific TCRs for use in TCR gene therapy.
Results
High-avidity allorestricted T cell clones specific for survivin are derived 
by DC priming. We introduced survivin ivt-RNA alone, or in com-
bination with HLA-A2 ivt-RNA, into mature DCs prepared from 
HLA-A2+ or HLA-A2– donors, respectively. These DCs were cocul-
tured with autologous responding CD8+ lymphocytes to induce 
either HLA-A2 self-restricted or allorestricted survivin-specific T 
cells. After two rounds of stimulation, primed cells were stained 
with HLA-A2–survivin96-104[97L] multimer (survivin-multimer) 
and CD8-specific antibody (Figure 1A). Double-positive cells 
(1.2%–2.2%) were detected in both self-restricted and allorestrict-
ed samples prior to sorting. Very few positive cells were present 
in self-restricted cultures that bound control HLA-A2–multim-
er, utilizing a peptide of cytomegalovirus pp65 protein (CMV-
multimer, 0.2%). However, substantial numbers of cells from 
allorestricted cultures bound CMV-multimer (0.9%), most likely 
representing T cells that recognized HLA-A2 as an alloantigen, 
irrespective of survivin peptide. The survivin-multimer+ T cells 
were isolated and cloned immediately by limiting dilution, and 
the remaining sorted cells were cultured as bulk T cell lines. After 
26 days, the T cell lines were reanalyzed for multimer binding. 
Whereas fewer than 5% of self-restricted CD8+ T cells bound sur-
vivin-multimer, more than 70% of allorestricted cells were sur-
vivin-multimer positive. Again, substantial numbers of cells in 
this T cell line bound CMV-multimer.
Both T cell lines were assessed for the capacity to kill HLA-A2+ tar-
get cells that were pulsed exogenously with either survivin96-104[97L] 
(survivin) peptide or control influenza matrix protein58–66 (flu) 
peptide. The self-restricted T cell  line mediated a low rate of 
killing of survivin-pulsed T2 cells, in accordance with the low 
numbers of survivin-multimer+ cells; it did not kill flu-pulsed 
target cells (Figure 1B). In contrast, the allorestricted T cell line 
killed both target cells. Because HLA-A2–alloreactive T cells pres-
ent in the culture recognize target cells irrespective of specific 
peptide (25), they mask the detection of survivin-specific T cells. 
Therefore, HLA-A2–allorestricted survivin-specific T cells must 
be identified at the clonal level.
Clones derived from limiting dilution cultures were screened 
for cytotoxicity against the same two peptide-pulsed target cells. 
Figure 
De novo priming of survivin-specific T cells with RNA-pulsed DCs. (A) Survivin-multimer staining of bulk CD8+ T cell lines of HLA-A2+ and 
HLA-A2– donors after DC priming (Pre-sort) and after 26 days of expansion following multimer sorting (Post-expansion). CMV(pp65)-multimer 
served as a specificity control. Percentage double-positive cells are displayed in the upper-right quadrant. (B) Cytotoxic activity of multimer-
sorted lines measured against T2 (HLA-A2+) cells pulsed with flu or survivin peptide (10–5 M) is presented as percent specific lysis. (C) Cytotoxic 
specificity of different T cell clones was measured against flu- and survivin-pulsed T2 cells (10–5 M) and presented as percent specific lysis. 
The x axis shows clone designation. (D) Cytotoxic activity of allorestricted survivin-specific T cell clones A71, A66, and A72 against Mel-1379 
(HLA-A2– [A2–], survivin+ [S+]), T2 cells loaded with 10–5 M flu peptide (A2+, S–), and Mel-624.38 tumor cells (A2+, S+) at an E/T ratio of 5:1. Flu-
pulsed T2 cells were used as survivin-negative control, since we identified no tumor cell lines that were survivin negative. (E) Functional avidity 
of CTLs (E/T, 10:1) was measured against T2 cells pulsed with graded amounts of survivin peptide. Relative values of half-maximal killing 
are depicted at the right. Flu-pulsed T2 cells (10–5 M) were not recognized (data not shown). Cytotoxicity data represent means of duplicates 
measured at each E/T ratio or peptide concentration.
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Representative results of one screening assay demonstrate that 
survivin-specific T cell clones were not isolated from the self-
restricted cultures, whereas different clones derived from the 
allogeneic cultures killed either both targets or only recognized 
survivin-pulsed cells (Figure 1C). A total of 120 T cell clones were 
analyzed, and no self-restricted clone with survivin specificity was 
isolated (Table 1). In contrast, the allogeneic cultures yielded 60% 
of clones that recognized both targets and 28% that recognized 
only survivin-pulsed target cells. The first group represented 
HLA-A2–alloreactive cells and was discarded.
Three clones showing potential survivin specificity were analyzed 
for cytotoxic activity. Target cells lacking either survivin or HLA-A2 
were poorly recognized, whereas cells coexpressing HLA-A2 and 
survivin were efficiently killed (Figure 1D). The peptide sensitivity 
of killing was assessed using T2 cells pulsed with varying concen-
trations of survivin peptide, revealing half-maximal values ranging 
from 1.3 × 10–6 to 5 × 10–11 M (Figure 1E).
Survivin-specific reactivity is transferred to recipient lymphocytes by TCR 
gene expression. The TCR sequences of clones A66, A71, and A72 
were isolated, codon optimized, and modified to express mouse 
TCR constant regions to improve surface expression, as described 
previously (26, 27). Retroviral vectors encoding both TCR chains 
were used to transduce activated PBLs of HLA-A2– donors. The 
3 survivin-specific Tg-TCRs were expressed on comparable per-
centages of PBLs, as shown by binding of murine TCRβ constant 
region antibody (Figure 2A). The TCR-transduced PBLs killed 
survivin-pulsed T2 cells with different peptide sensitivities. Based 
on half-maximal values for cytotoxicity, a hierarchy of functional 
avidity was revealed that corresponded to the original T cell clones 
(TCR-A71 < TCR-A66 < TCR-A72) (Figure 2B).
TCR-transduced PBLs were also tested for their capacity to kill 
tumor cells that expressed survivin, with or without HLA-A2. Sur-
face HLA-A2 was detected on tumor cells with specific antibody 
(Supplemental Table 1; supplemental material available online 
with this article; doi:10.1172/JCI43437DS1), and survivin mRNA 
levels were assessed by RT-PCR (Figure 2C). PBLs expressing the 3 
Tg-TCRs killed UT-SCC-15, U-373, and FM-86 tumor cells, which 
naturally coexpressed HLA-A2 and survivin. Recognition required 
expression of survivin-specific Tg-TCRs, since GFP-transduced 
and untransduced PBLs did not mediate  appreciable  killing 
(Figure 2D). Similar results were found for 4 additional tumor lines 
(data not shown). KT-195 tumor cells displayed high levels of sur-
vivin mRNA, but they were HLA-A2 negative and were not recog-
nized by TCR-transduced effector cells. Following transfection with 
HLA-A*0201–encoding cDNA, KT-195-A2 cells gained HLA-A2 
surface expression and acquired sensitivity to effector cells modi-
fied with each of the 3 TCR-modified effector cells. In contrast, cells 
transfected with control vector (KT-195-VC) remained resistant 
to killing (Figure 2E). PBLs expressing TCR-A71, which had the 
lowest peptide sensitivity, recognized the FM-86 and KT-195-A2 
target cells at somewhat lower levels. These two tumor cell lines 
expressed the lowest levels of HLA-A2 (Supplemental Table 1), 
indicating that T cell functional avidity impacted sensitivity of 
tumor cell recognition when pMHC ligand density was limited.
IFN-γ was  also  released by TCR-modified PBLs but not by 
untransduced or GFP-transduced PBLs following stimulation 
with tumor cells (Figure 2F). This cytokine release was pMHC spe-
cific, since it was only induced by tumor cells coexpressing survivin 
and HLA-A2 (data not shown).
The analysis of the KT-195 triplet of tumor cells demonstrated 
that Tg-TCR recognition was dependent upon HLA-A2. To dem-
onstrate that HLA-A2 was not directly recognized in the absence of 
survivin peptide, we prepared artificial APCs (aAPCs), consisting of 
particle-bound anti-CD28 antibodies and recombinant HLA-A2-Ig 
molecules that were loaded exogenously with flu or survivin pep-
tides. These aAPCs were analyzed for their capacity to induce IFN-γ 
secretion by PBLs expressing TCR-A72, which had the best func-
tional avidity. Survivin-dependent recognition of this Tg-TCR 
was apparent, since only survivin-pulsed aAPCs led to detectable 
cytokine secretion. The recognition of survivin-pulsed aAPCs was 
also dependent upon Tg-TCR expression in the effector cells, since 
untransduced PBLs showed no response to the survivin-pulsed 
aAPCs (Figure 2G).
Survivin-specific TCR-modified cells mediate MHC-restricted fratri-
cide. In a clinical setting, therapeutic Tg-TCRs would normally be 
expressed in lymphocytes of HLA-A2+ patients bearing HLA-A2+ 
survivin+ tumors. Even though the survivin-specific Tg-TCRs were 
well expressed short-term on activated cells of both HLA-A2+ and 
HLA-A2– donors, TCR-transgenic lymphocytes of HLA-A2+ donors 
yielded lower recoveries after several days of culture (data not 
shown). Therefore, we made a closer inspection of recipient lym-
phocytes over a period of 2 weeks following transduction with the 3 
Tg-TCRs. The percentages of PBLs that expressed Tg-TCRs ranged 
from 28% to 52%, and the expression profiles of each Tg-TCR 
in HLA-A2– and HLA-A2+ recipient lymphocytes were comparable 
(Figure 3A). Appearance of apoptotic cells in the total population 
was monitored by staining with 7-aminoactomycin D (7-AAD), 
which intercalates into double-stranded nucleic acids of apoptotic 
and dead cells. While no differences in 7-AAD+ cells were noted on 
day 1 after TCR transduction, dramatic differences in percentages of 
7-AAD+ cells were seen after 13 days when the HLA-A2– and HLA-A2+ 
populations were compared (Figure 3B). Apoptosis of HLA-A2– 
lymphocytes ranged from 21% to 24% in TCR-modified PBLs, near 
the value of GFP-transduced and untransduced PBLs. In strong 
contrast, 72%–87% 7-AAD+ cells were detected in the HLA-A2+ 
populations  containing  TCR-transduced  T  cells.  This  high 
rate of apoptosis was dependent upon the presence of Tg-TCR– 
expressing T cells in the total lymphocyte population, since GFP-
transduced and untransduced PBLs remained near 20%. For com-
parison, PBLs were transduced with a high-affinity TCR (T58) 
derived from an allorestricted T cell clone recognizing an epit-
ope of tyrosinase protein presented by HLA-A2 (25) (Figure 3C). 
In this case, HLA-A2+ recipient lymphocytes did not show any 
dramatic increase in apoptotic cells compared with untransduced 
Table 
Classification of survivin-specific T cell clones after DC priming
	 HLA-A2+		 HLA-A2–		
	 (self-restricted)	 (allorestricted)
No reactivity 46 (100%) 9 (12%)
Alloreactive 0 (0%) 44 (60%)
Survivin-reactive 0 (0%) 21 (28%)
Total number 46 (100%) 74 (100%)
Clones (n = 120) were classified for specificity using 10% specific lysis 
of peptide-pulsed T2 cells as the positive cutoff: no reactivity designates 
clones recognizing neither target cell; alloreactive clones recognized 
survivin- and flu-pulsed T2 cells; and survivin-reactive clones recog-
nized only survivin-pulsed T2 cells. The number and respective percent-
age of the total clone number are given.
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PBLs or TCR-modified PBLs from an HLA-A2– donor (Figure 3D). 
The accumulation of apoptotic cells was compared over time for 
HLA-A2– and HLA-A2+ populations, containing T cells express-
ing survivin-specific Tg-TCRs (Figure 3E) or tyrosinase-specific 
Tg-TCR  (Figure  3F),  demonstrating  that  high-level  apopto-
sis required the presence of T cells expressing survivin-specific 
Tg-TCRs and only occurred in HLA-A2+ recipient  lymphocyte 
populations. It should be noted that the differences between the 
percentages of T cells expressing a Tg-TCR and the percentages 
of cells undergoing apoptosis in HLA-A2+ recipient PBLs revealed 
that death was not limited to T cells expressing survivin-specific 
Tg-TCRs. Thus, T cells bearing survivin-specific Tg-TCRs mediated 
fratricide against a substantial number of HLA-A2+ lymphocytes 
lacking Tg-TCR expression.
Because the TCR-transgenic T cells were stimulated to achieve 
efficient expansion, we examined whether activated T cells could 
be directly killed by TCR-transduced PBLs (Figure 4A). After stim-
ulation with either phytohemagglutinin (PHA) or a combination 
of CD3- and CD28-specific antibodies, activated HLA-A2– lym-
phocytes were not recognized by effector cells expressing Tg-TCR, 
even  though  they  expressed  high  levels  of  survivin mRNA 
(Figure 4B). In contrast, unstimulated HLA-A2+ lymphocytes 
were killed to a substantial degree by effector cells expressing 
survivin-specific Tg-TCR. Furthermore, killing increased after 
lymphocyte activation (Figure 4A), coinciding with increases 
in the basal level of survivin mRNA transcripts (Figure 4B). We 
also assessed whether cytotoxic T lymphocyte (CTL) clones could 
serve as targets for survivin-specific TCR-modified effector cells. 
CTLs derived from different HLA-A2+ donors, with specificity 
for either tumor-associated peptides (A42, ref. 28; Tyr-F8, ref. 29) 
or an Epstein-Barr virus–derived ligand (FaLe) (D.J. Schendel, 
unpublished observations), were well recognized, whereas CTL 
clone JB4 (30), originating from an HLA-A2– donor, was not 
killed (Figure 4C). These CTL clones expressed survivin mRNA 
Figure 
Redirection of antigen specificity by retroviral transfer of survivin-specific TCR genes. PBLs of a healthy HLA-A2– donors were transduced with 
TCR-A71, -A66, and -A72. (A) Unsorted TCR-transduced PBLs were analyzed on day 10 for Tg-TCR expression using murine TCRβ constant 
region–specific antibody. (B) The relative cytotoxicity is given for nonsorted TCR-transduced PBLs following stimulation with T2 cells loaded with 
graded amounts of survivin peptide at an E/T ratio of 20:1. Relative values of half-maximal killing are depicted at the right. (C) RNA expression 
of survivin in tumor cells was assessed by RT-PCR using survivin-specific primers and β2-microglobulin–specific primers (β2m) as a control. 
Survivin-specific cytotoxicity of TCR-modified PBLs was assessed in a standard 4-hour chromium release assay using different tumor cell lines 
at varying E/T ratios: (D) UT-SCC-15, U-373, and FM-86 (all: A2+, S+) and (E) KT-195, KT-195-VC (A2–, S+), KT-195-A2 (A2+, S+) as target cells. 
Untransduced PBLs and PBLs transduced with a GFP control vector served as controls. Cytotoxicity data represent means of duplicates mea-
sured at each E/T ratio or peptide concentration. (F) IFN-γ release at 24 hours is depicted following coculture with tumor cell lines at an E/T ratio 
of 2:1. (G) Unloaded or survivin or flu peptide–loaded aAPCs were cocultured with either untransduced PBLs or PBLs expressing TCR-A72 at 
an E/T ratio of 1:2. IFN-γ values for F and G are shown as mean of duplicates ± mean deviation. These experiments were done with 6 different 
donors, except for B and G (n = 2). Asterisk indicates values below the detection limit.
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(Figure 4D), albeit at variable levels. Two controls demonstrated 
the specificity of recognition. First, effector PBLs had to express 
a survivin-specific Tg-TCR, since GFP-transduced and untrans-
duced PBLs did not mediate appreciable killing of target cells. 
Second, HLA-A2– activated PBLs and HLA-A2– CTLs were not 
killed by any effector population, demonstrating that TCR rec-
ognition was HLA-A2 restricted.
Activated T cells express several TAAs that might target them for fratri-
cide. The wider impact of MHC-restricted fratricide was considered 
with respect to other TAAs, including several TAAs prioritized by 
the NCI Translational Research Working Group (5). Therefore, 
we analyzed mRNA levels in activated PBMCs and enriched CD8+ 
T cells (Figure 5) and considered two factors in this assessment. 
First, mRNA levels were compared in unstimulated versus stim-
ulated T cells (CD3/CD28 activation) and expressed as x-fold 
increases (Figure 5, x axis). Second, transcript levels of each TAA 
in activated cells were normalized to 18S rRNA and expressed as 
crossing-point (CP) values, in order to demonstrate their over-
all prevalence with respect to each other (Figure 5, y axis). The 
CP value defined the cycle number in the logarithmic phase of 
the PCR, where the product was the same in all the samples that 
were compared; thus, low CP values revealed high levels of mRNA 
template, while high CP values indicated rare mRNA templates. 
Transcript levels of numerous TAAs increased upon activation 
of PBMCs and CD8+ T cells from around 10-fold to more than 
107-fold when compared with unstimulated cells (Figure 5, right 
quadrants). As expected, TAA transcripts were expressed in acti-
vated cells at widely different levels, reflected by CP values rang-
ing from 13 to 35 (Figure 5, y axis). Transcripts for several TAAs 
remained very low, with or without lymphocyte activation (CP, 
>30; Figure 5, bottom quadrants). Survivin transcripts displayed 
the greatest fold increase after lymphocyte stimulation (>107-fold) 
and were abundant (CP, 21). In contrast, tyrosinase transcripts 
did not  increase upon activation and were very rare (CP, 35). 
Figure 
MHC-restricted fratricide of survivin-specific TCR-modified PBLs. HLA-A2– and HLA-A2+ activated lymphocytes were transduced with the sur-
vivin-specific TCR-A71, -A66, and -A72. (A) Expression of Tg-TCRs was analyzed using murine TCRβ constant region–specific antibody at day 4 
after TCR transduction. The numbers indicate the percentage of Tg-TCRβ chain expression. (B) TCR-modified PBLs were further cultured for 
2 weeks and stained with 7-AAD to discriminate living and dead cells. The open histograms show staining 1 day after transduction; the filled gray 
histograms display the staining on day 13. The percentage of 7-AAD+ dead cells on days 1 and 13 is indicated in the upper-right corner. (C and 
D) The same analysis was made using PBLs transduced with a high-affinity TCR (T58) specific for a peptide derived from tyrosinase protein 
presented by HLA-A2 (25). Tg-TCRβ chain expression and percentage of apoptotic cells are shown as in A and B. Percentages of 7-AAD+ PBLs 
on days 1, 4, 7, 11, and 13 after TCR-transduction with (E) survivin- or (F) tyrosinase-specific TCR genes in activated lymphocytes of HLA-A2– 
(white bars) and HLA-A2+ donors (gray bars). The data are representative of 2 independent experiments with 2 individual donors each.
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Therefore, the TAAs showing abundant mRNA levels (Figure 5, 
top quadrants) might also have the potential to generate targets 
for MHC-restricted fratricide.
Discussion
These studies  revealed  that  transgenic expression of HLA-A2–
restricted survivin-specific TCRs in activated PBLs led to massive 
apoptosis that was MHC restricted, since this only occurred in 
HLA-A2+ recipient lymphocytes. Expression of survivin in activated 
TCR-modified PBLs resulted in presentation of survivin-specific 
pMHC ligands and led to concurrent self-recognition and fratricide. 
MHC-restricted fratricide likely accounted primarily for our failure 
to expand TCR-engineered effector cells prepared using HLA-A2+ 
recipient lymphocytes, whereas expansion was readily achieved 
with HLA-A2– recipient lymphocytes. Even though survivin-specific 
Tg-TCRs displayed excellent peptide sensitivities and good tumor 
cell recognition, which are important properties for selection of 
therapeutic Tg-TCRs, fratricide of HLA-A2+ recipient lymphocytes 
would preclude their use in TCR gene therapy, except in the clinical 
setting of HLA-A2–mismatched stem cell transplantation.
It has been reported previously that mouse T cells exposed to 
high levels of specific antigen can display anergy or even suicide 
through TCR-mediated induction of apoptosis (31, 32). Further-
more, suicide induced in human T cells by tumor cells expressing 
high levels of antigen altered antitumor immunity by eliminating 
high-affinity T cells (33). It is possible that TCR-induced suicide 
accounted for some of the apoptosis seen in the HLA-A2+ popu-
lations containing T cells expressing survivin-specific Tg-TCRs. 
However, the percentage of lymphocytes that underwent apoptosis 
was much higher than the fraction of T cells expressing a Tg-TCR; 
therefore, active fratricide clearly contributed to the death of 
Tg-TCR–negative lymphocytes. This contention was underlined 
by the demonstration that Tg-TCR effector cells had the capacity 
to directly kill both activated T cells and CTL clones of HLA-A2+ 
donors, irrespective of their particular TCR specificities.
Uncovering MHC-restricted fratricide helped to explain the loss 
of HLA-A2+ lymphocytes expressing survivin-specific Tg-TCRs over 
time and might also account for several other observations regard-
ing survivin-specific T cells. After strong enrichment of T cells by 
survivin-multimer sorting and further culture, self-restricted T cell 
lines expressed only low percentages of CD8+ multimer+ T cells, 
whereas allorestricted lines retained high percentages of double-
positive cells. Thus, it appears that expansion of survivin-specific 
self-restricted T cells was self-limited. We also noted early prolif-
eration of self-restricted T cell clones in the majority of limiting 
dilution cultures, but T cell colonies showing robust prolifera-
tion over several weeks all proved to be nonspecific. We speculate 
that early clonal proliferation of survivin-specific clones may have 
occurred when low numbers of T cells were buffered by large num-
bers of feeder cells, but HLA-A2–restricted apoptosis may have 
hindered their later outgrowth. Because HLA-A2– cells could not 
display the corresponding pMHC ligands, they were resistant to 
HLA-A2–restricted fratricide, and numerous HLA-A2–allorestrict-
ed survivin-specific T cell clones could be isolated. These results 
appear to be concordant with previous studies that described 
HLA-A2–restricted survivin-specific T cells that were propagated 
as T cell lines in vitro or detected in peripheral blood samples of 
cancer patients ex vivo, whereas survivin-specific T cell clones were 
difficult to obtain (9–18, 34).
Recently, one survivin-specific CTL clone that was isolated 
from an HLA-A2+ breast cancer patient recognized the same 
pMHC ligand as the Tg-TCR described here (18). This patient-
Figure 
Cytotoxic activity of survivin-specific TCR-modified PBLs. The cytotoxicity of survivin-specific TCR-engineered PBLs using lymphocytes and 
T cell clones as target cells was determined in a standard 4-hour chromium release assay using varying E/T ratios, and results are presented 
as percent specific lysis. (A) Unstimulated or PHA- or CD3/CD28-activated lymphocytes of HLA-A2– and HLA-A2+ donors were used as target 
cells at the given E/T ratios. (B) mRNA levels of survivin and β2-microglobulin (β2m) were analyzed by RT-PCR. (C) HLA-A2+ T cell clones with 
specificity for the TAA MART-1/melan-A (A42, ref. 28), tyrosinase (Tyr-F8, ref. 29), or Epstein Barr virus (FaLe) were assessed as target cells for 
TCR-modified effector cells. An alloreactive clone (JB4, ref. 30) derived from an HLA-A2– donor served as a negative control. (D) Corresponding 
survivin mRNA levels of the T cell clones were determined and depicted as in B. Cytotoxicity data represent means of duplicates measured at 
each E/T ratio. These data are representative of 2–4 individual donors.
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derived CTL clone was shown to recognize all HLA-A2+ survivin+ 
tumor cell lines in a small panel, with the exception of the FM-86 
cell line. The authors surmised that FM-86 cells were not recog-
nized due to disturbed pMHC ligand expression, since the tumor 
cells were found to have high levels of survivin mRNA. As shown 
here, this tumor cell line expresses relatively low levels of surface 
HLA-A2. We included FM-86 cells in our analyses and found 
that these tumor cells were recognized by effector cells trans-
duced with each of the 3 Tg-TCRs; however, killing was less with 
effector cells expressing TCR-A71, the Tg-TCR that endowed the 
PBLs with the lowest functional avidity. The failure of the pub-
lished patient CTL clone to kill FM-86 cells would be explained 
if it had a functional avidity decidedly lower than that of PBLs 
expressing TCR-A71.  In addition, our Tg-TCRs were codon-
optimized and modified to express murine constant regions, 
which imbued them with good surface expression and strong 
capacity to interact with tumor cells expressing low levels of 
pMHC ligand. Furthermore, it has been reported that TCR/CD3 
expression or TCR signaling is frequently disturbed in patient-
derived T cells, thereby hindering their capacity to recognize 
tumor cells. Such alterations may also have impacted the capac-
ity of the patient-derived CTLs to recognize FM-86 tumor cells 
displaying low pMHC ligand density.
Because our survivin-specific TCRs were well expressed as trans-
genic proteins  in activated recipient  lymphocytes of HLA-A2– 
healthy donors, we could bypass deficits that impinge on expres-
sion, signaling, or function of patient-derived CTL clones. The 3 
Tg-TCRs effected wide differences in functional avidity in recipient 
lymphocytes, varying by more than 4 orders of magnitude in peptide 
sensitivity. Based on analysis of numerous T cell clones (ref. 25  
and D.J. Schendel, unpublished observations), we would clas-
sify TCR-A71 as having a relatively low affinity, whereas TCR-A72 
had a very high affinity. Effector PBLs expressing TCR-A71 showed 
reduced recognition of FM-86 and KT-195-A2 tumor cells, which 
expressed the lowest levels of surface HLA-A2, indicating a rela-
tionship between T cell functional avidity and pMHC ligand den-
sity in efficacy of tumor cell recognition. It should be noted, how-
ever, that a correlation could not be drawn with respect to levels of 
survivin mRNA, since these tumor lines both showed high levels 
of survivin transcripts.
While our studies identified fratricide that was restricted by 
HLA-A2,  it  is also possible  that T cells with adequate avidity 
could recognize additional survivin-derived peptides presented by 
other MHC molecules, leading to self-restricted fratricide even in 
HLA-A2– donors. The frequent failure to obtain self-restricted T 
cell clones specific for some self-peptides is often interpreted to 
be a consequence of deletional tolerance. Based on the results pre-
sented here, additional studies are warranted to explore the role 
of MHC-restricted fratricide in controlling the development of T 
cells specific for proteins that are well expressed in activated lym-
phocytes. The authors of two reports speculated that fratricide 
may have inhibited effective expression of a murine TCR specific 
for p53 in activated human lymphocytes (35) or limited expansion 
of T cells specific for hTERT (36), although direct experimental 
evidence of fratricide was not provided in these studies. On the 
other hand, other technical limitations could influence the expan-
sion and isolation of such T cells.
The quantification of mRNA indicated that several other TAAs 
could potentially become targets for T cell–mediated fratricide, 
based on their high levels of expression in activated lymphocytes. 
In contrast, transcripts that were very rare, even upon T cell acti-
vation, would be less likely to generate pMHC ligands for self-
restricted fratricide. This contention is supported by the failure 
of the high-affinity tyrosinase-specific TCR-T58 to induce wide-
spread apoptosis in HLA-A2+ lymphocytes. TCR-mediated frat-
ricide specific for any TAA will be dependent on several factors, 
including protein expression, location, and turnover, as well as 
antigen processing and presentation of specific peptides by self-
MHC molecules. Nevertheless, it would seem prudent to include 
analysis of RNA and protein expression in activated lymphocytes 
Figure 
Analysis of mRNA levels for TAAs in activated T cells. Quantitative mRNA expression of 22 TAAs was performed using activated lymphocytes 
of 4 healthy donors using LightCycler technology, and the values are given as mean with SEM. For each donor, the TAA expression profile of 
nonactivated PBMCs and nonactivated enriched CD8+ T cells was compared with that of CD3/CD28-activated PBMCs and CD8+ T cells. Differ-
ences in mRNA levels detected in unstimulated versus stimulated cell populations were expressed as x-fold increases and are depicted on the 
x axis. The y axis represents the CP values, in order to demonstrate the overall prevalence of TAAs in activated cells. The CP value defines the 
cycle number in the logarithmic phase of the PCR where the product is the same in all the samples that are compared. Low CP values represent 
high levels of mRNA template, while high CP values indicate rare mRNA templates. An mRNA template with a CP value of less than 30 is con-
sidered rare. The housekeeping gene 18S rRNA was processed as an internal control for normalization of samples. The data were statistically 
analyzed as described in Methods.
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as additional criteria in the selection process of candidate TAAs for 
development of TCR gene therapy.
MHC-restricted fratricide may also have consequences for tumor 
vaccine development, since this same mechanism could limit pro-
liferation of high-avidity T cells in lymph nodes after vaccination 
with survivin or other TAAs that are expressed in lymphocytes 
(37). Some T cells might escape to the periphery, but substantial 
accumulation at tumor sites might again be self-limiting because 
of fratricide, thereby impacting clinical efficacy. Furthermore, 
MHC-restricted fratricide could have a local spreading effect, 
causing neighboring T cells with unrelated specificities to be 
eliminated due to presentation of target pMHC ligands, irrespec-
tive of their own TCR specificities. This contention is supported 
by our observation of high sensitivity of activated lymphocytes to 
killing by survivin-specific TCR-transduced PBLs, as well as the 
recognition of T cell clones of various specificities derived from 
HLA-A2+ but not HLA-A2– donors.
Striving to attain effective antitumor immunity using TCR-
transgenic effector T cells with high avidity might have the unin-
tended consequence of causing MHC-restricted fratricide of other 
adaptive immune cells, if the TCR displays specificity for a pMHC 
ligand that is well expressed by activated lymphocytes. Our results 
emphasize that judicious selection of TAAs will be important for 
designing successful TCR gene therapies.
Methods
Cells. The cell lines Mel-624.38 (HLA-A2+ [A2+], survivin+ [S+]) (38), Mel-1379 
(A2–, S+; M. Panelli, University of Pittsburgh, Pittsburgh, Pennsylvania, 
USA), UT-SCC-15 (A2+, S+; M. Schmitz, Technische Universität Dresden, 
Dresden, Germany), U-373 (A2+, S+; P.J. Nelson, Ludwig-Maximilians-
Universität, Munich, Germany), KT-195 (A2–, S+; H. Gröner, Deutsche 
Krebsforschungszentrum, Heidelberg, Germany), and T2 (CRL-1992, 
ATCC) were cultured as described previously (25). KT-195-VC and KT-
195-A2 are transfectants of KT-195, generated by transduction with 
retroviral vectors encoding GFP (MP71-iG) or HLA-A*0201 and GFP 
(MP71-A2iG). FM-86 cells were purchased from European Searchable 
Tumor Cell Bank and Database (University Tübingen, Tübingen, Ger-
many) and cultured as described in ref. 39. The T cell clones A42 (28), 
FaLe (EBV-specific, generated in our facility using autologous B-LCL), 
JB4 (30), and Tyr-F8 (29) were cultured as described (30) and used as 
target cells 6 days after restimulation.
Generation of survivin peptide–specific T cells with RNA-pulsed DCs. The collec-
tion of blood and patient material was approved by the “Ethikkommission 
der Medizinischen Fakultät der Ludwig-Maximilians-Universität,” Munich 
and donors gave informed consent. De novo priming of self-restricted and 
allorestricted peptide–specific T cells was performed using mature DCs, elec-
troporated with 50 μg of survivin ivt-RNA, with or without 50 μg HLA-A2 
ivt-RNA. The linearized plasmids pGEM4Z/survivin/A64 and pCDM8-
HLA-A2 (E. Weib, Ludwig-Maximilians-Universität, Munich, Germany) 
were used as templates for RNA transcription. Survivin peptide–specific 
T cells were sorted using an HLA-A2-survivin96–104[97L] pentamer (survivin-
multimer, ProImmune) and either expanded as bulk T cell lines or cloned 
in limiting dilution cultures (25).
Retroviral TCR gene transfer. TCR sequences of survivin-specific clones A71, 
A66, and A72 were determined, and TCRβ-2A-TCRα transgene cassettes 
were synthesized (GENEART) and integrated into MP71-PRE as previously 
described (25). To enhance surface expression, TCR constant regions were 
exchanged by their mouse counterparts (26) and transgene cassettes were 
codon optimized (27). Vector plasmids were used for production of retro-
viral particles and subsequent transduction of T cells (40).
FACS. Anti-CD8,  anti–mouse TCRβ  antibody detecting  the mouse 
constant region of transgenic TCRβ  (BD Biosciences — Pharmingen), 
anti–HLA-A2 antibody (AbD Serotec), survivin-multimer, and HLA-A2-
CMVpp65495–503 control multimer (CMV-multimer, D. Busch, Technische 
Universität, Munich, Germany) were used for analysis or sorting. Viability 
of TCR-modified PBLs was determined by incubation with 7-AAD (BD 
Biosciences — Pharmingen).
Cytotoxicity and IFN-γ release assays. Cytotoxic activities of bulk T cell lines, 
T cell clones, and TCR-modified PBLs were analyzed in standard 4-hour 
chromium release assays (25). For initial analysis at day 13 after the second 
unspecific stimulation, T cells were incubated with 1.5 × 103 survivin96–104[97L] 
(survivin, LMLGEFLKL) or influenza matrix protein58–66 (flu, GILGFVFTL) 
peptide–loaded T2 cells (peptides: Metabion) as previously published (25). 
Bulk T cell lines were cocultured at various effector to target cell ratios (E/T 
ratios). For further analysis, allorestricted clones A71, A66, and A72 were 
analyzed by coculture either with 1 × 103 tumor cells (Mel-1379, Mel-624.38) 
or with flu peptide–loaded T2 cells (E/T, 10:1). Functional avidity of T cell 
clones and TCR-modified PBLs was determined by incubation with 1 × 103 
survivin peptide–loaded T2 cells (10–12 to 10–5 M) at an E/T ratio of 10:1 for 
the T cell clones and 20:1 for TCR-modified PBLs. TCR-modified PBLs were 
cocultured with tumor cell lines, target PBLs or T cell clones using 2 × 103 
target cells at the designated E/T. Specific, relative, and half-maximal lysis 
was calculated as described using duplicate samples at each E/T ratio or 
peptide concentration (25). Target PBL cultures were used directly after isola-
tion or stimulated for 3 days using 100 IU/ml IL-2 (Chiron) and 5 μg/ml PHA 
(Roche) or anti-CD3, -CD28 antibody (40). TCR-modified PBLs (5 × 104) 
were incubated with given tumor cells at an E/T ratio of 2:1, and 24-hour 
supernatants were assessed by ELISA (BD Biosciences). aAPCs were generat-
ed as described previously (41), and 1 × 106 aAPCs were used either unloaded 
or loaded with 10–5 M survivin or flu peptide in cocultures with TCR-A72–
transduced or unmodified PBLs at an E/T ratio of 1:2.
RT-PCR. Isolation of full-length RNA, cDNA synthesis, and PCR ampli-
fication of survivin and β2-microglobulin sequences were performed as 
previously described (12, 40).
Real-time PCR for quantification of TAAs. To evaluate quantitative mRNA 
expression of TAAs, cryopreserved PBMCs of 2 donors as well as freshly 
drawn PBMCs of 2 donors were analyzed. For each donor, the TAA expres-
sion profile of nonactivated PBMCs and enriched CD8+ T cells (CD8+ T 
cell Isolation Kit II, Miltenyi Biotec) was compared with that of activated 
PBMCs and CD8+ T cells. Activation of cells was performed as described 
above. Total RNA was extracted (TriReagent, Biozol), and equal RNA 
amounts were reverse transcribed using oligo(dT)15 primer and AMV 
reverse transcriptase (First Strand cDNA Synthesis Kit for RT-PCR, Roche). 
Detection of TAA expression was performed using the LightCycler PCR 
Master Mix (Roche). Primers used for quantitative RT-PCR are listed in 
Supplemental Table 2. PCR amplification was performed with initial 10 
minutes denaturation at 95°C, 35 cycles of amplification with 1 second 
at 95°C, 10 seconds at 56°C, and 25 seconds at 72°C except for HMMR 
(using 59°C as annealing temperature) and hTERT, survivin, tyrosinase 
(using a kit from Search-LC). Evaluation of results was done by directly 
plotting CP values (normalized by the housekeeping gene 18S rRNA) as 
shown in Figure 5, as well as by conversion of the CPs into relative concen-
tration of transcripts. Transcript levels obtained from nonactivated cells 
were set as 1 to determine an x-fold increase or decrease in transcripts in 
activated PBLs and CD8+ T cells.
Statistics. The basis for data analysis for the different assays displayed 
in Figures 1–4 is provided in the individual figure legends. The values 
shown in Figure 5 represent mean values of transcript levels measured in 
cells of 4 donors, repeated in 2 independent experiments, with the excep-
tions that PSA was only measured in 3 donors and c-kit in only 2 donors. 
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The error bars represent SEM. The means and SEM were calculated using 
GraphPad Prism Software.
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Abstract  
Hyaluronan-mediated motility receptor (HMMR/Rhamm) is overexpressed in 
numerous tumor types, including acute myeloid leukemia (AML). Several studies 
have reported the existence of T cell responses directed against HMMR in AML 
patients, linked to better clinical outcome of disease. Therefore, we explored the use 
of HMMR-specific T cell receptors (TCR) for transgenic expression in lymphocytes 
and their in vivo impact on solid as well as disseminated tumors. We obtained TCR 
via an in vitro priming approach, in combination with a CD137-mediated enrichment 
step. Comparison of recipient lymphocytes expressing transgenic TCR (tgTCR) 
revealed a similar tumor recognition pattern as seen for the original T cells. Adoptive 
transfer experiments using a humanized xenograft mouse model resulted in 
significantly retarded tumor outgrowth, which could be further enhanced using IL-7- 
as well as IL-15-induced memory lymphocytes as tgTCR recipient cells. A 
combination of IL-7/IL-15-induced memory T cells showed an enhanced potency to 
retard the outgrowth of disseminated tumor cells, while CD8-enriched memory T cells 
had the ability to completely inhibit tumor growth. These findings show that 
transgenic expression of this TCR in memory-like CD8+ recipient T cells is a potent 
therapeutic agent for adoptive T cell therapy of AML as well as HMMR-expressing 
solid tumors.   
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Introduction 
Acute myeloid leukemia (AML) is a fast-progressing disease with an increasing 
incidence in elderly patients, limiting use of aggressive therapies. The most common 
treatments include risk-adapted polychemotherapy regimens (1, 2), 5-aza-2-
deoxycytidine (3) or stem cell transplantation (SCT) (4, 5). The persistence of 
resistant tumor cells leads to relapse in a high percentage of patients. 
Immunotherapies, including adoptive T cell transfer, provide an alternative approach 
to eliminate residual leukemia. Consistent with adoptive transfer of tumor-infiltrating 
lymphocytes (TIL) (6) or genetically-modified PBL expressing chimeric antigen 
receptors (CAR) (7), adoptive transfer of patient-derived lymphocytes expressing 
transgenic antigen-specific T cell receptors (tgTCR) has the potential to target solid 
as well as disseminated tumors. The latter immunotherapy allows MHC-restricted, 
antigen-specific TCR to be isolated beforehand and later used to modify lymphocytes 
in a patient-specific manner, taking into account MHC allotypes and antigen profiles 
of the tumor. Strategies to isolate high-affinity TCR, restricted by common MHC 
alleles with specificity for broadly expressed tumor-associated antigens (TAA) have 
been described (8-11), however use of humanized mouse models to verify the quality 
of TCR-transgenic lymphocyte responses in vivo lag in development.  
In addition to well-known leukemia-associated antigens, like survivin, Bcl-2 
and PRAME, hyaluronan-mediated motility receptor (HMMR/Rhamm) represents a 
potential target for tgTCR therapy of AML. HMMR is highly expressed during 
embryogenesis and neural crest formation, while in adults expression is limited to 
testis, placenta, thymus, tonsils and bone marrow (12, 13). Moreover, it is broadly 
expressed in numerous types of tumors, including breast cancer, melanoma and 
leukemia. Several studies analyzing antigen-specific immune responses in AML 
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patients revealed that prolonged survival correlated with the prevalence of HMMR-
specific T cells (14-17). Use of HMMR-derived peptides for antitumor vaccination 
resulted in a strong HMMR-specific immune response but failed to cure disease (18-
20). This discrepancy between induction of peptide-specific immune responses and 
failure to eradicate tumor cells is partly accounted for the existence of only low-avidity 
T cells due to negative selection. Transfer of T cells expressing allorestricted high-
affinity TCR could overcome this limitation.    
In this study, we describe the development of designer lymphocytes 
expressing tgTCR specific for HMMR, starting with generation of allorestricted 
HMMR-specific T cells through to the assessment of TCR-transduced PBL in vivo in 
a humanized mouse model. We used an MHC multimer-independent method to 
isolate high numbers of HLA-A2 allorestricted HMMR-specific T cells using a CD137-
based enrichment step (21, 22) and selected the TCR from one HMMR-specific clone 
to make TCR-transgenic PBL. First we characterized the function of TCR-transduced 
lymphocytes in vitro and confirmed that they had the same specificity as the original 
clone. Then TCR-transgenic lymphocytes were assessed for their capacity to infiltrate 
and retard solid tumor growth in a NOD/scid IL2Rgnull (NSG) mouse model. Initial 
studies directed us further to optimize the phenotype of TCR-transgenic lymphocytes 
used for adoptive transfer. By inducing an IL-7/IL-15-dependent memory phenotype 
within the TCR-transduced populations, we improved the impact on tumor killing in 
vitro and tumor outgrowth in vivo. To further characterize the role of optimized TCR-
transgenic lymphocytes on disseminated human tumor cells, we successfully 
developed a luciferase-based tracking model to assess tumor load in vivo. In the 
settings of both solid tumor and disseminated leukemia, we showed that a single 
injection of TCR-transgenic HMMR-specific lymphocytes led to significant reduction 
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of tumor burden. These findings support the further pursuit of adoptive cell therapy 
using HMMR-specific TCR-transgenic lymphocytes. 
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Results 
Induction of HMMR-specific T cells and enrichment via CD137 
We used our established in vitro dendritic cell (DC) priming approach to generate 
human allorestricted HMMR-specific T cells as a source of high-affinity TCR (8, 9). 
Mature DC (mDC) of an HLA-A2-negative donor were simultaneously loaded with ivt-
RNA encoding HLA-A2 and HMMR, as the MHC allotype and TAA of interest. In vitro 
priming of autologous CD8-enriched T cells was initiated on day 0 using RNA-loaded 
autologous mDC at a 10:1 ratio, as described previously (9). Primed cultures were 
restimulated once on day 7 using mDC prepared in the same manner (Figure S1A). 
After a 14-day resting phase, the bulk cultures were reactivated with RNA-loaded 
mDC that had been previously cryopreserved and T cells were subsequently stained 
with CD137-specific monoclonal antibody. After stimulation, 35.9% of the primed cells 
were CD137 positive. They were subjected to magnetic bead sorting, yielding a purity 
of 83.0% CD137+ cells (Figure S1B). T cell clones were generated via limiting dilution 
directly after enrichment and restimulated every two weeks, as previously described 
(9).  
Following a 4-week culture period, emerging T cell clones were analyzed in a 
standard chromium-release assay using K562-A2 cells as positive target cells (HLA-
A2+, HMMR+) (Figure S2A, 2B) and T2 cells pulsed with an irrelevant peptide (flu) as 
negative controls (HLA-A2+, HMMR-). The isolated T cell clones could be assigned to 
one of three groups showing different patterns of reactivity: no reactivity for either 
target cell, HLA-A2 alloreactivity for both target cells and exclusive HLA-A2 
allorestricted HMMR-specific killing of K562-A2 cells (Figure 1A). Of 152 clones 
analyzed, the HMMR-reactive clones represented the highest fraction (52%), 
followed by 25% HLA-A2-alloreactive and 23% non-reactive T cell clones (Figure 
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1C). We further analyzed the potentially HMMR-specific T cell clones for their 
capacity to kill an additional HLA-A2+, HMMR+ tumor cell (THP-1) (Figure S2A, S2B) 
and to secrete IFN-γ in response to tumor stimulation (Figure 1B). Additionally, we 
screened them for capacity to recognize one defined immunogenic epitope of HMMR 
(HMMR-R3; ILS), which was shown to be recognized by tumor-infiltrating T cells in 
AML patients (19). All of these T cell clones recognized K562-A2 and THP-1 to 
varying degrees. Lysis of ILS peptide-loaded T2 cells by clones 17, 61, 78 and 121 
indicated potential recognition of this HMMR-nonamer, but this was not seen with 
IFN-γ secretion, failing to confirm that it was the particular epitope seen by these T 
cell clones. HMMR-reactive clones that recognized K562-A2 and THP-1 cells but not 
flu-pulsed T2 cells were further analyzed for secretion of several T helper-1 (Th1) 
cytokines (IL-2, IFN-γ, MIP-1α and TNF-α) that have been linked with poly-
functionality of high-avidity T cells (Schendel, unpublished observations) (23). Based 
on analysis of 14 well-growing clones, 64% (9 clones) secreted all four cytokines, 
while 36% (5 clones) secreted three cytokines in response to both HLA-A2+, HMMR+ 
tumor lines (THP-1 and K562-A2), but not to flu-pulsed T2 cells as a negative control 
(Figure 1D).  
 
Characterization of HMMR-reactive clones 67 and 150 
Our further analyses concentrated on CTL67 and CTL150 which expressed different 
TCR sequences (data not shown). CTL150 discriminated quantitatively between 
THP-1 and K562-A2 tumor cells, whereas CTL67 did not. While CTL67 was less 
cytotoxic in recognition for K562-A2, it showed higher secretion of IFN-γ after 
exposure to tumor cells (Figure 1E, 1F). 
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In the next set of experiments, we determined whether expression of these 
TCR as transgenes in activated peripheral blood lymphocytes (PBL) could equip 
effector cells with specificity comparable to the original T cell clones. The TCR 
sequences of CTL67 and 150 were isolated, codon optimized and their constant 
regions exchanged for the murine counterparts, as described (24). Following 
retroviral transduction of recipient lymphocytes, we were only able to detect 
expression of TCR150, whereas expression of TCR67 failed in transduced 
lymphocytes (Figure S3A).  
 
Tumor specificity of transgenic PBL expressing TCR150 
Expression of TCR150 was demonstrated on CD4+ as well as CD8+ cells (Figure 2A), 
as detected by staining of the murine constant region of the tgTCR, as described 
(24). The TCR-transgenic PBL were tested for tumor recognition measuring IFN-γ 
secretion after stimulation with K562-A2 and THP-1 tumor cells (Figure 2B) and high 
levels of IFN-γ were detected. This was dependent on tgTCR expression because 
mock-transduced PBL and PBL transduced with a GFP control vector were not 
induced to secrete IFN-γ following stimulation with these tumor cells. HMMR 
specificity was shown by absence of IFN-γ responses by TCR150-transgenic PBL 
stimulated with flu-pulsed T2 cells. Interestingly, the TCR-transgenic PBL displayed 
the quantitative differences in recognition of THP-1 and K562-A2 seen with the 
original clone.  
The TCR150-transgenic PBL were also analyzed for cytotoxic potential. They 
were compared with mock control PBL and PBL transduced with a second TCR 
(TCR-A72) with specificity for an epitope of the anti-apoptotic protein survivin that 
was also expressed by all tumor cell lines (data not shown). Both THP-1 and K562-
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A2 cells were recognized by both TCR-trangenic populations, albeit only weak 
responses were seen against THP-1 (Figure 2C). Because the levels of cytotoxicity 
were low, probably due to the low percentage of CD8+ cells expressing the tgTCR, 
we enriched TCR-transgenic cells using magnetic bead isolation of cells expressing 
the murine constant region of the tgTCR. Enrichment yielded more than 80% TCR-
positive cells (Figure S3B and not shown) but also resulted in a significant fraction of 
dead cells. This may have been caused by activation-induced cell death, mediated by 
antibody binding to the tgTCR. Nevertheless, the cytotoxic capacity of the viable 
enriched TCR150- and TCR-A72-transgenic PBL was greatly increased, 
demonstrating the tgTCR-dependent killing of both tumor cell lines. The failure of 
HLA-A2-, HMMR+ K562 cells to be recognized by either population demonstrated the 
HLA-A2-restriction of both tgTCR. 
To confirm that recognition by TCR150 was HMMR-specific, we used a 
lentiviral vector to introduce shRNA (short hairpin RNA) specific for HMMR into 
HMMR-expressing target cells. We first analyzed the efficacy of HMMR knock-down 
in HMMR+ tumor lines by measuring intracellular staining for HMMR protein in 
comparison to the HLA-A2+ human breast cancer cell line MCF-7, which is known to 
be HMMRlow (Figure S2A, S2B). The HMMR+ tumor cell lines, THP-1 and mel624.38, 
showed a strong reduction of HMMR expression (Figure S2C). Therefore this shRNA 
was suitable for knock-down of HMMR in target cells. 
The parental tumor cell lines, THP-1 and mel624.38 (HLA-A2+, HMMR+), were 
recognized by TCR150-transgenic PBL to different degrees (Figure 2D). Following 
introduction of shRNA, the treated tumor cells were no longer recognized by 
TCR150-transgenic cells. The HMMRlow MCF-7 cells also were not recognized by 
TCR150-transduced PBL. As a control we showed that all three tumor lines were 
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recognized by an HLA-A2 alloreactive CTL and this killing was not altered by knock-
down of HMMR (data not shown). In addition we could show that the shRNA-treated 
and the parental melanoma cell lines were recognized to similar degrees by a MART-
1-specific CTL (Figure S2).   
          The shRNA knock-down of HMMR with subsequent loss of recognition 
confirmed that TCR150 was specific for HMMR. Since none of the clones, including 
CTL150, recognized the HMMR-R3 epitope (ILS), we moved towards identifying the 
epitope using an HMMR gene transfection approach: mDC from an HLA-A2-negative 
donor were loaded with ivt-RNA encoding HLA-A2, together with ivt-RNA encoding 
full length HMMR (1-725) or with an ivt-RNA deletion mutant encoding the first 170 
amino acids of HMMR. TCR-transgenic PBL expressing a tyrosinase-specific TCR 
(T58) were used as an effector control (9). As depicted in Figure 2E, TCR150-
transgenic PBL recognized DC expressing full length HMMR as well as DC loaded 
with the deletion mutant, revealing that the targeted epitope is within the first 170 
amino acids of the HMMR protein. The stimulation of TCR-transgenic PBL with T2 
cells pulsed with several synthetic peptides that bind to HLA-A2 molecules did not 
lead to specific responses (data not shown). Further studies will be required to 
determine the peptide-epitope for TCR150.  
 
Targeting of solid tumors in vivo using TCR150-transgenic PBL 
To characterize the function of TCR150-transgenic lymphocytes in vivo, we utilized 
adoptive transfer of TCR-transgenic PBL into NSG mice, which lack murine T cells, B 
cells and NK cells (25). The effect of TCR150-transgenic PBL on growth of a solid 
tumor mass was assessed following subcutaneous injection of 1x106 THP-1 cells in 
matrigel in the right flank. Human TCR150-transgenic PBL were injected i.v. 24 hours 
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later. In preliminary experiments, tumor growth in a non-treated control group was 
first detected around day 14 after tumor inoculation (data not shown). Therefore, in 
the adoptive transfer experiments, growth was measured on a day-to-day basis from 
this time point. The impact of injected TCR150-transgenic or mock control PBL was 
assessed using 2x105 (Figure 3A and 3C) or 5x105 (Figure 3B and 3D) TCR+ 
lymphocytes, providing an E:T of 1:5 or 1:2, with the starting tumor cell number. The 
TCR-transduction provided 10 - 20% TCR-positive PBL in all adoptive transfer 
experiments and the numbers of mock-treated PBL matched the highest number of 
TCR150-transduced lymphocytes injected. PBL transduced with a tyrosinase-specific 
TCR (T58) and mock-treated control cells had no impact on THP-1 tumor outgrowth, 
consistent with the tumor being tyrosinase-negative. In contrast, injection of 2x105 
TCR150-transgenic lymphocytes reduced tumor growth to a significant extent (p< 
0.001) (Figure 3A). Injection of the higher dose (5x105) of TCR150-transduced 
lymphocytes on day 1 significantly retarded tumor growth (p<0.001) but not more 
than 2x105 cells (Figure 3B). Injection of a second dose of TCR150-transgenic 
lymphocytes (2x105) on day 14 into mice initially given the lower dose (data not 
shown), did not lead to further reduction in tumor size. The overall survival of mice 
was prolonged by 8 days in the TCR150-treated group receiving a single dose of 
2x105 cells, whereas the T58-treated mice showed identical mean survival times as 
the mock-treated control group (Figure 3C). A single injection of 5x105 TCR150-
transgenic lymphocytes led to longer survival of individual mice, compared to those 
given 2x105 TCR150-PBL (Figure 3D).  
 The discrepancy between reduction in tumor size and survival might be 
explained by infiltration of lymphocytes adding to tumor volume. 
Immunohistochemical staining of excised tumors demonstrated the presence of 
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human T cells exclusively in mice treated with TCR150-transgenic lymphocytes, as 
evidence for TCR-mediated migration to the tumor site (data not shown). It was not 
possible to detect significant numbers of TCR150-expressing cells in either peripheral 
blood or spleens of these mice (data not shown).  
 
Modulation of TCR-transgenic lymphocytes enhances tumor control 
To prolong survival of TCR-transgenic lymphocytes in vivo, we attempted to induce 
different memory T cell phenotypes in the transduced lymphocyte populations. We 
initiated standard cultures with IL-2 and then changed the cytokine milieu of the PBL 
five days after TCR transduction, as indicated in Table 1. We determined the 
phenotypes of the TCR-transduced lymphocytes on day 5, before addition of new 
cytokines, as well as on day 13 before adoptive transfer into mice. Analysis of 
CD62L-expression levels was performed after pre-gating on CD8+/CD45RA- cells, 
allowing discrimination between central memory (TCM) (CD62L+) and effector memory 
(TEM) (CD62L-) phenotypes (Figure 4A). TCR-transduced PBL showed an equal 
division into CM and EM phenotypes on day 5, which was preserved on day 13 when 
the cells were cultured under either IL-7 or Tc17-conditions. TCR-transduced PBL 
cultured further in the presence of only IL-2 or with IL-15 led to a decrease in the TCM 
fraction on day 13. IL-15 culture conditions yielded cells on day 13 with an induced 
non-differentiated TEM status (CD28+, CD27+) (data not shown). This phenotype was 
also observed for EM lymphocytes cultured under IL-7 and Tc17 conditions (data not 
shown).  
To assess further differences in the cytokine-induced phenotypes, we 
performed intracellular staining (ICS) for IFN-γ and TNF-α in the four populations of 
TCR-transduced lymphocytes cultured for 13 days (Figure 4A). The four populations 
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were cultured with or without THP-1 cells for 6 h and analyzed for intracellular 
cytokines, in combination with lymphocyte subset surface markers. Increased 
amounts of intracellular cytokines were detected only in CD8+ T cells after stimulation 
with tumor cells (Figure 4B and data not shown). This indicated that TCR150-
transgenic PBL responded in a CD8-dependent fashion to antigen stimulation. 
Moreover, similar proportions of double-positive (IFN-γ+, TNF-α+) cells were found in 
TCR-transduced lymphocytes cultured under IL-2, IL-7 or IL-15 conditions. In 
contrast TCR-transduced PBL cultured with Tc17-conditions yielded at least a two-
fold higher percentage of IFN-γ+/TNF-α+ double-positive T cells. Mock-control PBL 
served as a background control and showed no differences in percentages of 
cytokine double-positive cells after tumor stimulation.  
The TCR-transgenic lymphocyte subsets were assessed for their in vitro 
cytotoxicity against THP-1 and mel624.38 target cells (Figure 4C), while K562 cells 
served as a negative control (data not shown). Both tumor cell lines were recognized 
by TCR150-transgenic PBL, whereas TCR-T58-dependent killing was restricted to 
the tyrosinase+ melanoma cell line. TCR-transgenic PBL tested on day 5 after 
transduction resulted in an increased specific lysis of target cells, when compared to 
TCR-transgenic PBL cultured over 13 days only in the presence of IL-2. Cytotoxic 
capacity was not altered when TCR-transgenic PBL were cultured under Tc17 
conditions and only slightly increased when TCR-transgenic PBL were exposed to IL-
7 conditions. Interestingly, TCR-transgenic PBL cultured in the presence of IL-15 
showed a strongly increased killing capacity for both tumor cells, compared with all 
other TCR-transgenic PBL populations.  
To assess specific tumor recognition of the TCR-transgenic PBL cultured 
under different conditions in adoptive transfer experiments, 1x106 THP-1 (Figure 5A) 
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or 4x105 mel624.38 (Figure 5C) cells were injected s.c. into NSG mice. All modified 
PBL subsets induced a reduction in the outgrowth of both tumors when compared to 
mock PBL. Comparing the effect of IL7- or IL-15-treated lymphocytes with TCR-
transgenic PBL cultured under IL-2 or Tc17 conditions, we were not able to detect a 
difference in the tumor outgrowth of THP-1, whereas that of mel624.38 was reduced 
to a significantly greater extent. To investigate whether this observation was due to 
tumor load, we injected a lower dose of 4x105 THP-1 cells and treated the mice in a 
similar manner. While tumor outgrowth in mice treated with mock PBL or IL-2-treated 
TCR150-transgenic PBL (Figure 5B and data not shown) was not changed compared 
to the tumor curves following injection of 1x106 THP-1 cells, TCR150-transgenic PBL 
cultured in IL-7 or IL-15 significantly reduced the outgrowth of the lower number of 
THP-1 cells (Figure 5B).  
Reflecting the retarded tumor outgrowth, the overall survival of mice given 
1x106 THP-1 or 4x105 mel624.38 cells followed by treatment with TCR150-transgenic 
PBL conditioned with IL-7 (THP-1 day 34; mel624.38 day >40) or IL-15 (THP-1 day 
36; mel624.38 day > 40) was prolonged significantly for both tumors, but particularly 
mel624.38 cells (Figure 5F). In contrast, Tc17-conditioned PBL resulted in shorter 
survival (THP-1 day 28; mel624.38 day 30) compared with conventional IL-2-treated 
TCR-transgenic PBL (d5) (THP-1 day 31.5; mel624.38 day 33). The failure to detect 
human T cells in spleens or peripheral blood of sacrificed mice was not altered by the 
in vitro culture conditions (data not shown). 
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TCR150-transduced memory T cells limit outgrowth of disseminated tumor 
cells 
Since we observed that IL-15- as well as IL-7-induced memory T cells expressing 
TCR150 showed improved ability to retard growth of solid HMMR+ tumors, we tested 
their impact on disseminated leukemia cells. For these experiments the firefly 
luciferase gene was introduced into THP-1 cells by lentiviral transduction. After 
sorting for a purity of 100% luciferase-expressing cells, we injected 1x106 THP-1luc 
cells i.v. into NSG mice. After 24 h, 2x105 TCR150-transgenic PBL conditioned with 
IL-7 in combination with 2x105 TCR150-transgenic PBL conditioned with IL-15 were 
adoptively transferred i.v. into mice. As a control, we used similar amounts of T58-
transgenic PBL, a TCR specific for tyrosinase, since THP-1 cells are tyrosinase 
negative. In this control group, we detected leukemic cells in the femur of mice 14-21 
days after injection (Figure 6 and Figure S4). The initial detection of leukemia was 
followed by a rapid spread, causing lesions in the kidneys, liver, spine and, in rare 
cases, in the lungs and ovaries. Approximately 10-15 days after the first detection of 
tumor cells, mice displayed paralysis of the hind legs, at which point they were 
removed from the study and sacrificed. The overall survival of the mice treated with 
T58-transduced PBL was 31.6 days. In contrast, a single dose of 4x105 TCR150-
transgenic PBL given 24 h after tumor inoculation was sufficient to dramatically retard 
tumor outgrowth, whereas injection of 2x105 TCR150-transgenic PBL conditioned 
with IL-15 had no effect (Figure S4). Additionally, in one group we attempted to 
prolong the survival of lymphocytes in vivo (4x105) by exogenous IL-15 administration 
given i.p. daily from day 1 through day 10. This treatment resulted in no additional 
improvements. However, a dramatic effect was observed when exogenous IL-15-
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treatment was combined with the administration of 4x105 CD8-enriched TCR150-
transgenic PBL. This resulted in complete control of the leukemia beyond day 50. 
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Discussion 
Selection of a well-defined target antigen is crucial for immunotherapeutic 
approaches employing adoptive T cell transfer. Several studies have indicated that 
HMMR is over-expressed in many tumor types including prostate cancer, breast 
cancer, melanoma and chronic and acute leukemia (14-16, 26, 27). Over-expression 
of HMMR is strongly associated with a worse prognosis in solid tumors and 80% of 
melanoma metastasis show a dramatic over-expression of this protein (13, 14). In 
contrast, HMMR expression in disseminated tumors such as leukemias is related to a 
better clinical outcome and linked with an HMMR-specific immune response (14). In 
vaccination studies using an immunogenic HMMR-derived peptide, patients 
developed a potent immune response that correlated with clinical benefit, while no 
signs of toxicity were observed (20, 28). We elected to explore development of 
HMMR-specific T cells for TCR gene therapy in AML, since over 70% of AML show a 
significant over-expression of this protein, while expression in normal tissue is limited 
to testis, thymus, bone marrow, tonsils and placenta (15). Further characterization of 
the HMMR-positive cell types in these organs will show the suitability of HMMR-
directed therapy using TCR-transgenic lymphocytes.  
The priming of allorestricted, HMMR-specific T cells allowed us to isolate T cell 
clones from healthy donors (9). To overcome the limitation of T cell isolation by 
peptide-derived multimers, restricted to a single known epitope, we utilized T cell 
enrichment via the activation marker CD137. Several other studies demonstrated the 
use of this CD8-specific activation marker to enrich antigen-specific T cells or to 
deplete alloreactive T cells (21, 22). By using this approach we isolated 52% HMMR-
specific T cell clones recognizing two HMMR-positive, HLA-A2-positive tumor cell 
lines, while the control T2 cell line (HLA-A2+) pulsed with flu-peptide was not 
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recognized. A major fraction of HMMR-specific T cell clones was able to secrete the 
Th1-cytokines IFN-γ, IL-2, MIP-1α and TNF-α, indicating their polyfunctional 
phenotype (23). Selection of CTL67 and CTL150 for further studies showed that they 
used different TCR rearrangements. These two CTL also showed different profiles of 
specific cytotoxicity and varying patterns of cytokine secretion. Both clones failed to 
recognize the HMMR-R3 peptide (ILS) and showed negligible recognition of the HLA-
A2+, HMMR- target cell control. We did not identify any T cell clones recognizing the 
reported immunogenic peptide HMMR-R3 (ILS). This peptide appears to dominate 
the immune response in AML patients, whereas T cells recognizing the R3-peptide 
are rare in healthy individuals (19). 
Using codon-optimized, murinized TCR sequences of TCR150 and TCR67 for 
retroviral transfer into recipient lymphocytes, we only detected surface expression of 
TCR150. Failure to express TCR67 could be due to inefficient TCR α- and β-chain 
pairing or to an overall low expression of the transferred genes. In contrast, TCR150 
was expressed well on both CD4 and CD8 T cells. Tumor recognition by TCR150-
transgenic PBL showed the same pattern of specificity as the original CTL. Moreover, 
tumor recognition by TCR150-transgenic PBL, both in vitro and in vivo, was antigen-
specific. Enrichment of the TCR-transgenic fraction of PBL led to a dramatic increase 
in specific tumor cell lysis. Furthermore, shRNA-mediated knock-down demonstrated 
that recognition by TCR150-transgenic lymphocytes was dependent on HMMR 
expression by tumor cells. By introducing a deletion mutant of HMMR into DC, 
comprising only the first 170 amino acids, we were able to show that the recognized 
epitope is located within this fragment. Identification of the cognate epitope could not 
be determined by testing candidate peptides carrying known HLA-A2-binding 
motives, necessitating more complex approaches to identify this epitope in the future.  
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After confirming specificity and function in vitro, we determined the impact of 
TCR150-transduced PBL in vivo using as recipients the NSG mouse strain, lacking 
all murine T cells, B cells and NK cells (25). This strain is known to be a suitable host 
for engraftment of human tumors of both solid and disseminated types (25, 29). We 
first injected human tumor cell lines subcutaneously in matrigel to create solid 
tumors. In contrast to other studies using mouse model systems, we intended to 
explore the impact of TCR150-transduced PBL without pre-conditioning of the host 
mice (30), although such pre-conditioning may also impact on the tumor and 
contribute to better antitumor responses. Additionally, we tried to mimic the clinical 
relapse situation by intravenous injection of TCR-transduced PBL after tumor 
inoculation. In this setting, we observed that a single injection of 2x105 TCR150+ PBL 
was sufficient to retard solid tumor outgrowth to a significant extent, resulting in a 
prolonged overall survival. These observations were quite surprising since the ratio of 
TCR150+ PBL to tumor cells was at a maximum of one effector cell per two tumor 
cells and TCR-transgenic PBL were injected only once. Nevertheless, the reduction 
in tumor growth using this mode of application is striking when compared with other 
studies performing intratumoral injection of much higher cell numbers, or pre-
incubating tumor cells with effector cells in vitro prior to adoptive transfer (31, 32). 
Under these conditions, persistence of TCR150+ T cells in the mice following 
intravenous application of 2x105 or 5x105 cells is probably too low to induce better 
control of the tumors. Further studies, injecting varying doses and regime frequencies 
of TCR150-transgenic PBL may lead to further improvements.  
The persistence of engineered PBL in NSG mice in other studies ranged from 
10-20 days (31) and could be increased by selecting central memory T cells (TCM) or 
by administration of human IL-15 to the mice after adoptive transfer of lymphocytes 
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(33, 34). Other reports claimed that cells with a Tc17-phenotype were most potent for 
eradicating tumors in mouse models (35, 36). To further explore these options in our 
system, we cultured TCR150-transduced lymphocytes in the presence of different 
cytokines to induce cells with effector memory (TEM), central memory (TCM) or Tc17-
phenotypes, respectively (37). In agreement with previous studies, we observed that 
a TCM-phenotype was induced by IL-7, while IL-15 resulted in a more TEM-like 
phenotype. In vitro functional analysis showed that only the IL-15 culture conditions 
increased the lytic capacity of TCR-transgenic PBL, while their cytokine production 
was altered most by Tc17 conditions. The Tc17-phenotype had no impact on tumor 
growth in our experiments, whereas TCR150-transgenic PBL cultured in the 
presence of IL-7 or IL-15 led to significant reduction of tumor outgrowth when 
mel624.38 cells were targeted. In contrast, outgrowth of THP-1 was not altered under 
these conditions. In vitro recognition of this tumor by the original CTL150 and by 
TCR150-transgenic PBL was always low, suggesting that this AML was somewhat 
resistant to CTL. The reasons for this remain to be explained, but may depend on 
antigen-processing and presentation, or on expression of inhibitory molecules or 
cytokines.  
To address the function of TCR150-transgenic lymphocytes on disseminated 
human leukemia cells, we used a combination of IL-7- and IL-15-pre-conditioned 
PBL, due to the superior antitumor effects seen with solid tumors. TCR150-
transgenic PBL given in a single dose of 4x105 were sufficient to significantly retard 
leukemia compared to PBL transduced with an irrelevant TCR (T58). A dose 
dependent difference in tumor outgrowth was seen between injection of 4x105 and 
2x105  TCR150-transgenic PBL. Further therapeutic improvements were achieved 
when IL-15 was administered exogenously on a daily basis, in particular when used 
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in combination with 4x105 CD8-enriched TCR150-transgenic lymphocytes. The 
combination of TCR150-transgenic CD8+ T cells with IL-15 resulted in a strongly 
prolonged control of the leukemic cells, supporting a CD8-dependent function of 
TCR150. Further analysis of additional HLA-A2+ HMMR+ leukemia and solid tumor 
cells, both in vitro and in vivo, may extend the potential of TCR150+ IL-15-conditioned 
lymphocytes for use in TCR gene therapy. 
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Methods 
Cell lines 
The human acute monocytic cell line, THP-1 (HLA-A2+, HMMR+; TIB-202) (38) was 
cultured in RPMI 1640 medium, supplemented with 10% fetal calf serum (Invitrogen). 
The packaging cell line 293T (human embryonal kidney, CRL-1573) (39) as well as 
the human breast carcinoma cell line MCF-7 (HTB-22) (40) were cultured in 
Dulbeccoʼs MEM with 4 mM L-glutamine, 100 U/ml penicillin/streptomycin and 1 mM 
sodium pyruvate. The human chronic myeloid leukemia cell line, K562 (HLA-A2-, 
HMMR+; CCL-243) (41) and K562-A2 (HLA-A2+, HMMR+; medium supplemented 
with 1 µg/ml G418, gift from H. Pohla, Laboratory for Tumor Immunology, Ludwig-
Maximilians-University, Munich, Germany), the melanoma cell line mel624.38 (HLA-
A2+, HMMR+; gift from M.C. Panelli, National Institutes for Health, Bethesda, USA) 
(42) as well as the human lymphoid cell line T2 (43) were cultured in RPMI 1640 
medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, 1 mM sodium 
pyruvate and 1 mM non-essential amino acids. The CTL A42 was cultured and 
restimulated as described previously (44). Exogenous peptide pulsing of T2 cells or 
DC was performed using 10-5 M peptide (HMMR166-175: ILSLELMKL, MART-125-36: 
ELAGIGILT and influenza matrix protein58-66: GILGFVFTL) (Metabion) and performed 
as described previously (9).  
 
Production of in-vitro transcribed RNA 
The plasmid pReceiver-B02 with the HMMR insert (Acces. No. U29343; 
GeneCopoeia) and the plasmid pCDM8HLA-A2, containing the HLA-A*0201 cDNA 
(gift from E. Weiß, Department of Biology, Ludwig-Maximilians-University, Munich, 
Germany) were linearized and used as templates for ivt-RNA production using the 
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mMESSAGE mMACHINE T7 kit (Ambion). Production followed the manufacturerʼs 
instructions.  
 
Flow cytometry analysis  
For analysis of surface marker expression, cells were labeled with the following 
fluorescence-conjugated monoclonal antibodies: CD3 (PerCP, SK7, BD), CD4 (FITC, 
13B8.2, BeckmanCoulter), CD8 (FITC, HIT8a, BD), CD8 (APC, SK1, BD), CD25 (PE-
Cy7, M-A251, BD), CD27 (Alexa Fluor 700, M-T271, BD), CD28 (FITC, CD28.2, BD), 
CD45RA (PerCP-Cy5.5, HI100, eBioscience), CD62-L (APC, DREG-56, BD), CD137 
(APC, 4B4-1, BD), CD279 (PE, MIH4, eBioscience), murine TCR constant beta-
chain-region (APC, H57-597, BD). After a 60 min incubation, cells were washed and 
analyzed by flow cytometry using an LSRII instrument (BD). Data analyses were 
performed using the FlowJo 8 software (Tree Star Inc.).  
 
Intracellular cytokine staining  
Cells were cultured for 6 h, with or without tumor cells (20:1, E:T), in the presence of 
brefeldin A (eBioscience), with a final concentration of 15x. Before fixation, cells were 
washed and stained using the Live/Dead Fixable Blue Dead Stain Kit (Invitrogen), 
followed by staining with the following antibodies: CD4 (APC-Cy780, RPA-T4, 
eBioscience), CD8 (V500, RPA-T8, BD), CD69 (PerCP, FN50, BD). Fixation and 
permeabilization was performed using the FoxP3 Staining Buffer Set (eBioscience) 
according to the following steps (all performed at 4°C): fixation of cells using 
Fix/Perm Buffer for 30 min followed by two washing steps with Perm Buffer and 
staining for 30 min with the intracellular markers CD3 (PE-Cy7, SK7), IFN-γ (V450, 
B27), IL-2 (FITC, 5344.111), IL-4 (PE, 3010.211) and TNF-α (Alexa Fluor 700, 
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MAb11) (all BD). After two additional washing steps, cells were analyzed by flow 
cytometry (LSRII instrument; BD). Data analyses were performed using the FlowJo 8 
software (Tree Star Inc.). Staining of intracellular HMMR was as for ICS starting with 
fixation, using the primary HMMR antibody (non conj., 2D6, Abcam) and secondary 
goat-anti mouse IgG2 (PE, Dianova) in sequential staining. 
 
De novo priming of T cells with RNA-pulsed DC 
Collection of blood from healthy donors was approved by the “Ethics Board of the 
Medical Faculty of the Ludwig-Maximilians-University” Munich, Germany and donors 
gave informed consent. In vitro priming of allorestricted T cells was performed using 
mDC, electroporated with 48 µg of HMMR ivt-RNA in combination with 24 µg HLA-A2 
ivt-RNA. Stimulation of bulk cultures was performed as described (9) and as 
demonstrated in Figure S1.  
 
CD137-mediated enrichment of HMMR-specific CTL 
After a two-week resting phase, bulk culture lymphocytes were restimulated using 
RNA-pulsed mDC at a ratio of 10:1. Cells were adjusted to 1x107/100 µl MACS buffer 
9 h after stimulation and labeled with 1 µg/107 cells of anti-CD137-biotin antibody for 
15 min at 4°C (4B4-1, Ancell). Cells were washed, resuspended and incubated with 
anti-biotin-microbeads containing MACS buffer, according to manufacturerʼs 
instructions (Miltenyi). After a washing step, cells were separated using an LS MACS 
column (Miltenyi). Flow cytometry analysis of purity was performed using a CD8-FITC 
antibody combined with streptavidin-PE (BD). Enriched cells were either cultured as 
bulk culture cell lines or were cloned immediately in limiting dilution cultures using 
autologous feeder cells, as published (9). 
	   25	  
  
Retroviral TCR gene transfer 
TCR sequences of HMMR-specific CTL67 and 150 were determined by PCR. The 
constant regions were exchanged using the murine counterpart (45) and TCR 
sequences were codon optimized (46) to enhance expression. The synthesized 
TCRβ-2A-TCRα transgene cassettes (GENEART) were integrated into MP71-PRE, 
as previously described (8). Vector plasmids were used for production of retroviral 
particles and subsequent transduction of T cells (24). 
 
Lentiviral transfer of shRNA 
The vectors containing shRNA targeting HMMR as well as the helper plasmids were 
kind gifts of M. Heemskerk. Using two pLKO.1-puro vectors with two independent 
shRNA sequences targeting HMMR, third generation lentiviruses were produced in 
293T cells. The targeted cell lines mel624.38 and THP-1 were cultured in the mixed 
viral supernatant of both virus types for 48 h and selected for transduced cells using 
puromycin (Enzo Life Science) at a final concentration of 2 µg/ml. 
 
Lentiviral transduction and generation of luciferase-expressing cells 
The firefly luciferase construct was cloned into the pCDH vector containing a GFP-
expression cassette under the control of the EF-1alpha promoter (System 
Biosciences). Third generation lentiviruses were produced in 293T cells. THP-1 cells 
were transduced overnight in the presence of polybrene and enriched by 
fluorescence-activated cell sorting using GFP as a marker. 
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Cytokine treatment of TCR-modified PBL 
TCR transfer experiments using modified culture conditions were performed using X-
Vivo 15 medium (Lonza) supplemented with 1.5 g/l N-acetyl-L-cystein, 50 mM 
HEPES, 2 mM L-glutamin and 10% human serum. TCR retroviral transduction was 
performed as previously published and cells were cultured with IL-2 up to day 5 (24). 
Cells were then washed and resuspended in culture medium supplemented with new 
cytokines until use in functional assays in vitro or adoptive transfer experiments in 
vivo (Table 1).  
 
Chromium release and cytokine-release assays 
Cytotoxic activities of T cell lines, CTL, and TCR-modified PBL were analyzed in a 
standard 4 h chromium-release assay (9). For initial analysis at day 13, T cells were 
incubated with 2×103 K562-A2 cells or influenza matrix protein58–66 (flu, GILGFVFTL) 
peptide-loaded T2 cells, as previously described. Analysis of T cell clones at later 
time points was performed using the designated numbers of tumor cells and 1x104 T 
cells for the chromium-release assay. 2x103 T cells were stimulated to obtain 24 h 
supernatants for multiplex analysis, performed according to manufacturerʼs 
instructions using a human 17-Plex assay kit (BioRad). TCR-modified PBL, day 5 or 
day 13 after transduction, were cocultured with tumor cell lines using 2×103 target 
cells at the designated E:T. Specific lysis was calculated as described using duplicate 
samples at each E:T ratio (9). To obtain 24 h supernatants, TCR-modified PBL 
(4×104) were incubated with given numbers of tumor cells or mature, RNA-pulsed DC 
at an E:T ratio of 20:1, followed by a standard ELISA analysis for IFN-γ (BD).  
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Mice and adoptive transfer experiments 
All animal experiments were approved by the local authorities according to the legal 
regulations for animal experimentation. For the solid tumor model, 6-8 week old NSG 
mice were subcutaneously injected with 4x105 or 1x106 tumor cells resuspended in 
matrigel (BD) on day 0. The indicated numbers of TCR-modified or mock-treated 
lymphocytes were adoptively transferred intravenously into recipient mice on day 1. 
The tumor size was measured every other day using a caliper and calculated as mm2 
(length x width). Mice were sacrificed when the tumor area reached a volume of 300 
mm2 or 150 mm2 for THP-1 and mel624.38, respectively. For the disseminated 
leukemia model, luciferase-positive cells were intravenously injected on day 0 
followed by adoptive transfer of TCR-modified on day 1. IL-15 treatment, using a 
daily dose of 10 µg/mouse, was started on day 1 and was injected intraperitoneally 
through day 10 (47). For in vivo imaging, mice were anesthetized by isoflurane 
inhalation. Luciferine (SynChem) was injected intravenously before measurement of 
light emission using the IVIS Lumina machine (Caliper Life Sciences). 
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Figure legend 
Figure 1. In vitro characterization of HMMR-specific T cell clones 
(A) Clones induced by in vitro-priming using DC prepared from an HLA-A2-negative 
donor pulsed with HLA-A2 (48 µg) and HMMR (24 µg) ivt-RNA. Lytic capacity (% 
specific lysis) was assessed in a standard 4 h chromium-release assay using K562-
A2 (HLA-A2+, HMMR+) cells as a positive target and HLA-A2+ T2 cells pulsed with an 
irrelevant peptide (flu) as a negative control. (B) Screening of well-growing T cell 
clones was performed using K562-A2 (HLA-A2+, HMMR+) and THP-1 (HLA-A2+, 
HMMR+) as positive target cells, T2 cells pulsed with flu peptide (T2 flu) as a negative 
control, and T2 cells loaded with the HMMR-nonamer “ILS” (T2 ILS) (* not tested). 
The percent of specific lysis at an E:T of 5:1 is shown (upper graph) as well as IFN-γ 
secretion of 2x103 T cells stimulated with 1x103 tumor cells, assessed by a standard 
ELISA (lower graph). (C) Percentage of T cell clones showing no reactivity, 
alloreactivity or HMMR-specific reactivity in the initial screening assay. (D) HMMR-
specific T cell clones secreting four (black) or three (grey) out of four cytokines tested 
in a multiplex analysis (IFN-γ, IL-2, MIP-1α, TNF-α). Supernatants were taken at 24 
hours from cultures of 2x103 T cells stimulated with 1x103 target cells. (E) Lytic 
capacity shown as % specific lysis of two HMMR-specific CTL67 and CTL150, 
cocultured with the tumor cell lines THP-1 and K562-A2, as well as T2 cells pulsed 
with the ILS-peptide or the flu-peptide, respectively, at an E:T of 1:5. (F) Cytokine 
secretion profiles of CTL67 and CTL150 given in pg/ml for 2x103 cells at 24 h. 
Secretion of IFN-γ (black), IL-2 (open), and TNF-α (grey) was detected in a multiplex 
assay following stimulation with the four target cells described in B.  
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Figure 2. Characterization of TCR150-transduced lymphocytes using in vitro 
assays 
(A) Flow cytometry staining of TCR150-transduced lymphocytes showing expression 
of TCR150 in CD3, CD4 and CD8 T cells (from left to right). (B) IFN-γ ELISA of 4x104 
lymphocytes stimulated with 2x103 tumor cells for 24 h. THP-1 and K562-A2 cells 
were used as positive stimulating cells while T2 cells, pulsed with flu-peptide, were 
used as negative stimulating cells. PBL were transduced with TCR150 or a GFP-
control vector. Mock PBL served as a background control. Data are given in pg/ml. 
(C) Specific lysis of target cells mediated by untransduced PBL (mock) (closed 
circles), TCR150-transduced (closed squares) or survivin-specific TCR-A72-
transduced PBL (closed triangles). Open symbols represent specific lysis of targets 
using PBL enriched for the given TCR-expressing fraction (see Figure S3B). (D) 
Specific lysis of parental THP-1 (black circles) and mel624.38 (black squares) or 
HMMR-specific shRNA-treated THP-1 (gray circles) or mel624.38 (gray squares) by 
TCR150-modified PBL, measured in a standard chromium-release assay. In addition, 
the HMMRlow cell line MCF-7 (black triangles) and mock-PBL versus THP-1 (open 
circles) or mel624.38 (open squares) served as controls. (E) IFN-γ secretion of 
HMMR-specific TCR150- or tyrosinase-specific T58-transduced PBL after stimulation 
with autologous, HLA-A2- mature DC. DC were pulsed with HLA-A2-encoding RNA 
alone or in combination with HMMR1-725, representing the full length HMMR CDS, or 
with HMMR1-170, representing a deletion mutant coding for amino acids 1-170.  
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Figure 3. Potential of TCR150-transgenic lymphocytes to retard solid tumor 
outgrowth in vivo 
(A) Tumor outgrowth (mm2) of 1x106 THP-1 cells injected s.c. into NSG mice on day 
0 followed by adoptive transfer i.v. of mock-transduced PBL (closed circles; n=6) 
tyrosinase-specific T58-PBL (closed triangles; n=3) or HMMR-specific TCR150-
modified PBL (closed squares; n=9), on day 1 at a dose of 2x105 TCR-transgenic 
PBL per mouse (*** p<0.001). For statistical analysis, a two-way ANOVA analysis 
was used. (B) Tumor outgrowth (mm2) of 1x106 THP-1 cells injected on day 0 
followed by adoptive transfer of mock-PBL (closed circles; n=6) or TCR150-modified 
lymphocytes on day 1, at a cell-dose of 2x105 (closed squares; n=9) or 5x105 TCR+ 
PBL (open squares; n=3). Statistics using a two-way ANOVA indicated no significant 
difference between the two PBL doses. (C) Percent survival of mice treated in the 
experiment described in Figure 3A. Mice injected with TCR150-modified PBL showed 
a significant prolonged survival of 8 days compared to mice given mock-transfected 
cells (Mantel-Cox test *p=0.0022) (D) Survival of mice in the experiment shown in 
Figure 3B. Mice injected with 5x105 PBL showed no significant improved survival 
compared to mice given 2x105 PBL (Mantel-Cox test p=0.3312). All experiments 
were performed at least twice with similar results.  
 
Figure 4. Influence of cytokine milieu on recipient lymphocytes in vitro  
(A) Surface staining of human PBL transduced with TCR150 using human CD62L 
antibodies on pre-gated CD8+, CD45RA- cells that were cultured over a 5-day or 13-
day period in the presence of different cytokines as given in Table 1. (B) Percentage 
of intracellular IFN-γ and TNF-α double-positive cells within the CD8+ T cell fraction 
by flow cytometry analyses. Open bars represent non-stimulated PBL, while filled 
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bars represent PBL stimulated at an E:T of 20:1 ratio with THP-1 cells for 6 h. Mock-
transfected PBL were used as a background control compared to TCR150-
transduced cells, also cultured after addition of different cytokines. (C) Lytic capacity 
of T58- or TCR150-modified PBL, cultured under varying cytokine conditions, using 
THP-1 and mel624.38 as target cells. Specific lysis was measured in a standard 4 h 
chromium-release assay.  
 
Figure 5. In vivo effects of conditioned TCR150-transgenic lymphocytes 
(A-C) Tumor size in mm2 of tumor of (A) 1x106 THP-1 cells, (B) 4x105 THP-1 cells or 
(C) 4x105 mel624.38 cells, inoculated s.c. on day 0.  Adoptive transfer of 2x105 TCR-
positive PBL was performed on day 1. TCR150-modified lymphocytes were pre-
conditioned with IL-2- (filled circles), IL-7- (filled squares), IL-15- (filled triangles) or 
Tc17-medium (filled diamonds), respectively. Mock-transfected PBL served as 
control (open circles). A two-way ANOVA test showed a significant reduction of tumor 
outgrowth (* p<0.01; ** p<0.001). Results were confirmed in at least two independent 
experiments. (D-F) Percent survival of mice treated in the experiments described in 
Figure 5A through 5C. (D) Mice with THP-1 tumors (1x106) and injected with 
TCR150-PBL (IL-15) showed survival prolonged by 10 days (Mantel-Cox test 
*p=0.0011). (E) Mice injected with reduced numbers of tumor cells (4x105 THP-1) 
showed similar survival rates after injection of mock-treated PBL compared to 1x106 
tumor cells used, while the injection of TCR150-modified lymphocytes prolonged the 
survival significantly (Mantel-Cox test *p=0.0256). (F) mel624.38-bearing mice 
injected with TCR150-PBL (IL-7 or IL-15) showed a significantly improved survival 
compared to mice injected with TCR150-PBL (IL-2) (Mantel-Cox test *p= 0.0045 or 
**p=0.001). Results were confirmed in at least two independent experiments. 
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Experiments were performed at least twice in independent experiments with similar 
results. 
 
Figure 6. Usage of IL-7- and IL-15-conditioned TCR150-transgenic PBL to target 
disseminated tumor cells in vivo 
THP-1luc cells were intravenously inoculated on day 0 at a dose of 1x106 cells/mouse, 
followed by adoptive transfer of 2x105 each of IL-7 and of IL-15 conditioned T58- or 
TCR150-modified PBL on day 1. Tyrosinase-specific T58-modified PBL served as a 
negative control since THP-1 cells are tyrosinase negative. In addition mice were 
treated with exogenous IL-15 (10 µg/mouse/day) or TCR150-modified CD8+-enriched 
T cells (2x105 IL-7 and IL-15 cells for each conditioning) in combination with IL-15 
administration. IL-15 was added daily starting from day 1 through day 10 via 
intraperitoneal injection. A weekly monitoring of mice started two weeks after tumor 
inoculation and is depicted from day 21 onwards. Additional monitoring was 
performed when mice showed severe signs of paralysis before they were sacrificed. 
Depicted are representative mice out of groups of three mice. Remaining mice are 
shown in Figure S4.  
 
Figure S1. Scheme of de novo priming approach in combination with the 
CD137-mediated enrichment of antigen-specific T cells 
(A) Workflow of the in vitro priming approach to induce HMMR-specific, allorestricted 
T cell clones. (B) Flow cytometry staining of restimulated bulk cultures before and 
after CD137-mediated magnetic bead enrichment.   
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Figure S2. HMMR and HLA-A2 expression in target cells 
(A) Surface staining of HLA-A2 (open histograms) on tumor cell lines K562-A2, THP-
1, mel624.38 and MCF-7. K562 was used as a negative control, shown by filled 
histograms. (B) Intracellular staining of HMMR in the parental target cell lines 
depicted in (A) (open histograms), with the isotype-control staining shown in filled 
grey histograms. (C) HMMR-expression in HMMR-specific shRNA-treated cell lines, 
THP-1 and mel624.38, is shown in filled light grey histograms, while HMMR-staining 
in parental cell lines is given as open histograms. (D) IFN-γ (pg/ml) secreted during a 
24 h-coculture of 5x104 MART-1/MelanA-specifc CTL A42 with 1x105 mel624.38, 
mel624.38 treated with HMMR-specific shRNA or mDC pulsed with a MART-126-35 
peptide, respectively. 
 
Figure S3. Expression levels of TCR67 and TCR150 in PBL and enrichment of 
TCR-positive PBL  
(A) Expression levels of TCR67 and TCR150 in recipient lymphocytes detected by 
flow cytometry. Transgenic TCR expression was assessed by staining for the murine 
b-constant region of the TCR-construct (y-axis) versus counter-staining for human 
CD3, CD4 and CD8. (B) Enriched fractions of PBL transduced with TCR150 or TCR-
A72, respectively.  
 
Figure S4. Usage of IL-7-/ IL-15-conditioned TCR150-transgenic PBL to target 
disseminated tumor cells in vivo 
In vivo imaging of additional two mice treated according to the experiment shown in 
Figure 6. as well as mice treated with 2x105 TCR150-PBL (after IL-15 pre-
conditioning conditions).
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